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QUILL ON SCALPEL
Nonoperative Management for Adults 
With Blunt Splenic Trauma
W.J. Temple, MD, FACS, FRCSC
Director o f surgery, Tom Baker Cancer Centre, Calgary. Member, Editorial Board, Canadian 
Journal o f  Surgery
In this issue (pages 27 to 29) Stephen and colleagues show 
that, by clinical assessment, some 
patients with lacerated spleens from 
blunt trauma may be managed safe­
ly without laparotomy. It is evident 
that these patients were a very 
select group. In the nonoperative 
group, 24% of the patients present­
ed with delayed signs and symp­
toms, blood transfusion require­
ments were less and a peritoneal tap 
was not performed. All these fea­
tures were in sharp contrast to 
those in the surgically managed 
group. The findings of Stephen and 
colleagues support those of a simi­
lar, retrospective study done in our 
centre.1
However, this conservative ap­
proach, as indicated by Stephen and 
colleagues, is fraught with hazards 
if strict criteria are not adhered to. I 
would like to re-emphasize them, 
because, in our centre over the last 
few years, inappropriate application 
of these principles has resulted in 
patients suffering substantial mor­
bidity.
The criteria that I believe should 
be applied for nonoperative man­
agement of adults with blunt sple­
nic trauma are as follows:
•  Minimal abdominal signs, iso­
lated to the left upper quadrant.
•  A negative abdominal tap, if 
performed.
•  A clinically stable patient re­
quiring less than 2 units of blood to 
stabilize blood pressure and main­
tain vital signs.
•  A splenic or perisplenic lesion 
documented radiologically.
In making a decision to use a 
nonoperative approach, the surgeon 
must carefully weigh the risks and 
benefits of observation for a docu­
mented splenic injury. The risk of 
overwhelming sepsis after splenec­
tomy is lower in adults than in 
children but is still of some con­
cern. When surgery is delayed after 
conservative management has 
failed, a much lower splenic salvage 
rate and higher transfusion require­
ments have been reported.2 Trans­
fusion of more than 2 units of 
blood is associated with as much 
morbidity from the risk of hepatitis 
as is the potential for overwhelming 
pneumococcal sepsis if splenectomy 
is performed. Rebleeding after dis­
charge in patients treated conserva­
tively has not been documented, but 
this risk appears to be negligible.
The potential morbidity of con­
servative management must be 
weighed against the dramatic im­
provements in splenorrhaphy, 
which can be performed successful­
ly in 88% of grades I and II and in 
60% of grade III splenic injuries, 
found in the majority of patients 
suitable for a conservative ap­
proach.3 My own modification of 
the Dexon-mesh wrap technique 
salvaged the spleen in six consecu­
tive patients with grade III or IV 
splenic injuries. This technique has 
controlled blood loss quickly with­
out subsequent rebleeding. It is best 
described as a compression sple­
norrhaphy. The technique is as fol­
lows: The spleen is mobilized rapid­
ly into the midline from its peritone­
al and retroperitoneal attachments, 
as in a standard splenectomy. A 
vascular clamp may be applied 
across the pedicle for a few min­
utes. The clamp, which immediately 
stops the bleeding and gives the 
surgeon time to work on the spleen, 
is removed as soon as possible. A 
piece of Dexon mesh is used to 
wrap the entire spleen, leaving a 
small opening for the pedicle in the 
following manner. The mesh is cut 
half-way along one side to the cen­
tre. The pedicle is placed at the 
centre of the mesh. The short gastr­
ic vessels may be ligated to decrease 
the width of the pedicle. The cut in 
the mesh is then closed with a 
running suture, starting snugly at 
the pedicle and progressing to the 
edge of the mesh. Malitene may be 
applied over the bleeding areas or 
placed into the laceration to assist 
hemostasis. The mesh is then 
wrapped over the spleen, as one 
would wrap a gift, and the excess
CJS, VOL. 34, NO. 1, FEBRUARY 1991 7
TEMPLE
trimmed. A running suture is used 
to close the mesh, making it into a 
bag. The key to success is to de­
crease the size of the mesh bag 
progressively with running sutures 
until the spleen is compressed 
enough that the bleeding stops. 
This may result in the spleen being 
smaller than its original size but is 
likely a temporary condition.
This compression technique is 
quick and effective, taking only 10 
to 15 minutes, and is a dependable
alternative for any patient with sple­
nic injury not fulfilling the criteria 
for conservative management. The 
preliminary results of this technique 
are so impressive that it will likely 
prove useful in avoiding splenecto­
my in some patients, even when 
there is associated splenic damage 
and multiple intra-abdominal inju­
ries.
Stephen and his colleagues are to 
be congratulated for bringing this 
subject once more to our attention.
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QUILL ON SCALPEL
A
Fear of Flying and Surgery
Nelson S. Mitchell, MD, FRCSC
Department o f Surgery, Royal Victoria Hospital, Montreal
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A s a schoolboy during World War II, I was obsessed with 
aircraft and flying. Spitfires, Hurri­
canes, Me 109s and 110s, drawn in 
various configurations of flight, 
took up every available space in my 
school books. I built and flew — or 
more often crashed — countless 
balsa models.
About the time I began training 
in surgery I learned that 1 was 
afraid of flying. Trips to meetings 
or courses in Toronto, Chicago or 
points distant, presented great lo­
gistical problems . . . how to avoid 
the jet and travel on the ground.
At the beginning of my surgical 
practice a surgical acquaintance 
took me flying in his two-seater 
Super-Cub. As I sat behind him, 
unable to protest, we flew under a 
bridge in the Halifax harbour. For­
tunately this act of wanton foolish­
ness was followed by a ride in a 
float plane where the great safety of 
flight was emphasized. I began fly­
ing lessons shortly thereafter. Pilot 
licence, night flying and instrument 
ratings and the purchase of an 
aircraft soon followed. Eighteen 
years later I have spent 1500 hours 
flying all over North America and 
five times that time in the operating 
room. I have found that much of 
pilot training has implications for 
the surgeon.
Before each flight the charts, the 
weather at departure, en route and 
at the destination must be evaluated 
for an expeditious and safe trip. 
The surgical approach must also be 
planned with knowledge of anatom­
ical charts, taking into account the 
objective of surgery, possible devia­
tions and obstacles that might arise.
If the weather at the destination is
marginal an alternative aerodrome 
must be selected . . . .  Will the 
patient need to be transferred to the 
intensive care unit postoperatively? 
Is a bed available?
Before starting the engine(s) the 
pilot must be completely familiar 
with the equipment he is using. He 
walks around the aircraft inspecting 
it and its systems. In the cockpit, 
further static and operational 
checks are made according to a 
prearranged plan. A complete un­
derstanding of the structure and 
functions of the patient is taken for 
granted, but how many of us ensure 
that we have done so with a check 
list? How many operations have 
been delayed or the result compro­
mised by faulty or absent equip­
ment, which a preoperative check 
might have turned up?
During the taxi and take-off 
phase, while the flight can still be 
aborted, further regimented system 
checks are made. Aloft the pilot 
continuously monitors his engine 
and system instruments and his 
progress. He constantly contem­
plates what could go wrong with 
machine or weather and how he 
would deal with it. The surgeon, 
likewise, should continuously con­
sider if the procedure is going ac­
cording to plan. As the dissection 
proceeds he should look for danger 
signals and contemplate what com­
plications might occur and how 
best to avoid them. Is there a 
danger of entering bowel or a ves­
sel? How can the risk be minimized 
and what to do if the dreaded event 
occurs?
As prelanding checks are read off 
on the approach to the airport, so 
the end of the operation is a time to
review postoperative orders and re­
habilitation plans. Upon landing a 
debriefing is carried out and points 
of interest are recorded in the log. 
How often does the surgeon discuss 
with the operating team the con­
duct of a operation with a view to 
improving performance?
In all of the above my pilot 
training was the most useful to me 
in risk management and damage 
control. The surgeon can avoid 
most intraoperative complications 
by anticipating them, but when they 
arise, panic can be avoided by hav­
ing a predetermined plan. Even in 
its absence, the conviction in­
grained during training that virtual­
ly every problem is solvable will 
stand both pilot and surgeon in 
good stead.
I am mildly apprehensive during 
every flight. I have been truly 
frightened only twice, both times 
because of unfamiliarity with a sys­
tem or failure of planning. I have 
had two engine failures, but these 
were without consequence as con­
tingency plans were available and 
were used. Early in my pilot train­
ing, before these responses were 
developed, I wrecked an aircraft.
The operating room has always 
been a place in which I am some­
what frightened. When complica­
tions arose I had to train myself to 
remain calm. Anticipation and con­
tingency planning has reduced 
these to rare occurrences. Those 
surgeons who disclaim any fear in 
the operating room are likely to 
have at least some “incidents” dur­
ing their careers: the Department of 
Transport calls a wreck without 
injury an incident, reserving “acci­
dent” for a worse occurrence. ■
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Pushing for a fast start: 
driver Chris Lori, over-all 1990 
World Cup bobsled champion 
and team member Douglas 
Currier Their unique athletic 
abilities and conditioning 
have helped place Canada's 
bobsledding team on track for 
gold medal contention at the 
W inter Olympics in 1992.
Weekend athletes, inspired 
by the all-out efforts of world 
class competitors, forget their 
own limitations, take an over- 
ambitious approach to their 
sport and find that it often 
leads to injury and pain.
When sports injuries call for 
double strength relief, consider 
new Anaprox DS: reliable 
Anaprox action — now with 
double the muscle!
Ergamisol* + 5-FU.
The first adjuvant therapy proven to 
reduce recurrence by 41%.
LEVAMISOLE AND FLUOROURACIL FOR ADJUVANT THERAPY OF 
RESECTED COLON CARCINOMA
too preliminary to allow firm conclusions. Toxic effects of 
levamisole alone were infrequent, usually consisting of 
mild nausea with occasional dermatitis or leukopenia, 
and those of levamisole plus fluorouracil were essentially 
the same as those of fluorouracil alone-i.e., nausea, 
vomiting, stomatitis, diarrhea, dermatitis, and leukopenia. 
These reactions were usually not severe and did not greatly 
impede patients’ compliance with their regimen.
We conclude that adjuvant therapy with levamisole and 
fluorouracil should be standard treatment for Stage C 
colon carcinoma. Since most patients in our study were 
treated by community oncologists, this approach should 
be readily adaptable to conventional medical practice. 
CN Engl J Med 1990; 322:352-80’
Abstract Twelve hundred ninety-six patients with resected 
colon cancer that either was locally invasive (Stage B2) or 
had regional nodal involvement (Stage C) were randomly 
assigned to observation or to treatment for one year with 
levamisole combined with fluorouracil. Patients with Stage 
C disease could also be randomly assigned to treatment 
with levamisole alone. The median follow-up time at this 
writing is 3 years (range, 2 to 5%).
Among the patients with Stage C disease, therapy with 
levamisole plus fluorouracil reduced the risk of cancer 
recurrence by 41 percent (P <  0.0001). The overall death 
rate was reduced by 33 percent (P ~  0.006). Treatment 
with levamisole alone had no detectable effect. The results 
in the patients with Stage B2 disease were equivocal and
S JANSSENPH AR M AC EU TIC A
Mississauga. O ntario
THERAPY SHOULD BE INITIATED WITHIN 5 WEEKS OF SURGERY.
NEW
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New Bronchoscopic Instruments: 
a Toothpick and a Corkscrew
C.L.N. Robinson, MD, FRCS, FRCSC
U nusual foreign bodies require ingenuity to remove. I describe 
here two cases in which unusual 
instruments were used to remove 
unusual foreign bodies from the 
right and left lower-lobe bronchi of 
a 55-year-old man and a 6-year-old 
boy.
Case Reports
Case 1
During the fitting of a gold 
crown to a defective molar a 
55-year-old dentist accidentally in­
haled the crown when it slipped his 
colleague’s fingers. The crown set­
tled in the right lower-lobe bron­
chus (Fig. 1). Although the dentist 
did not experience any serious 
symptoms he did have minor 
wheezing on the right side of the 
chest. When I first saw the patient 
in the Emergency Department I 
thought the crown could be re­
moved easily by bronchoscopy. 
However, when I tried to grasp the 
crown, which was lying with the 
blunt side down and was quite firm­
ly impacted, with an angled alliga­
tor forceps, the leading edge was
FIG. 1. Posteroanterior and lateral 
views showing metal (gold) crown in 
right lower-lobe bronchus.
Emeritus clinical professor o f surgery, Faculty o f  Medicine, University o f  British Columbia, 
Vancouver
Accepted for publication Nov. 27, 1989
Reprint requests to: Dr. C.L.N. Robinson, 604-750 West Broadway, Vancouver, BC V5Z1H5
* -  For prescribing information see page 36 CJS,
too slippery, and attempts to re­
move it simply pushed it further 
down the bronchus.
To overcome this I had a “tooth­
pick” instrument made (Fig. 2). It 
was 50 cm long, had a thickened, 
serrated handle and a small, sharp, 
angled point.
Two days later I made another 
attempt to remove the crown. With 
an assistant holding the broncho-
FIG. 2. “Toothpick” with 50-cm long 
handle and fine angled tip.
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FIG. 3. Long instrument with cork­
screw at end.
scope steady I was able to get the 
toothpick around the edge of the 
crown, rotate it enough to grasp 
the sharp edge firmly with an alliga­
tor forceps and remove it trailing. 
The crown was fitted correctly a 
few days later.
Case 2
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SESAP VI Question
Item 145
Administration of polyvalent pneumococcal vaccine to a child who has 
undergone splenectomy
*
A
i
A
-‘U
A 6-year-old boy accidentally in­
haled a plastic, cone-shaped head of 
a toy bullet, which became lodged 
in the left lower-lobe bronchus. It 
was pointed down and firmly im­
pacted. The cylinder-like end of the 
bullet was pointed upwards making 
it impossible for me to grasp the 
bullet without damaging the wall of 
the bronchus. The cone end of the 
bullet had a tiny hole. Therefore I 
had a long instrument made with a 
corkscrew at one end (Fig. 3). The 
corkscrew was inserted through the 
hole, and the bullet was removed 
safely, trailing, without damaging 
the bronchial wall.
I wish to thank Keir & Sons, Vancouver 
for making the two instruments.*
(A) virtually eliminates the risk of overwhelming postsplenectomy 
infection (OPSI)
(B) reduces the risk of OPSI by approximately one third
(C) is of no benefit unless given prior to splenectomy
(D) is of no benefit because many of the bacteria causing OPSI are 
not pneumococci
(E) is contraindicated for children who have undergone splenecto­
my for hematologic diseases. For the incomplete statement 
above select the best of the five completions.
For the critique of Item 145 see page 69.
(Reproduced by permission from SESAP VI Syllabus; Surgical Educa­
tion and Self-Assessment Program No. 6. For enrolment in the Surgical 
Education and Self-Assessment No. 6, please apply to the American 
College of Surgeons, 55 East Erie St., Chicago, IL 60611.)
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Detection of Micrometastases 
From Primary Breast Cancer
D.J. Courtemanche, MD;* A.J. Worth, MD, FRCPC;t R.W. Coupland, MD, FRCPC;$ 
J.K. MacFarlane, MD, MSc, FRCSC§
The monoclonal antibody LICR-LON-M8 was used in a series of experiments to 
determine how an immunohistochemical technique could be used as a diagnostic test 
for micrometastatic disease in patients with operable, primary breast carcinoma.
Optimal tissue and antigen preservation was obtained with fixatives containing 
either picric acid or a heavy metal such as mercury to allow staining with the 
monoclonal antibody diluted to 1:12 000 to 1:16 000 from unpurified mouse ascites. 
Tissue affected by primary and metastatic disease stains in a characteristic fashion, 
which is distinct from benign breast tissue. All the ductal tumours stained positively 
for malignant cells with the monoclonal antibody preparation. Within the bone 
marrow, occasional granulocytes and granulocyte precursors stained positively if the 
endogenous peroxidase activity was incompletely blocked. These cells were readily 
differentiated from tumour cells on cytologic examination.
With these monoclonal antibody and immunohistochemical staining techniques it 
may now be possible to detect early micrometastatic disease in the bone marrow 
patients with primary breast cancer.
L’anticorps monoclonal LICR-LON-M8 a ete utilise dans une serie d’experiences 
visant a determiner comment une methode immunohistochimique pouvait etre 
utilisee comme epreuve diagnostique des micrometastases chez les patientes 
souffrant d’un cancer primitif operable du sein.
Une conservation optimale des tissus et de l’antigene fut obtenue a l’aide de 
fixatifs renfermant soit de l’acide picrique ou un metal lourd tel que le mercure et 
permettant une coloration avec l’anticorps monoclonal dilue a 1:12 000 ou 1:16 000 
provenant d’ascite non purifie de souris. Les tissus atteints d’un cancer primitif ou 
envahis par des metastases se colorent de fa?on caracteristique, ce qui les 
differencient des tissus mammaires sains. Toutes les tumeurs canaliculaires ont 
donne une coloration positive en presence des preparations d’anticorps monoclo- 
naux. Dans la moelle osseuse, quelques granulocytes et des precurseurs des 
granulocyctes ont pris la coloration quand l’activite de la peroxydase endogene etait 
incompletement bloquee. Ces cellules se differenciaient nettement des cellules 
tumorales a l’examen cytologique.
Avec ces anticorps monoclonaux et les techniques de coloration immunohistochi- 
miques, il pourrait maintenant etre possible de deceler precocement les micrometas­
tases dans la moelle osseuse des patientes souffrant de cancer primitif du sein.
B reast carcinoma is the most common carcinoma in women, 
affecting approximately 6% o f all 
women in their lifetime.1 The bio­
logic behaviour of breast cancer
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appears to be inadequately predict­
ed by standard staging methods. It 
remains unclear if this is a “system­
ic” disease at the time of diagnosis 
or if the tumour invades locally, 
nodally and then distantly over 
time. Some patients with locally 
advanced disease remain disease- 
free after treatment, and, in con­
trast, some patients with stage I 
lesions die early after treatment. 
For patients with stage I disease, 
the 5-year survival rate is 85% and 
for those with stage II disease it is 
70%.2 Clearly, a large number of 
patients are “under-staged” by cur­
rently available techniques.
Monoclonal antibodies provide 
sensitive probes for the investiga­
tion of biologic systems.3-5 Many 
are reactive to breast carcinomas, 
but their clinical role has yet to be 
defined.6-12 LICR-LON-M8 (M8) is 
one of several anti-breast monoclon­
al antibodies that have been made 
from membrane extracts of human 
breast milk.67 The antigen is 
thought to be a T- or Tn-related 
precursor of the MN surface-anti­
gen group.13-15 This is an immune 
lipopolysaccharide, which appears 
to be very stable.
We describe several experiments 
using this antibody, performed in 
an attempt to develop a clinical test 
that would detect the presence of 
micrometastatic disease in the bone 
marrow of patients with primary 
breast carcinoma.
Methods
The monoclonal antibody M8 was 
supplied by Dr. B. Gusterson of the 
Ludwig Institute for Cancer Re­
search in London, England, and by 
Dr. R. Buick of the Ontario Cancer 
Institute as unpurified ascitic fluid 
(with 0.1% NaN3 as preservative). 
The technique of hybridoma pro­
duction of monoclonal antibody has 
been described,4 and the staining
characteristics of M8 in benign and 
malignant breast tissues have been 
well documented.6 7
Fresh tissue (surgical specimens) 
and tissue previously fixed in 10% 
buffered formalin (BF) or picric acid 
formalin (PAF) were obtained from 
the pathology departments of the 
Vancouver General Hospital and the 
Cancer Control Agency of British 
Columbia. A variety of fixative solu­
tions was used to preserve the fresh 
tissue.
Immunohistochemical staining 
was carried out by the avidin-biotin 
peroxidase complex method,16 with 
M8 as the primary antibody.
Several experiments were con­
ducted to determine the optimal 
method of fixing and staining the 
tissues.17-18
First, serial dilutions of the anti­
body were used to stain breast 
carcinoma tissue that was previous­
ly fixed in 10% BF or PAF to 
determine the optimal dilution of 
the antibody. Second, fresh tissue 
was fixed in each of 10% BF,19 
PAF,20 B5 (sodium acetate-merc­
uric chloride-formalin fixative),21 
Bouin’s solution22 or 95% alcohol 
to determine the best method of 
preservation of the antigen. Follow­
ing this, a variety of specimens of 
benign and malignant breast tu­
mours were stained to verify the 
staining characteristics reported in 
the literature.6 7
From bone-marrow samples of 
patients without metastatic carcino­
ma, a series of spread and particle- 
section control slides were made. 
One aspiration specimen was crude­
ly inoculated with dilutions of a cell 
suspension prepared from a fresh 
breast-carcinoma biopsy specimen. 
A series of crude dilutions of tu­
mour cells in suspension were 
added to equal volumes of bone- 
marrow aspirate, and smears and 
particle sections were prepared and 
stained in a “spiking” experiment. 
Additionally, two biopsy specimens 
that yielded positive results on cyto­
logic examination from patients 
with metastatic breast cancer were 
examined.
Slides were read independently by 
two pathologists, and all specimens 
had positive and negative controls.
Results
Initially, for the previously fixed 
and blocked tissue, the best results 
were obtained at a 1:16 000 dilu­
tion for tissue fixed in PAF and in a 
1:4000 dilution for tissue fixed in 
10% BF (Table I). The original 
specimen in BF was 2 years old, 
and, subsequently, for freshly fixed 
tissue a dilution of 1:12 000 was 
found optimal for all fixatives ex­
cept 95% alcohol. The quality of the 
slides (freedom from artefact) was 
best for specimens fixed in Bouin’s 
solution (Table II).
Using the above information, we 
examined breast biopsy specimens
Table I. Determination of UCR-L0N-M8 (M8) Monoclonal Antibody Dilution for Optimal Staining
Dilution
Picric acid formalin 
(n =  21)
10%  buffered formalin  
( n = 1 4 )
Stroma Carcinoma Benign Stroma Carcinoma Benign
1:2 000 +  + + + + + + +  +  + -
1:4 000 +  + + + + + - +  + -
1:8 000 + + + + - - + —
1:16 000 - +  + - - - -
1:32 000 - + - - -
-  to + + +  represents an arbitrary scale of staining intensity: -  =  no staining, +  =  weak 
staining, + + ,  + + +  =  progressively stronger staining. 
n =  total number of sections stained.
“ A
A
1
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t
to confirm the staining characterist­
ics of the antibody.6-7 Benign breast 
tissue shows a characteristic apical 
luminal membrane staining, but tis­
sue from carcinomas shows staining 
of the entire membrane as well as 
cytoplasmic staining that varies in 
intensity23 (Fig. 1). All of the ductal 
carcinoma specimens tested stained 
with this antibody (Fig. 2). Speci­
mens of primary breast carcinoma 
of other types did not stain as 
consistently7 (Table III).
Normal bone marrow showed no 
staining other than stain absorbed 
by a few granulocytes and granulo­
cyte precursors in endogenous per­
oxidase activity had not been com­
pletely blocked.2425
Apart from the difficulty of plac­
ing a clump of tumour cells into a 
well-organized benign marrow, the 
inoculation of normal marrow with 
carcinoma cells worked relatively 
well. At 105 and 104 cells/mL, it 
was possible to differentiate clumps 
of cancer cells in the particle sec­
tions from the normal marrow (Fig. 
3). These cells retained the cytolog­
ic characteristics of malignancy. At 
concentrations below 103 cells/mL 
no malignant cells could be detected
V T a b le  II. M o n o c lo n a l A n tib o d y  S ta in in g  Q u a lity  U s in g  V a rio u s  F ixa tives
Fixa tive M onoclona l antibody dilution Quality*
BF X 24  h 1:1 5 0 0 Good
X 3 h -  70%  a lc o h o l
B o u in ’s  so lu tio n  x 2 4  h 1 :1 2  0 0 0 E xce llen t
x 3 h -  70 %  a lc o h o l (b e tte r  se c tio n s )
PAF x 24  h 1 :1 2  0 0 0 E xce llen t
A x 3 h -  70%  a lc o h o l
B5 X 24  h 1 :1 2  0 0 0 Good
x 3  h -  70%  a lc o h o l (b e tte r  se c tio n s )
9 0 %  a lco ho l X 2 4  h 1:1 500 Good
A X 3 h -  70%  a lc o h o l
* H is to lo g ic  p re s e rv a tio n  and fre e d o m  fro m  a rte fa c t.
BF =  10%  b u ffe re d  fo rm a lin , PAF =  p ic r ic  ac id  fo rm a lin , B5 = s o d iu m  a c e ta te -m e rc u r ic
c h lo r id e - fo rm a lin  f ix a tiv e .
FIG. 1. Benign breast tissue showing apical luminal membrane staining with 
LICR-LON-M8 (M8) (arrow) (avidin-biotin peroxidase complex [ABC] technique 
with M8 as primary antibody and hematoxylin counterstain, original magnification 
X 250).
(Table IV). No malignant cells were 
detected on any of the spreads. The 
incidental finding of two or three 
benign squamous cells contaminat­
ing one of the slides emphasized 
the ability of monoclonal antibody 
M8 to detect cells present at low 
concentrations.
Bone-marrow biopsy specimens 
containing large numbers of meta­
static carcinoma cells were stained 
and showed the same characterist­
ics as the primary tumours. The 
cells had the cytologic features of 
malignancy and could readily be 
differentiated from the normal 
bone-marrow cells.26-27 Single cells 
within the section not readily seen 
on hematoxylin-eosin-stained sec­
tions could easily be visualized 
when the monoclonal antibody was 
used.28-29
Discussion
The results show that it is possi­
ble to enhance the detection of 
micrometastatic disease in patients 
with primary breast carcinoma by 
using LICR-LON-M8 as a mono­
clonal antibody “probe.” This has 
also been demonstrated with other 
monoclonal antibodies.28' 32 These 
results rest on the premise that 
normal bone-marrow cells will not 
stain, and that, in a patient with a 
primary breast carcinoma, any cells 
that stain within the bone marrow 
represent metastatic disease.7
Clinical verification of this as­
sumption is lacking. Detection has 
been reported to correlate well with 
known risk factors for a poor prog­
nosis.
Redding and colleagues31 have 
shown that the bone marrow of 
patients with aggressive primary tu­
mours, determined by standard 
grading techniques, was more likely 
to stain positive for carcinoma cells. 
Eighty-three percent of patients 
who had estrogen-receptor-negative
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tumours with vascular and nodal 
invasion had bone marrow that 
stained positively for cancer cells 
compared with 11% of patients with 
estrogen-receptor-positive tumours 
without vascular or nodal invasion.
Dearnaley and associates28 re­
ported the short-term follow-up of a 
small group of patients whose bone 
marrow had been examined with 
the monoclonal antibody epithelial
membrane antigen (EMA). The pa­
tients whose bone marrow tested 
positive had a shorter interval be­
fore clinical relapse occurred; how­
ever, their overall survival was not 
documented, perhaps because the 
follow-up was not long enough. 
Moreover, the characteristics of the 
primary tumour were not noted, 
therefore it is impossible to deter­
mine whether the positive bone
marrow was an independent risk 
factor.
The experience gained in this set 
of experiments will be used in a 
prospective clinical trial. In this trial 
women who undergo surgery for 
primary breast carcinoma will, with 
informed consent, have four bone- 
marrow samples harvested at the 
time of their breast surgery. The 
tumours will be staged according to 
standard techniques and the bone- 
marrow samples will be evaluated 
separately in a double-blind fashion. 
The results of the bone-marrow 
screening will not be made available 
to the patients or their treating 
physician so as not to influence the 
patients’ ongoing care.
Careful follow-up will be obtained 
and an assessment made of the 
prognostic implications of bone- 
marrow samples that test positive 
or negative as an isolated test in 
correlation with other methods of 
tumour evaluation.
Several questions remain to be 
answered:33
•  Can positive bone-marrow 
staining be reliably detected in the 
clinical situation in patients with 
micrometastases?
•  Does detection in this manner
*
FIG. 3. Clump of malignant cells in 
benign marrow at dilution of 104 
cells/mL (ABC technique with M8 as 
primary antibody and hematoxylin 
counterstain, original magnification X 
250).
FIG. 2. Invasive ductal carcinoma showing holomembrane staining of varying 
intensity and cytoplasmic staining (compare cells indicated by arrow and arrow­
head) (ABC technique with M8 as primary antibody and hematoxylin counterstain, 
original magnification X 250).
T a b le  I I I .  P atte rn  o f  C a rc in o m a  S ta in ing
T ype  of carcinom a G rade %  sta in ing  (no.)
In f i l t ra t in g  ducta l 1 1 0 0  (6 )
II 1 0 0 (1 1 )
III 100  (8 )
M e d u lla ry A ll 7 5  (4 )
C o llo id A ll 80  (5 )
L o b u la r A ll 1 0 0  (6 )
Table IV . D e tec tio n  o f C ancer in M o c k  P o s itive  Bone M a rro w  S p e c im e n s
D ilu tio n , ce ils /m L C a n cer* C om m ents
10 5 + C e lls  c lu m p e d  to g e th e r
10 4 + C e lls  c lu m p e d  to g e th e r
1 0 3 — —
10 2 — S qu a m o us  c e lls  de tec ted  
(see  te x t)
10 - —
'P o s s ib le  cancer c e lls ;  +  =  p o s it iv e , - =  n e g a tive .
. j
A
*
A
A
A
M
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provide any new useful information 
about prognosis, compared with 
current methods of staging?
•  Is the information likely to be 
of any benefit to the patient?
•  Will patients with early meta­
static disease be more likely to be­
nefit from adjuvant chemotherapy?
Conclusions
Much remains to be learned 
about the biology of breast cancer. 
Monoclonal antibodies are just one 
of the tools being used in this 
learning process. At present there is 
no clearly defined role for the use of 
this powerful tool in the routine 
diagnosis and treatment of breast 
cancer.
Having shown that it is possible 
to detect breast cancer cells in an 
experimental situation, it is now 
necessary to test this hypothesis in 
the clinical setting. The monoclonal 
antibody M8 is only one of many 
such products being evaluated in 
the hope of improving our knowl­
edge of the behaviour of carcinoma 
and our ability to treat patients.
The authors thank the following for 
their assistance with this study: Don 
Howard, Dr. B. Gusterson, Dr. A.M. 
Neville and Bev Thomas.
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CANADIAN ONCOLOGY SOCIETY
Monoclonal Antibody LICR-LON-M8 
Does Not Predict the Outcome 
of Operable Breast Cancer
D.J. Courtemanche, MD;* A.J. Worth, MD, FRCPC;f R.W. Coupland, MD, FRCPC;$, J.L. Rowell;§ 
J.K. MacFarlane, MD, MSc, FRCSC1
The prognostic value of the monoclonal antibody LICR-LON-M8, which has been 
shown to detect micrometastatic disease, was evaluated in a prospective, 
double-blind, clinical study of bone-marrow specimens from patients with operable 
breast cancer.
Four bone-marrow specimens, obtained from each of 50 patients at the time of 
excision of the primary breast tumour, were examined immunohistochemically, with 
LICR-LON-M8 as the primary antibody.
All of the primary tumour specimens demonstrated positive staining for 
malignant disease with LICR-LON-M8. The bone-marrow specimens of four patients 
demonstrated positive staining: three specimens were “suspicious” for malignant 
cells and one contained definite malignant cells on cytologic examination. This gave 
a 2% rate of detectable micrometastatic disease at the time the primary tumour was 
excised. Patient follow-up averaged 21.5 ± 9.1 months. The test results did not 
correlate with outcome. A negative test result with LICR-LON-M8 did not imply a 
better prognosis.
The authors conclude that examination of bone-marrow specimens stained with 
LICR-LON-M8 in patients with operable breast cancer is of no clinical value. 
Furthermore, the low rate of micrometastases detected is at variance with that 
reported by others. In view of the natural history of breast cancer, the authors 
believe that their results were not unexpected and they question the importance of 
other results.
La capacite pronostique de l’anticorps monoclonal LICR-LON-M8, lequel s’est 
montre capable de deceler les micrometastases, a ete evaluee dans une etude clinique 
prospective, a double insu, d’echantillons de moelle osseuse provenant de patientes 
porteuses de tumeurs du sein operables.
Quatre echantillons de moelle osseuse preleves chez chacune de 50 patientes au 
moment de l’excision de la tumeur primitive du sein ont fait l’objet d’un examen 
immunohistochimique a l’aide du LICR-LON-M8.
Toutes les tumeurs primitives se sont revelees positives a la coloration au 
LICR-LON-M8. Les echantillons de moelle osseuse de quatre patientes ont presente 
une coloration positive: trois echantillons etaient “douteux” pour la presence de 
cellules malignes et l’autre montrait definitivement des cellules malignes a l’examen 
cytologique. Ceci donne un taux de micrometastases decelables de 2% lors de 
l’excision de la tumeur primitive. La surveillance des patientes est en moyenne de 
21.5 ± 9.1 mois. Les resultats des epreuves n’offrent pas de correlation avec Tissue 
de la maladie. Un resultat negatif n’a pas signifie un meilleur pronostic.
Les auteurs concluent que Texamen des echantillons de moelle osseuse a l’aide du 
LICR-LON-M8 chez les patientes souffrant d’un cancer du sein operable n’a pas 
d’interet clinique. De plus, le faible taux de micrometastases decelees differe de ce 
qui est rapporte par d’autres. Vu Thistoire naturelle du cancer du sein, les auteurs 
croient que leurs resultats etaient previsibles et ils mettent en doute Timportance 
d’autres resultats.
I n the study of breast cancer, monoclonal antibodies are a re­
search tool looking for a practical 
clinical application. Many laborato­
ries have produced monoclonal anti­
bodies that will react with human 
breast cancer cells.12 Among these 
are the LICR-LON-M series of mu­
rine monoclonal immunoglobulin G 
antibodies produced originally at
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the Ludwig Institute for Cancer 
Research.34 This series of mono­
clonal antibodies has been made to 
resemble membrane extracts of 
human breast milk.
A sample of one of these, LICR- 
LON-M8, was made available to the 
University of British Columbia for 
investigation. The hybridoma tech­
nique of monoclonal antibody pro­
duction has been well described.5 
The material is supplied in the form 
of unpurified mouse ascites.
A preliminary series of experi­
ments was reported in which the 
optimal methods of tissue fixation 
and staining were determined and 
the reported properties of this anti­
body verified.34-6 The antibody re- 
producibly stained all ductal carci­
noma specimens tested.
It was also determined that mi- 
crometastatic disease in the bone 
marrow could, theoretically, be de­
tected, and the staining character­
istics of carcinoma cells in marrow 
were noted. Other investigators 
have determined that as few as one 
malignant cell in 10 marrow cells 
may be detected in this way.7
We report a prospective study of 
the value of this monoclonal anti­
body as an independent staging 
technique in patients with operable 
breast cancer. The questions we
explanation of the study. The study 
protocol was approved by the Uni­
versity of British Columbia, Clinical 
Screening Committee for Research 
and Other Studies Involving Human 
Subjects and the medical ethics 
committees of the individual hospi­
tals involved. Study data, which 
were collected on a standardized 
form, included the following: demo­
graphics, tumour history, clinical 
staging, pathological staging and 
relevant histologic detail, tumour 
hormone receptor status, im- 
munohistochemical results for the 
primary tumour and the marrow 
specimens and clinical follow-up 
data.
The biopsies were done under 
general anesthesia just before exci­
sion of the primary tumour. Four 
bone-marrow biopsy specimens 
were obtained from each patient: 
two at right angles to each other 
from each posterior superior iliac 
spine. The biopsy specimens were 
fixed in Bouin’s solution for 40 
minutes and then in 70% alcohol.10 
They were dehydrated in alcohol, 
embedded in paraffin, sectioned and 
stained with hematoxylin and eosin 
and using the avidin-biotin peroxi­
dase complex method (Vector Labo­
ratories, Burlingame, Calif.) with 
the monoclonal antibody M8 as the
were trying to answer were: Can we 
identify a subgroup of patients with 
operable breast cancer who have 
occult micrometastatic disease at 
the time the primary tumour is 
excised? and Does a positive test 
result give any independent prog­
nostic information, and, if so, will 
this information benefit the patient?
To date several studies have dem­
onstrated the ability to detect mi­
crometastatic disease in patients 
with breast cancer; however, the 
value of this information remains 
unknown.8 Positive test results cor­
relate highly with already known 
risk factors for metastatic disease.9
Methods
Patients with primary, operable, 
breast cancer (stages I, II and IIIA) 
who were not involved in any other 
ongoing breast cancer study at the 
University of British Columbia were 
entered into the study. All appeared 
free of malignant disease on bone 
scanning and chest radiography and 
had normal results of liver function 
tests. No patient had a history of 
remote or current malignant disease 
of any other type.
Participation was voluntary. Con­
sent forms were signed after an
FIG. 1. Positive staining with LICR-LON-M8 antibody: (left) invasive ductal carcinoma; (right) intraductal carcinoma (avidin- 
biotin peroxidase complex technique with M8 as the primary antibody and hematoxylin counterstain, original magnification X 
250).
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primary antibody.11 Positive and 
negative control studies were per­
formed for each specimen.
Sections known to contain tu­
mour cells from the formalin-fixed, 
paraffin-blocked, primary tumour 
specimen, were similarly stained 
with hematoxylin and eosin and 
were immunohistochemically stud­
ied as controls (Fig. 1).
Patients were followed up at 
3-month intervals by the treating 
surgeon, family doctor or breast- 
tumour clinic of the Cancer Control 
Agency of British Columbia.
Ethics
The immunohistochemical test 
result was not released to the treat­
ing physicians, since the implica­
tions of the test result were not 
known at the start of the study, and 
it was important not to bias the 
ongoing care of these patients in 
any way.
Statistics
Data fitted to two X  two tables 
for comparison of results between 
groups were analysed with Yates’ 
modification of the x2 test. A p 
value less than 0.05 was considered 
statistically significant.
Results
Between March 1986 and Sep­
tember 1989, 53 patients were en­
tered into the study. Complete data 
and up-to-date follow-up were avail­
able for 50 of these patients. One 
patient was lost to follow-up, one 
patient was excluded after diagnosis 
of a concurrent colonic carcinoma 
and one man was excluded.
Ages ranged from 28 to 93 years 
(mean 57.6 ± 12.8 years). Thirty 
patients were postmenopausal and 
20 premenopausal.
The average follow-up was 21.5 
± 9.1 months. The 50 patients 
were divided into two groups: 
group 1 comprised 27 patients with 
follow-up of more than 2 years and 
group 2 contained 23 patients with 
follow-up of less than 2 years. This 
was done because the difference in 
recurrence rate between the two 
groups approached statistical signif­
icance (Table I).
In group 1, 10 patients had stage 
I disease, 12 had stage II and 5 had 
stage IIIA. In group 2, 12 patients 
had stage I disease, 10 had stage II 
and 1 had stage IIIA. There were 
46 ductal and 4 lobular carcinomas. 
Forty-one tumours were estrogen- 
receptor positive (EP+); 6 showed 
vascular invasion (VI+) (Table II).
Thirty-two modified radical mas­
tectomies were performed; 17 pa­
tients underwent segmental mastec­
tomy with axillary dissection. In 
only two patients with stage I dis­
ease were the results of cytologic 
examination of the lymph nodes 
positive (Table III). All of the prima­
ry tumours stained with the mono­
clonal antibody, and four bone-mar­
row biopsy specimens did also.
Follow-up
Of the 22 patients having stage I 
disease, 10 were followed up for 
more than 1 year; 9 are alive and 
well, and 1 was free of disease when 
she died (Table IV). Of the 12 
patients with stage I disease, fol­
lowed up for less than 1 year, 11
Table 1. Comparison of Recurrence Rate and Follow-up*
Recurrence
4- Follow-up yr Yes No Total
< 2 2 21 23
> 2 7 20 27
A Total 9 41 50
*x2 =  1-47.
Table II. Stage and Type of Carcinoma in 50 Patients Studied
Group/stage Type ER+, no. V I+ , no. V I- ,  no.
1/1 ( / 7  =  10) Ductal 9 8 1
Lobular 1 1 _
1/11 (n= 12) Ductal 10 9 2
Lobular 2 1 _
1/IIIA (n =  5*) Ductal 5 4 2
2/I (rr=  12) Ductal 12 12 _
2/II (n= 10) Ductal 9 5 _
2/IIIA (rr =  1) Ductal 1 - 1
‘ One of these patients had bilateral tumours.
ER+ =  estrogen-receptor positive, VI+ =  vascular invasion, VI -  =  no vascular invasion.
Table III. Treatment Received by the Patients in the Study
Stage
Number of 
patients Treatment
I 11 Segmental mastectomy and axillary dissection with radiation to the
11
remaining breast 
Modified radical mastectomy
II 8 Segmental mastectomy and radiation to the remaining breast
14 Modified radical mastectomy
IIIA 1 Segmental mastectomy and radiation to the remaining breast
4 Modified radical mastectomy
1 Bilateral lumpectomy and radiation
CJS, VOL. 34. NO. 1. FEBRUARY 1991 23
COURTEMANCHE ET AL
are alive and well and 1, a 
56-year-old postmenopausal wom­
an, is alive with disease. She had 
local recurrence 11 months after 
segmental mastectomy and axillary 
dissection (0 /8  lymph nodes tested 
positive for malignant cells on cyto­
logic examination; tumour classifi­
cation: T1NOMO, ER+, VI — ).
Three patients in group 1 with 
stage 1 tumours had bone-marrow 
specimens immunohistologically 
positive to M8; all are alive and 
well.
There were 22 stage II patients: 
12 were followed up for more than 
2 years and 8 were alive and well at 
the last follow-up, 1 who died was 
disease-free and 3 were alive with 
recurrent disease. These three were 
a 62-year-old postmenopausal 
woman who had recurrence 31 
months after modified radical mas­
tectomy (14/20 lymph nodes exam­
ined cytologically were positive for 
malignant cells; tumour classifica­
tion: T2N1M0, ER+, VI+), a
94-year-old woman who had a re­
currence 36 months after biopsy 
and radiotherapy (tumour classifica­
tion: T2N0M0, ER+, VI —) and a 
54-year-old woman who had lumbar 
metastases 22 months after modi­
fied radical mastectomy (3/12 
lymph nodes were cytologically pos­
itive for malignant cells) and che­
motherapy (tumour classification: 
T2N0M0, ER+, V I-).
The 10 patients who had stage II 
disease and were followed up for 
less than 2 years were all alive and 
well at the last follow-up. The bone- 
marrow specimens did not stain 
with M8 in any of the patients with 
stage II disease.
Of the six patients with stage 
IIIA disease, five were followed up 
for more than 2 years: one was alive 
and well, and one, a 64-year-old 
woman, was alive with disease. She 
had a recurrence 41 months after 
preoperative chemotherapy followed 
by modified radical mastectomy
(0/12 lymph nodes cytologically 
positive for malignant disease) and 
postoperative chemotherapy (tu­
mour classification: T3BN0M0, 
ER+, VI+).
Three stage IIIA patients died of 
their disease. One was a 58-year-old 
postmenopausal woman who had 
recurrence 18 months after modi­
fied radical mastectomy (0/18 
lymph nodes cytologically positive 
for malignant cells; tumour classifi­
cation: T3N0M0, ER+, V I-). The 
second was a 40-year-old pre­
menopausal woman whose disease 
recurred 22 months after modified 
radical mastectomy (3/10 lymph 
nodes positive for malignant cells; 
tumour classification: T3N0M0,
E R -, VI+). The third was a 
40-year-old premenopausal woman 
whose disease recurred 17 months 
after modified radical mastectomy 
(8 /9  lymph nodes cytologically 
positive for malignant cells; tumour 
classification: T3N2AM0, ER+, 
VI — ).
The lone patient with stage IIIA 
disease and less than 2 years’ fol­
low-up, a 49-year-old premenopaus­
al patient, is alive with disease. She 
had recurrent disease 12 months 
after bilateral lumpectomy, treated
with radiotherapy and hormone 
therapy for bilateral tumours (tu­
mour classification: T3BN0M0, 
E R - ,  VI+). Her bone-marrow spec­
imens stained positively for malig­
nant disease with M8.
Overall, the bone-marrow speci­
mens of four patients stained posi­
tively with M8 (Table V). Three of 
these patients had stage I disease 
and were alive and well more than 2 
years after treatment. The fourth 
had stage IIIA disease with bilateral 
aggressive disease (Fig. 2); she was 
alive with disease 12 months after 
initial treatment. The three patients 
with stage I disease had positive 
cells that were not cytologically 
typical of metastatic disease (Fig. 
2).
The bone-marrow specimens of 
46 patients stained negatively for 
malignant disease with M8. Three 
of these patients died of their malig­
nant disease and five had recur­
rence. There was no statistically 
significant difference between 
groups 1 and 2 (Table VI).
Discussion
The aim of this study, which was
T a b le  IV . Follow-up and Outcome by Stage and Group
Group S tag e N um ber of 
patients O utcom e N um ber
1 I 10 Alive and well 9
Died w ithout disease 1
II 12 Alive and well 8
Died without disease 1
Alive with disease 3
IIIA 5 Alive and well 1
Alive w ith disease 1
Died of disease 3
2 I 12 Alive and well 11
Alive w ith disease 1
II 10 Alive and well 10
IIIA 1 Alive w ith disease 1
T a b le  V. Patients Whose Bone-Marrow Biopsy Specimens Stained Positive Using LICR-L0N-M8
Antibody
N um ber of
Group S tage patients O utcom e C ytologic findings
1 1 3 All alive and well Possible malignant cells
2 IIIA 1 Alive w ith disease Malignant cells
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designed in 1985, was to evaluate 
an investigational tool as a practical 
clinical test. Although more com­
plex and expensive methods of 
bone-marrow assessment, showing 
a theoretically higher yield of tu­
mour cells, have been described, the 
techniques used in this study were 
selected because they could readily 
be applied to all patients.1213 This 
invasive test was designed to be 
acceptable to patients, surgeons 
and the members of the ethics com­
mittees.
At this level of sophistication the 
test has not proved to be of prog­
nostic clinical value. More research 
needs to be done. At present we 
consider other methods too invasive 
or expensive to be used as routine 
clinical tests.
Large volumes of aspirated bone- 
marrow cells can be separated on a 
Ficoll-Hypaque gradient, and then 
the “buffy coat” can be selectively 
examined for tumour cells.12 Porro 
and associates13 reported that 17% 
of patients with breast carcinomas 
who had no cytologically positive
lymph nodes, had cytologically pos­
itive bone marrow when this separa­
tion technique and immunofluores- 
cent examination with the mono­
clonal antibody MBrl were used. 
This remains a research rather than 
a clinical tool.
The low (2% to 8%) level of 
detection in our study is not sur­
prising considering the nature of 
the disease and the patient popula­
tion being studied.14 Given the sur­
vival curves for breast carcinoma 
(5-year survival for stages I, II and 
IIIA: 85%, 70% and 50% respective­
ly), only 13 of the 50 patients 
studied would be expected to re­
lapse within 5 years. How many of 
these should we expect to have 
cytologically positive bone-marrow
specimens at the time of surgical 
management of primary tumours? 
Indeed, Mansi and colleagues15 
found that only 2 of 82 relapse-free 
patients had cytologically positive 
marrow specimens 18 months after 
mastectomy. Other investigators, 
reporting higher detection rates, 
have not selected their patients pro­
spectively and have more patients 
with advanced or prognostically un­
favourable tumours.16
In this prospectively studied 
group of patients the rate of detec­
tion is so low that a prohibitive 
number of patients would need to 
be accrued to show a statistically 
significant difference at a twofold 
difference in outcome. In addition, 
although the presence of tumour
Table VI. Comparison of Recurrence of Disease and Immunohistochemistry* 
Recurrence of disease
Immunohistochemistry Yes No Total
Positive 1 3 4
Negative 8 38 46
Total 9 41 50
*x 2 =  0.09, not statistically significant.
FIG. 2. Positive staining with LICR-LON-M8 antibody: (left) cytologically typical malignant cells in bone marrow; (right) not 
obviously malignant cells in bone marrow (avidin-biotin peroxidase complex technique with M8 as the primary antibody and 
hematoxylin counterstain, original magnification X 250).
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i
cells in bone marrow can be detect­
ed, a positive result has not yet 
been shown to be an independent 
prognostic factor; the positive test 
results have only been correlated 
with tumour stage and grade. The 
cells detected may be cytologically 
typical for metastatic disease. They 
may theoretically also be degenerat­
ing nonviable clones of tumour cells 
or a reaction of myeloid cells to 
circulating tumour antigen excess. 
Other investigators have reported 
“suspicious” nonmyeloid cells not 
definitely metastatic carcinoma.16
Many cancer researchers are hop­
ing that monoclonal antibodies will 
allow detection of the 15% of pa­
tients with stage 1 disease who 
suffer recurrence and die of their 
disease. Theoretically this would 
allow treatment of these patients 
with adjuvant chemotherapy and 
possibly improve their survival.7
Although monoclonal antibodies 
have enabled the detection of mi- 
crometastatic disease, more refine­
ment is required to produce a useful 
clinical tool. Perhaps this type of 
investigation would be better ap­
plied to a subgroup of patients 
selected after standard tumour stag­
ing and grading.
Conclusions
In patients with operable breast 
cancer monoclonal antibodies can 
be used to detect occult micrometa- 
static disease. The rate of detectable
micrometastatic disease is low (2%). 
There may be other reasons for 
positive staining of bone-marrow 
specimens. At present monoclonal 
antibody examination of specimens 
from four bone-marrow biopsy sites 
with LICR-LON-M8 antibody is not 
a practical prognostic test in pa­
tients with operable breast cancer.
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Nonoperative Management of Blunt 
Splenic Trauma in Adults
Wesley J. Stephen, Jr., MD;* Peter D. Roy, MD, FRCSC;t Philip M. Smith, MD;* 
Wesley J. Stephen, Sr., MD, FRCSCJ
The management of isolated blunt splenic trauma in adults is controversial. The 
authors present a series of 17 patients with blunt splenic trauma who were selected 
for nonoperative management. Only one patient eventually required surgery, for a 
ruptured spleen. Complications included pneumonia (two cases) and pleural 
effusion, atelectasis and ileus (one case each). There were no deaths. Five patients 
required transfusion, for a total of 17 units of blood. The mean length of hospital 
stay was 9.4 days. Comparison with a group of 17 patients treated operatively 
during the same period showed that those treated nonoperatively had fewer 
complications, required less blood and had a similar length of hospital stay. The 
authors conclude that nonoperative management of selected patients with isolated 
blunt splenic trauma is safe, if the patient’s condition is closely monitored.
Le traitement des contusions et ruptures de la rate par traumatisme ferme chez 
l’adulte est un sujet de controverse. Les auteurs presentent une serie de 17 cas 
initialement traites sans intervention chirurgicale. Une telle intervention ne fut 
eventuellement necessaire que dans un seul cas de rupture. Parmi les complications, 
il y eut deux cas de pneumonie et un cas chacun d’epanchement pleural, d’atelectasie 
et d’ileus. II n’y eut aucune mortality Seulement cinq malades eurent besoin de 
transfusion sanguine, pour un total de 17 unites de sang. La duree moyenne de 
sejour fut de 9.4 jours. Une etude comparative de 17 malades operes pour 
traumatisme de la rate pendant la meme periode de temps revele que les malades 
traites sans intervention eurent moins de complications, moins de transfusions et 
une duree de sejour comparable. Le traitement selectif des traumatismes fermes de la 
rate par methode nonoperatoire peut etre entrepris en toute securite lors qu’il y a 
surveillance clinique etroite.
U ntil recently, the standard treatment for all injuries to the 
spleen was splenectomy. Atelecta­
sis, pleural effusion and early post­
operative infection have long been 
recognized as complications of sple­
nectomy. In 1952, King and Schu- 
macker1 described the syndrome of 
susceptibility to late infection after 
splenectomy in infants, and subse­
quent studies23 outlined a small but 
clear risk of overwhelming gram­
positive infection in patients of all 
ages after splenectomy. This led to 
the landmark studies from Toron­
to4-6 on nonoperative management 
of splenic injury in children. How­
ever, the literature is lacking, and 
somewhat contradictory, with re­
spect to the nonoperative manage­
ment of isolated blunt splenic trau­
ma in adults.
The concerns of nonoperative 
management include delayed splenic 
rupture, delay in recognizing other 
intra-abdominal injuries and a pos­
sible decrease in healing potential 
within the adult splenic architec­
ture. Other potential disadvantages 
are increased requirement for blood 
products, longer hospitalization and 
the possibility of delayed operation 
for ongoing hemorrhage.
The purpose of this study was to 
review our experience with nonop­
erative management of isolated 
blunt splenic trauma in adults with 
respect to success rate, hospital 
stay and blood requirements. In 
addition, we looked at a group of 
patients who underwent early oper­
ation for isolated splenic trauma 
during the same period at the same 
institutions.
Patients and Methods
The charts of 66 patients who 
sustained blunt splenic trauma and 
were seen between January 1980 
and December 1987 at Saint John 
Regional Hospital and Saint Jo­
seph's Hospital, Saint John, NB, 
were reviewed. These two institu­
tions are university hospitals that
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are staffed with attending surgeons 
and general surgical residents. The 
diagnosis of blunt splenic trauma 
was made at laparotomy or from 
liver-spleen scanning, ultrasonog­
raphy, computed tomography or 
from a combination of these investi­
gations.
Of the 66 patients, 21 adults had 
other major multiple-system inju­
ries and 11 were children under 14 
years of age. These 32 patients 
were excluded, leaving 34 patients 
for study.
Patients were treated operatively 
or nonoperatively at the discretion 
of the attending surgeon and 
housestaff; there were 17 in each 
group. There were no formal guide­
lines for the choice of therapy. We 
could not reliably extract from the 
charts details on the presence or 
absence of clinical signs, except for 
evidence of hypotension on admis­
sion to the emergency department. 
There was no randomization of pa­
tients. Interestingly, all nine sur­
geons inolved in the study had 
patients in both the operative and 
nonoperative groups.
The patients treated nonopera­
tively were managed with bed rest, 
monitoring of vital signs, frequent 
examination by housestaff and sur­
geons and serial blood counts. Pa­
tients treated operatively underwent 
laparotomy promptly.
pressure less than 90 mm Hg) com­
pared with only two (12%) of the 
nonoperative group; four (24%) of 
the nonoperative patients had de­
layed presentation (at 2, 7, 15 and 
21 days after trauma), but only one 
(6%) of the operative group present­
ed late (2 days after injury). This 
suggests that the patients in the 
operative group were more serious­
ly injured.
The operative patients had differ­
ent investigations from those in the 
nonoperative group (Table III). 
Thirteen (76%) of the operative pa­
tients had a positive diagnostic peri­
toneal lavage (DPL), whereas none 
of the conservatively treated pa­
tients had DPL. Three patients un­
derwent immediate laparotomy on 
purely clinical grounds. In another 
operative patient the diagnosis was 
made by liver-spleen scanning. In 
the conservatively treated patients 
the diagnosis was most frequently 
made by liver-spleen scanning (14
patients), followed in frequency by 
ultrasonography (5 patients) and 
computed tomography (1 patient). 
Several patients had multiple inves­
tigations. Two patients with a nega­
tive ultrasonogram and one patient 
with a negative computed tomogra­
phy scan subsequently underwent 
liver-spleen scanning, which gave 
positive results and, for the purpose 
of the study, was considered diag­
nostic.
There was no difference in the 
length of hospital stay (Table IV), 
but fewer patients treated nonoper­
atively required transfusions, and 
those who did so required less 
blood than patients in the operative 
group. Patients treated nonopera­
tively had fewer complications than 
those in the operative group (Table 
V).
Only one patient failed nonopera­
tive management and required lapa­
rotomy with resultant splenectomy 
on hospital day 6. In the operative
T a b le  1. Demographic Characteristics of Adults with Blunt Splenic Trauma According to Type of
Management
C h a ra c te r is t ic
N o n o p e ra t iv e
( n  -  1 7 ) O p e ra tiv e
Mean age, yr 30.6 32.8
Sex, M/F 17/0 11/6
Mechanism of injury, no. of patients 
Motor vehicle accident 10 10
Sports 2 3
Fall 4 3
Assault 1 1
-4
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Findings T a b le  II. Features of Presentation
N onopera tive , n u m b er of O perative , num ber of
Demographically the two groups F eatu re patien ts  (% ) patien ts  (% )
were similar in regard to age and Systolic blood pressure < 9 0 m m H g  2(12) 5(29)
mechanism of injury (Table I). In- Delay in presentation 4(24) 1(6)
terestingly, all six women in the 
study were in the operative group. 
The reason for this is not clear.
Although it was difficult to ascer­
tain physical signs and symptoms 
accurately, Table II compares two 
objective factors at the time of 
initial presentation: five (29%) of 
the operative patients presented 
with hypotension (systolic blood
T a b le  II I .  Comparison of Diagnostic Techniques
Technique
N onopera tive , num b er of 
investiga tions
O perative , num ber of 
investigations
Peritoneal lavage 0 13
Liver-spleen scanning 14 1
Abdominal ultrasonography 7* 0
Computed tomography 2* 0
Clinical diagnosis alone 0 3
'Includes two false-negative ultrasonograms and one false-negative computed tomography scan.
<
4
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group, 15 patients underwent sple­
nectomy; 2 had already achieved 
hemostasis and no further action 
was required. No patient underwent 
splenic repair or required reopera­
tion. There were no deaths in either 
group.
Discussion
The epidemiologic characteristics 
of both groups of patients are con­
sistent with those of previous re­
ports with respect to age, sex and 
mechanism of injury. Although 
both of our groups appear to be 
representative of isolated blunt sple­
nic injury, patients in our operative 
group were clearly more seriously 
injured. A clear selection bias is 
present, and any direct comparison 
between the two groups must be 
considered with this in mind. Never­
theless it is equally clear that trans­
fusion requirements, complications 
and length of hospital stay in our 
nonoperative group were entirely 
within acceptable limits. Nallatham- 
bi and colleagues7 warned clinicians 
about increased transfusion require­
ments and longer hospital stays for 
patients treated nonoperatively, but 
the findings of our study do not 
support this.
Only one patient in our nonoper­
ative group required operation with 
splenectomy after a trial of nonop­
erative management, for a failure 
rate of 6%. This is in keeping with 
favourable reports,8' 14 citing failure 
rates of zero to 41%, in which 
failure is defined as the necessity 
for an operation, with or without 
resultant splenectomy. In sharp 
contrast, other reports715-18 quote 
failure rates of 67% to 78%. The 
reason for this discrepancy is not 
clear. Possibly the unfavourable re­
ports contained “unselected” pa­
tients, including those in shock, or 
the indications for eventual surgical 
intervention were more liberal.
It is interesting that no patient 
from the nonoperative group under­
went DPL, but 13 patients (76%) in 
the operative group did, and all 
DPLs were positive. A positive tap 
was an indication for laparotomy in 
this study, which is is keeping with 
the Advanced Trauma Life Support 
guidelines19 and current surgical 
practice.
In summary, it is safe to observe 
adult patients with isolated blunt 
splenic trauma as long as the pa­
tient’s condition is stable at the 
time of presentation and close mon­
itoring of clinical status is possible.
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Table IV. Length of Hospitalization and Transfusion Needs*
Variable Nonoperative Operative
Length of hospital stay, d 9.4 9.6
Patients transfused, no. 5 12
Mean blood transfusion, units (range) 1.0 (0 -5 ) 3.0 (0-9)
'Patients were not randomized. Selection bias may be present.
Table V. Complications*
Complication Nonoperative Operative
Pneumonia 2 2
Pleural effusion 1 2
Atelectasis 1 1
Ileus 1 3
Wound infection 0 1
Urinary tract infection 0 1
Late operation 1 0
Death 0 0
Splenectomy 1 15
‘ Patients were not randomized. Selection bias may be present.
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W ound Infections in Orthopedic 
Effect of Extended Surveillance 
on Infection Rate
P. Pearce, RN; M. McKenzie, RN, BScN; G. Taylor, MD, FRCPC
Substantial evidence now exists that ongoing surveillance of surgical wound 
infections can contribute to reduced infection rates. What is not yet determined is 
whether surveillance should be limited to the postoperative hospital stay or should 
be continued after patient discharge. To determine the number of infections 
occurring after discharge, the authors contacted a random sample of their patients 
who did not have wound infections during their hospitalization after orthopedic 
surgery. This was done 30 days after the procedure. The authors selected 273 
patients of 1375 who underwent orthopedic surgery over a 7-month period and were 
able to contact 199 (73%). At the 30-day follow-up 23 patients (11.6%) had wound 
infections, as judged by wound discharge and physician prescription of antibiotics in 
20 and the patient’s description of pus issuing from the wound in 3. During the 
same period postoperative wound infections were found in only 19 (1.5%) of 1278 
patients who were subjected to in-hospital surveillance.
The authors conclude that, in patients who undergo orthopedic procedures, the 
majority of wound infections occur after discharge from the hospital and that 
infection rates based only on in-hospital surveillance greatly underrepresent true 
surgical wound infection rates for orthopedic procedures.
11 existe maintenant des preuves concluantes que la surveillance suivie des 
infections de plaies peut contribuer a faire diminuer le taux d’infections. II n ’a pas 
encore ete determine si cette surveillance devait se limiter au seul sejour hospitalier 
ou si elle devait etre poursuivie apres le conge de l’hopital. Dans le but d’etablir le 
nombre d’infections qui surviennent apres la sortie de l’hopital, les auteurs ont 
communique, avec un echantillonnage aleatoire de leurs patients qui n’avaient pas 
souffert d’infection au cours de leur hospitalisation pour chirurgie orthopedique. 
Ceci eut lieu 30 jours apres l’operation. Les auteurs ont choisi 273 patients parmi 
les 1375 qui avaient subi une chirurgie orthopedique au cours d’une periode de 7 
mois; ils ont reussi a en rejoindre 199 (73%). A en juger par la suppuration de plaie 
et la prescription d’antibiotiques chez 20 patients, et la description par le malade de 
pus s’ecoulant de la plaie chez 3 autres, il y avait infection de plaie chez 23 patients 
(11.6%) au controle du 30e jour. Durant la meme periode, des infections postopera- 
toires de plaies ont ete observees chez seulement 19 (1.5%) des 1278 patients qui 
furent soumis a une surveillance dans un hopital.
Les auteurs concluent que, chez les patients qui subissent une chirurgie 
orthopedique, la majorite des infections de plaies survient apres le conge de 
I’hopital, et qu’un taux d’infection base uniquement sur une surveillance hospita- 
liere sous-evalue considerablement les taux reels d’infections de plaies consecutives 
aux interventions orthopediques.
From the Infection Control Unit, University o f  Alberta Hospitals, Edmonton 
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Surgery:
Evidence is accumulating that routine surveillance for surgical 
wound infections with feedback of 
data to practising surgeons can re­
duce overall wound infection rates. 
As a result there is increasing inter­
est in this infection-control tech­
nique.1-3 The Centers for Disease 
Control in Atlanta4 and the Labora­
tory Centre for Disease Control in 
Ottawa5 both recommend use of 
this technique, as did the Surgical 
Infection Society, which also en­
dorsed it as a technique effective in 
reducing morbidity and costs relat­
ed to surgical wound infection.6
For hospitals or surgical special­
ties embarking on this form of 
surveillance, consideration must be 
given to the need for long-term 
follow-up. A number of studies have 
compared post-discharge infection 
rates with those from inpatient sur­
veillance alone.578 However, the 
value of post-discharge surveillance 
may vary from one surgical subspe­
cialty to another and from one 
institution to another. We have car­
ried out surgical surveillance on 
wound infections after orthopedic 
surgery for over 2 years. We be­
came concerned that our inpatient 
surveillance data might be unrealis­
tically low, because of the early 
discharge or transfer of patients. 
Therefore we undertook a tele­
phone survey of patients 1 month 
postoperatively to assess the value 
of this surveillance technique in our 
population.
Methods
The University of Alberta Hospi­
tals (UAH) is a 1355-bed hospital,
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acting as a tertiary referral centre 
for northern Alberta and western 
Northwest Territories. There are 11 
practising surgeons in the Division 
of Orthopedic Surgery. Inpatient 
surgeon-specific wound surveillance 
began in March 1987.
On a daily basis, an infection-con­
trol practitioner (ICP) collects op­
erating-room data sheets on all pa­
tients who undergo orthopedic sur­
gery. Beginning 48 hours postoper- 
atively, the ICP observes directly all 
surgical incisions not covered by 
plaster casts and returns every 48 
to 72 hours for 2 weeks or until the 
patient is discharged. The ICP 
takes wound swabs when wound 
abnormalities are evident.
Wounds were classified on the 
clean-dirty spectrum by standard 
criteria.9 Patients who died or were 
discharged less than 48 hours post- 
operatively were not considered in 
the analysis. Patients whose inci­
sions were covered by plaster casts 
for the entire duration of hospital­
ization but in whom there was no 
suggestion of infection (e.g., fever, 
pain, swelling) were considered as 
noninfected and so entered into the 
denominator. A wound infection 
was diagnosed if: (a) the ICP ob­
served pus issuing from the incision 
(excluding drain sites and stitch 
abscesses); (b) the ICP observed 
serosanguineous drainage and 
wound redness, and a culture was 
positive for a known pathogen (ex­
cluding common skin commensals); 
(c) deep-seated surgically related 
wound infection (e.g., osteomyelitis) 
was diagnosed by the surgeon, and 
the incision was not infected; or (d) 
the surgeon diagnosed wound infec­
tion associated with wound abnor­
malities that did not fit into any of 
the above categories.
The data were entered into a 
computer, and, with the use of the 
AICE software system designed for 
hospital infection control surveil­
lance and data management,10
monthly infection rates by surgical 
class were generated for each sur­
geon and the division as a whole. 
Surgeons were sent data on their 
own infection rates, with details on 
infections detected, as well as a 
report on the entire division’s infec­
tion rates. Summaries of 6- and 
12-month rates were also distribut­
ed.
Beginning in March 1988, for a 
7-month period, patients who un­
derwent regular inpatient wound 
surveillance but did not have a 
wound infection during that time 
were randomly selected by means of 
a random number generator in the 
AICE program, and contacted 30 
days after their surgical procedure. 
An ICP telephoned the patients and 
asked a standardized set of ques­
tions. If the patient was still in the 
UAH the chart was reviewed. If the 
patient was in another hospital, the 
nursing station at that hospital was 
contacted. Patients who were not 
available on the first attempt were 
called on two further occasions, and 
if contact was still not made the 
patient was removed from the 
study. At this time a wound infec­
tion was diagnosed: (a) if a physi­
cian had examined the incision and 
had made a diagnosis of wound 
infection (as stated to the patient or 
implied by the prescription of treat­
ment in association with wound 
abnormalities) or (b) if, having not 
seen a physician since discharge 
from hospital, the patient described 
pus issuing from the wound (ex­
cluding stitch abscesses).
This information was added to 
the basic information already en­
tered into the computer.
Findings
During the 7-month survey peri­
od 1375 patients underwent ortho­
pedic inpatient procedures: 1278 
(93%) were suitable for inpatient 
wound infection surveillance; 336 
(26%) had plaster casts covering 
their incisions up until discharge, 
so the incisions were not directly 
inspected but were assumed to be 
noninfected. Two hundred and sev­
enty-three were selected for the 
30-day follow-up. Of these, 199 
(73%) were contacted. The 74 not 
contacted were similar by age and 
sex to the group contacted. Within 
the group of 199 patients contact­
ed, 55 (28%) had not had the 
incision inspected because they had 
a plaster cast but had since had the 
cast removed or changed, so pres­
ence or absence of incisional abnor­
malities could be determined. When 
contacted 30 days postoperatively, 
only 20 were still in the UAH; 141 
had been discharged home, 13 to a 
local community hospital and 25 to 
a rehabilitation hospital. Table I 
shows surgical wound infection 
rates for the inpatient survey period 
and the extended survey group. Of 
the 23 wound infections diagnosed 
in extended follow-up, 4 (17%) oc­
curred in patients whose incision 
was not observed during their inpa­
tient stay because of a plaster cast. 
Three infections (13%) were diag-
Tab le  1. Wound Infections Found During Hospitalization and After Discharge in Patients Who 
Underwent Orthopedic Surgery
In -h o sp ita l, no. 30  d a fte r d ischarge .
Typ e  of in fec tions /no . no. in tections/no .
procedure patien ts (%  in lec tio n ) patien ts (%  infection)
Clean 11/1067 (1,03) 12/168 (7.1)
Clean-
contaminated 0 /4 9  (0) 1 /4 (25)
Contaminated 0 /1 8  (0) 0 /2  (0)
Dirty 8 /144  (5.56) 10/25 (40)
Totals 19/1278 (1.49) 23/199 (11.6)
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nosed by the patient’s description of 
pus and 20 (87%) by a physician’s 
diagnosis (11 by the surgeon and 9 
by the patient’s general practition­
er); 14 patients received antibiotic 
therapy.
Discussion
It is unlikely that any surveil­
lance system could routinely detect 
all wound infections, nor is it neces­
sary that all be detected, since the 
proposed mechanism by which 
wound infections are reduced by 
this technique is by permitting sur­
geon-surgeon comparisons, not 
comparison against an ideal. How­
ever, a surveillance system that de­
tects very few of the actual infec­
tions runs the risk of being coun­
terproductive by engendering a 
false sense of security among the 
recipients of the data. Other studies 
using active case-detection tech­
niques similar to ours have shown 
that substantial numbers of infec­
tions can be detected by postdis­
charge surveillance;6-8 none have 
shown such a large proportion as in 
our study. If the 199 randomly 
selected patients contacted 4 weeks 
after surgery were representative of 
the 1259 patients who did not have 
a wound infection at the end of the 
inpatient surveillance period, 145 
wound infections would have been 
detected in this group. It is clear, 
therefore, not only that extended 
surveillance is much more effective 
at detecting wound infections but 
also that, by relying on inpatient 
surveillance, we have been greatly 
underestimating the true infection 
rate. If we add the 19 inpatient 
infections detected to the 145 infec­
tions that would be detected by 
30-day telephone surveillance there 
would potentially be 164 wound 
infections in this population, only 
12% of which were detected by our 
current surveillance technique.
The diagnosis of wound infection 
made by telephone survey may be 
questioned. Certainly, routinely 
bringing the patient back to the 
hospital for direct examination or 
even going to the patient’s home to 
examine the incision11 would be 
preferable. This is impractical for a 
long-term program, particularly 
when many patients do not reside in 
the city where the surgery was 
performed. We, like others, relied 
on a physician’s diagnosis of wound 
infection6-8 or, if the patient had 
not seen a doctor, on the patient’s 
description of “pus” (discharge of 
opaque fluid from the incision). Ex­
tending the duration of follow-up 
during inpatient wound surveillance 
would not appear to be effective, 
since at the 30-day contact point 
very few patients were still in hospi­
tal. Consequently, some form of late 
follow-up appears necessary if a 
reasonable estimate of the true in­
fection rate is to be made. Relying 
on patient- or doctor-initiated re­
porting of infection is most unlikely 
to detect consistent numbers of 
infections.1213 Some form of active 
surveillance is, therefore, necessary.
The clean wound infection rate of 
7.1% found in this survey is much 
higher than that generally reported 
for inpatient surveillance pro­
grams13 but is not dissimilar to 
rates found in other long-term fol­
low-up studies.6-8 The number of 
wound infections diagnosed is di­
rectly related to the method of 
detection, breadth of the definition 
and the duration of follow-up. Con­
sequently, comparison of rates be­
tween studies should only be under­
taken when these factors are avail­
able. The effects of extended sur­
veillance on surgical infection rates 
are well documented in the medical 
literature.6-814 In our patients, a far 
higher percentage of wound infec­
tion occurred after discharge (89%) 
than previous studies have docu­
mented. Those studies did not focus 
particularly on orthopedic patients, 
who may differ from other surgical 
patients in this regard. For exam­
ple, the presence of a plaster cast 
prevents a proportion of inpatient 
wounds from being examined. This 
makes inpatient orthopedic wound 
surveillance difficult; 26% of the 
inpatients in our study could not 
have their incisions directly inspect­
ed during their hospital stay be­
cause of a cast. To delete such 
patients from the denominator 
would create a major gap in the 
completeness of our surveillance 
program, and, consequently, we 
chose to consider the wounds in 
these patients as not infected unless 
other signs of infection were pres­
ent. Nevertheless, minor incisional 
abnormalities diagnostic of infec­
tion could be present and only 
become apparent after discharge 
when the cast is removed. This 
factor was a major contributor to 
the number of infections diagnosed 
after discharge.
Orthopedic patients may be dis­
charged home or transferred to re­
habilitation units outside the hospi­
tal more rapidly or frequently than 
patients who have undergone other 
types of surgery. Furthermore, be­
cause our hospital is a tertiary care 
hospital, many surgical patients are 
transferred to their local hospital 
for convalescence.
We have discussed our findings 
with our orthopedic colleagues. Al­
though they support the wound 
surveillance program they wish to 
have data that reflect more closely 
the true infection rates, particularly 
for patients in whom the conse­
quences of infection are most seri­
ous. We plan, therefore, to make 
extended surveillance a permanent 
part of our program for patients 
who undergo joint replacement and 
possibly to include other groups at 
a later date.
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Detecting Breast Cancer 
After Reduction Mammoplasty
Reductive breast surgery may give rise to parenchymal scarring that makes 
subsequent clinical and radiologic assessment of tumours difficult. The features that 
help distinguish benign from malignant lesions are discussed. Biopsy is still 
necessary. A screening protocol that includes preoperative mammography in 
patients at increased risk is proposed.
La chirurgie conservatrice du sein peut provoquer une cicatrisation 
parenchymateuse qui rend difficile 1’evaluation clinique et radiologique future des 
tumeurs. Les caracteristiques qui aident a distinguer les lesions malignes des 
lesions benignes sont exposes mais la biopsie demeure toujours necessaire. Un 
protocole d’examen qui comprend la mammographie preoperatoire chez les patientes 
a risque eleve est propose.
H ypertrophy of the female breast is common and is often 
severe enough to cause negative 
effects both physically and psycho­
logically. These effects can be alle­
viated by surgical reduction. How­
ever, the parenchymal scarring that 
may arise after surgery can interfere 
with clinical and radiologic exami­
nation of the breast for cancer. The 
incidence of breast cancer is such 
that it will develop in 1 in 11 
women during their lifetime.12 It is 
therefore important that we be able 
to identify lesions that may be ma­
lignant. We present two cases of 
breast cancer after reduction mam­
moplasty.
Case Reports
Case 1
A 53-year-old woman presented 
with an 8-month history of sagging 
and inversion of the right nipple. 
Fourteen years earlier she had had 
a bilateral mastopexy. No recent 
mammogram was available. There 
were no strong risk factors for 
breast carcinoma. She had under­
gone a hysterectomy and unilateral 
oophorectomy for menorrhagia at 
44 years of age.
Physical examination revealed a 
mobile thickening, 2 to 3 cm in 
diameter, in the upper, inner quad­
rant of the right breast. The nipple 
was inverted and directed inferiorly 
(Fig. 1). There were no clinical 
findings to suggest metastatic dis­
ease. Mammography was arranged 
and she was referred to a general 
surgeon.
The mammogram revealed a spi- 
culated mass lesion suggestive of 
carcinoma (Fig. 2). Fine-needle aspi­
ration was carried out, and the 
aspirate was positive for malignant 
cells.
The patient underwent a modified 
right radical mastectomy. Patholog­
ical examination revealed a poorly 
differentiated, infiltrating, lobular 
carcinoma (Fig. 3); three of eight 
lymph nodes were positive for ma­
lignant cells. No signs of metastasis 
were found and she was referred for 
adjuvant chemotherapy.
Case 2
A 58-year-old woman had a re­
mote (1973) history of stage II 
infiltrating ductal carcinoma of the 
right breast that had been treated 
by modified radical mastectomy fol­
lowed by adjuvant radiotherapy to 
the chest wall and regional nodes. 
She had had postmastectomy recon­
struction with a myocutaneous flap. 
A reduction mammoplasty of the 
left breast was performed in 1984 
because of asymmetry. She had a 
revision of her mammoplasty in 
1985. It is of note that she had 
been taking Climacteron (testoster­
one and estradiol in oil) from 1979
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until 1987. She had also undergone 
a hysterectomy in 1968 for uterine 
fibroids.
Shortly after the revision mam- 
moplasty she had noted firmness in 
the upper portion of her left breast. 
In late 1987 a firm ridge developed 
in the upper outer quadrant of the 
left breast, associated with nipple 
inversion and puckering of the 
overlying skin. When she was seen 
4 months later, mammography re­
vealed a poorly defined, spiculated 
lesion 3.7 cm in diameter. Open 
biopsy was performed, and patho­
logical examination confirmed a 
moderately to poorly differentiated 
ductal carcinoma with dermal inva­
sion.
The risk factors included a 
strong family history: both a first- 
and a second-degree relative had 
died of metastatic breast carcinoma 
postmenopausally. Initial mammog­
raphy done in 1973 was interpreted 
as being consistent with bilateral 
fibrocystic disease. She had under­
gone mammography annually since 
her initial mastectomy until 18 
months prior to this presentation.
Further examination was sugges­
tive of metastatic disease in the 
liver, but the results were inconclu­
sive and she was placed on a treat­
ment protocol for locally advanced 
carcinoma.
Discussion
The Relation Between Breast 
Surgery and Cancer
The effect of surgical reduction 
of the female breast on the subse­
quent incidence of breast carcinoma 
is not known. Some believe that it 
may increase the risk of cancer. In 
1957, at a meeting of the American 
Society of Plastic and Reconstruc­
tive Surgery, Maliniac reported a 
case of breast cancer after reduction 
mammoplasty, involving a free nip­
ple graft, and proposed that damage 
to the mammary ducts gives rise to 
ductal stasis and may increase the 
neoplastic potential.3
It has also been hypothesized 
that removal of breast tissue pro­
portionately decreases the number 
of foci for potential neoplasia and 
should therefore decrease the sub­
sequent risk of carcinoma.4 This 
view is supported by Snyderman 
and Lizardo,5 who studied the num-
FIG. 1. Case 1. Inverted, interiorly 
directed nipple in breast with carcino­
ma.
ber of malignant lesions found be­
fore or during surgery or in routine 
sectioning of the resected tissues 
after reduction mammoplasty. They 
found a frequency of 0.4%. This 
represents a three- to fourfold in­
crease over the rate found in the 
general population and suggests 
that early occult lesions are being 
resected.6 A recent study by Lund, 
Ewertz and Schou4 supports this 
concept. They found a decreased 
relative risk of 0.59 for breast can­
cer after reduction mammoplasty, 
though this was statistically signifi­
cant only after 10 years of follow­
up. The relative risk was further 
decreased in women with reduction 
specimens weighing more than 
600 g bilaterally. They concluded 
that women who undergo reduction 
mammoplasty for breast hypertro­
phy run no greater risk of breast 
carcinoma than does the general 
population and that after 10 years
FIG. 2. Case 1. Mammogram showing 4-cm spiculated mass lesion with associated 
thickening and retraction of overlying skin.
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they show a significantly decreased 
risk.
Differentiating Benign 
Postoperative Changes From 
Carcinoma
Reduction mammoplasty could, 
perhaps, lead to the earlier detec­
tion of evolving tumours by allow­
ing more accurate clinical and self- 
examination than is possible with 
large, pendulous breasts.7 However, 
mammography performed after re­
duction mammoplasty may reveal 
changes similar to those associated 
with carcinoma.2 Mammographic or 
clinically palpable masses seen post- 
operatively may represent scarring, 
deep-seated hematoma, fat necrosis, 
benign mammary disease or malig­
nant disease; thus, assessment of 
these patients is difficult.8 If mam­
mography is to be of diagnostic 
value we must recognize the 
changes that may be seen in the 
breast, after either breast biopsy or 
reduction mammoplasty.
Postoperative benign mammo­
graphic changes can be divided into 
two major types: soft-tissue
changes and calcifications. The 
soft-tissue changes include skin 
thickening and retraction, architec­
tural distortions and asymmetric 
densities with spiculated or irregu­
lar margins and typically a central 
lucency.2910 Calcifications are 
coarser and less clustered in lesions 
that are benign. Iatrogenic lesions 
are most commonly present in the 
periareolar and inferior pole tissues, 
representing the areas of maximal 
surgical trauma and subsequent pa­
renchymal scarring.2
Mammographic changes sugges­
tive of malignant disease, on the 
other hand, include asymmetric 
densities, mass lesions with irregu­
lar or spiculated margins and cen­
tral opacity, thickening and retrac­
tion of the overlying skin, and 
punctate, clustered microcalcifica­
tions.10’11
Other factors differentiating post­
operative mammographic changes 
from those of malignant disease 
include the tendency of benign 
changes to resolve naturally and the 
lesser symmetry of spiculations, 
which also lack continuity with any 
overlying skin changes.29 Although
these features are helpful, they are 
often inadequate, and tissue biopsy 
is required to differentiate between 
malignant and postoperative benign 
iatrogenic lesions. Fine-wire local­
ization techniques may be necessary 
for abnormalities that are not palpa­
ble.
Clinical findings may also be 
helpful, in that palpation of a be­
nign scar typically reveals a vague 
thickening of a size that corre­
sponds to the mammographic ab­
normality, whereas an infiltrating 
carcinoma typically is firmer and 
larger than the mammographic ab­
normality.9
Screening Guidelines
Guidelines for surveillance in 
women who seek or have had breast 
reduction surgery would help physi­
cians identify, appropriately investi­
gate and treat any malignant lesions 
that do develop. We offer a screen­
ing protocol for this purpose (Fig. 
4), which includes monthly self- 
examination and regular examina­
tion of the breast and regional 
lymph nodes by a physician or 
experienced nurse clinician.
Preoperative and early postopera­
tive mammography (at 3 to 6 
months) would help delineate 
changes occurring secondary to 
surgery and rule out occult preop­
erative lesions. Along with clinical 
and self-examination of the breast, 
mammography must be considered 
in women more than 35 years old 
or with risk factors for breast carci­
noma. Further mammography 
should be requested on the basis of 
results and according to the recom­
mendations of the American Cancer 
Society (baseline mammography at 
35 to 40 years of age, periodic 
examinations between the ages of 
40 and 50 years and annually after 
the age of 50 years).6
Successive mammography in a 
given patient should be carried out
FIG. 3. Case 1. Section of breast tissue shows presence of poorly differentiated 
infiltrating lobular carcinoma (hematoxylin and eosin, original magnification X 
1000).
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Patients Seeking Reduction Mammoplasty
>35 yr 
risk factors clinical lesion
MAMMO RAPHY
<35 yr
no risk factors
NO MAMMOGRAPHY
STAGING
BASELINE MAMMOGRAPHY
( 3 - 6  mo postop)
REDUCTION MAMMOPLASTY
SBE & CBE
Follow-up with SBE/CBE and mammography as indicated by baseline and ACS recommendations
FIG. 4. Algorithm for screening in patients who undergo reduction mammoplasty. 
SBE =  self breast examination, CBE =  clinical breast examination, ACS =  
American Cancer Society.
at the same radiology suite to facili­
tate comparison of initial and fol­
low-up films. The responsibility for 
appropriate mammographic evalua­
tion should be that of both the 
primary care physician and the sur­
geon involved.
In those who, like our second 
patient, have had surgery for breast 
cancer and seek a reduction mam­
moplasty of the other breast to 
regain symmetry, a prophylactic 
mastectomy and immediate recon­
struction might be considered. Ei­
ther a silicone gel prosthesis or a 
pedicled regional flap could be used 
for reconstruction. This could ne­
gate the otherwise increased chance 
of a second primary developing and 
avoid the difficulties associated with
mammographic and clinical assess­
ment of the breast after reduction.
The use of a consistent screening 
protocol in women who either plan 
to have or have had reduction mam­
moplasty could lead to earlier detec­
tion of malignant disease, thereby 
reducing the overall morbidity and 
mortality.
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A Simplified Protocol for Banking Bone 
From Surgical Donors Requiring a 90-Day 
Quarantine and an HIV-1 Antibody Test
A.J.P. La Prairie BSc, TBS;* M. Gross MB, FRCS, FRCSCf
The banking of femoral heads from patients who undergo total hip arthroplasty 
provides a valuable resource for orthopedic surgery. Quality assurance of the 
banked bone used in clinical procedures requires documented policies for screening, 
procuring, storing and distributing.
Potential donors are screened at the time of donation for malignant disease, 
possible communicable disease, sepsis and high-risk life-styles. After negative 
culture results are confirmed and appropriate documentation has been completed, 
the bone is frozen at -7 0 °C . A quarantine period of 90 days follows. The donor is 
followed up 90 days or more postoperatively. At that time written consent is 
obtained for donation of the recovered tissue to the bone bank and for serology 
testing for human immunodeficiency virus (HIV-1) antibody, hepatitis B surface 
antigen (HBsAG), hepatitis B core antibody (HBcAb) and syphilis, and the donor is 
rescreened for contraindications.
This protocol meets or exceeds all existing standards. The combination of 
obtaining consent and serology testing at 90 days streamlines the logistics of 
banking bone from surgical donors.
La conservation des tetes de femurs provenant des patients qui subissent une 
arthroplastie complete de la hanche est la source d’un materiau d’une grande valeur 
en chirurgie orthopedique. L’assurance de la qualite des os conserves pour les 
interventions futures exige Tusage de politiques etablies pour effectuer la selection, 
le prelevement, la conservation et la distribution.
Au moment d’effectuer leur don, les donneurs potentiels sont soumis a des 
epreuves de depistage du cancer, des maladies transmissibles, des infections et des 
modes de vie a risque eleve. Apres confirmation des resultats negatifs par culture et 
apres obtention de la documentation appropriee, Tos est congele a -70 °C . Une 
periode de quarantaine de 90 jours suit. Le donneur fait l’objet d’une surveillance 
postoperatoire d’au moins 90 jours. A ce moment, le donneur signe une formule de 
consentement pour le don du tissu preleve et pour des epreuves de depistage 
serologique des anticorps au virus immunodeficitaire humain (VIH-1), de l’antigene 
de surface du virus de l’hepatite B (HBsAG), des anticorps a Tantigene nucleocapsi- 
dique de l’hepatite B (anti-HBc) et pour le test VDRL; le donneur fait aussi l’objet 
d’un nouveau depistage des contre-indications.
Ce protocole rencontre ou depasse toutes les normes actuelles. L’obtention apres 
90 jours du consentement ecrit, associee au epreuves de depistage serologique 
rationalise la logistique de la banque d’os provenant de donneurs chirurgicaux.
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F emoral heads and other bones from patients treated surgically 
for such conditions as osteoarthritis 
and hip fractures are an available 
resource for orthopedic surgery. 
Common uses o f allogeneic banked 
bone are as follows: (a) re-establish­
ing structural bone stock;*-3 (b) 
enhancing bone fusion (spinal sur­
gery);4-7 and (c) enhancing osseous 
integration of prostheses in arthro- 
plastic surgery.8"10
Autogeneic bone is the graft of 
choice.1112 It has several advan­
tages: there is no immune response 
or possibility o f viable peripheral 
osteoblast cells and no chance of 
disease transfer. However, lack of 
sufficient available bone, increased 
surgical time, blood loss associated 
with harvesting o f autogenous 
grafts, pain at the donor site and 
morbidity provide sufficient argu­
ments for the use o f allogeneic 
banked bone.2-613-17 
Quality assurance of banked bone 
requires documented standards for 
donor selection, tissue recovery, 
preservation techniques, storage, 
record keeping and distribution.18 
These allograft femoral heads must 
be free o f potentially transmissible 
diseases and sepsis. In 1988, the 
first documented case o f human 
immunodeficiency virus (HIV) trans­
mitted from a femoral head trans­
plant was reported.19 This motivat­
ed a proposal at a recent Canadian 
conference on allografts in orthope­
dic surgery that a test for the HIV 
antibody be done 90 days postoper­
atively on all living bone donors.20 
The American Association o f Tissue 
Banks (AATB) issued a revision to
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its standards.21 As of January 1988, 
the association advised that: (a) 
an absolute quarantine be placed 
on all tissues from living donors for 
at least 90 days; (b) after 90 days 
the donor be tested for the HIV 
antibody; and (c) the tissue be re­
leased for distribution only if the 
results of the tests for the HIV-1 
antibody are negative.
Protocols for banking bone from 
surgical donors have been well esta- 
blished41516-22' 24 but do not include 
the required quarantine and testing 
of the donor at 90 days for HIV-1 
serology.
In a recent survey of Canadian 
hospitals25 it was concluded that 
many inadequacies exist in the op­
eration of bone banks, including 
lack of consent from living donors 
and testing for the HIV-1 antibody.
In light of the increased interest 
in allograft bone transplantation, 
the possibility of transmitted dis­
ease and the medicolegal implica­
tions, we believe that a review of 
the practice of banking bone from 
surgical donors is due. This review 
must include reference to the new 
standards in HIV testing and ad­
dress the required patient consent 
for both release of tissues and the 
confidential serologic testing.
A protocol has been established 
at the Victoria General Hospital in 
Halifax (Fig. 1) that meets or ex­
ceeds all documented standards of 
the AATB, the Centers for Disease 
Control in Atlanta and the US Food 
and Drug Administration. The pro­
tocol addresses the required written 
consent for donation and serologic 
testing and the 90-day quarantine 
followed by HIV antibody testing. 
We believe this protocol provides 
necessary guidelines for Canadian 
bone banks.
Methods
The osteoarthritic patient receiv­
ing a hip prosthesis is screened by 
the surgeon for contraindications 
(Table I). Biopsy specimens (2 X 
bone nibbles, not swabs) are taken 
from the femoral head for aerobic 
and anaerobic cultures. The bone is 
then soaked in a 10% Proviodine 
solution, placed in a plastic dispos­
able jar (500 mL), sterile-wrapped 
sequentially with three freezer bags 
and passed off to the circulating 
nurse. An operating-room drape is 
added for protection, and a patient 
addressograph label is attached (in-
FIG. 1. Flow chart of process required 
to place acceptable donor femoral head 
in bone bank.
eluding name, identification number 
and date of birth). The donor infor­
mation form is filled out, including 
the surgeon’s name, the donor’s 
name, identification number, blood 
type, Rh factor, confirmation of 
screening, diagnosis and surgery 
performed. The form is signed by 
the surgeon and the circulating 
nurse. The wrapped femoral head is 
placed in a locked refrigerator 
maintained at 5°C and equipped 
with temperature monitor and 
alarm. The bone bank is notified. 
All documentation is sent to the 
bone-bank office.
Initial aerobic and anaerobic cul­
ture results are reported (by phone) 
to the bone bank after 48 hours. If 
they are negative, the bone is trans­
ferred to a freezer maintained at 
-70°C  and equipped with highl­
and low-temperature alarms. A 
technologist is on call at all times in 
case the unit fails. Access to this 
freezer is limited to the technologist 
and the bone-bank director. A chart 
recorder is in place to confirm main­
tenance of temperature. Once a 
week the freezer temperature moni­
tors and alarm are checked (cali­
brated if necessary) and the findings 
documented.
A confidential donor file, com­
plete with an assigned unique donor 
number (e.g., 89-101) is main­
tained at the bone bank. A final 
report of the results of the cultures
Table I. Contraindications to Donation of 
Bone to the Bone Bank
Recurrent or chronic infections 
Systemic viral infections 
History of viral hepatitis 
Malignant disease
Slow nerve viruses (Creutzfeldt—Jakob 
disease, rabies) or history 
Metabolic bone diseases (e.g., rheumatoid 
arthritis)
Long-term steroid therapy 
Disease of unknown etiology (systemic 
lupus erythem atosus, A lzhe im er’s 
disease, rheumatoid arthritis)
High-risk life-style or history 
Recipients of human derived growth factor 
hormone
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is sent to the bone bank after 6 
days. A report of positive culture 
results is brought to the attention 
of the bone-bank director for inter­
pretation.
A bone-bank follow-up sticker 
(Fig. 2) is sent to the medical 
records department at the end of 
the 90-day postoperative quaran­
tine. This “flag” is placed on the 
outer cover of the outpatient chart 
to remind the surgeon to obtain 
consent and samples for serologic 
testing at the clinical follow-up, at 
least 90 days after the tissue was 
harvested.
At the clinic, the patient’s social 
and medical history and postopera­
tive recovery are reviewed against 
any further possible contraindica­
tions to donation. Written consent 
is obtained for donation of bone and 
for serologic testing to screen for 
the HIV-1 antibody, hepatitis B sur­
face antigen (HBsAG), hepatitis B 
core antibody (HBcAb) and syphilis 
(VDRL test). Test results are direct­
ed in confidence to the bone-bank 
medical director.
FIG. 2. Large sticker applied to patient 
chart after 90-day quarantine period. 
Sticker acts as “flag” to remind physi­
cian to obtain written consent and 
serologic testing.
If the patient refuses consent, the 
refusal is noted in the bone-bank 
file, and the bone is discarded. 
Abnormal results for any of the 
serologic tests mandates that the 
femoral head be subjected to fur­
ther clinical study and that it be 
discarded if the test results are 
positive. All abnormal results are 
reported to the surgeon.
When the results of the serologic 
tests, the consent forms and the 
laboratory reports are complete, the 
donor file is reviewed and signed by 
the bone-bank medical director. The 
tissue is labelled with the unique 
donor number and is placed in the 
available bone inventory section of 
the bone-bank freezer, and the in­
ventory list is updated.
The surgeon may request a femo­
ral head from the bone bank. A 
minimum of 24 hours’ notice is 
required to confirm the availability 
of Rh-compatible bone-graft materi­
al and to deliver it to the operating 
room on time. Every effort is made 
to use bone-graft material that has 
been donated by one of the sur­
geon’s own patients.
The file for that femoral head is 
then rechecked by the technologist, 
its distribution is noted, and it is 
delivered to the operating room, 
complete with instructions and a 
recipient form. The recipient form 
includes the unique donor number, 
donor blood type (ABO and Rh) and 
name of the issuing technologist.
The circulating nurse confirms 
that the donor number on the allo­
graft package matches the recipient 
form and relays information to the 
surgeon about blood type, Rh fac­
tor and use of Proviodine at the 
time of procurement.
The outer plastic wrap is opened 
by the circulating nurse and the 
bone is transferred to the sterile 
table. A small biopsy specimen is 
taken for culture (results are sent to 
bone bank). The bone is soaked in a 
warm (40°C) antibiotic solution of
80 mg tobramycin, 1 g cefazolin 
(Kefzol) and 50 000 U bacitracin 
per 1000 mL of Ringer’s lactate 
solution for at least 10 minutes 
before use.
The completed recipient form in­
cludes recipient’s name, identifica­
tion number, diagnosis, surgeon’s 
name, surgery performed and use of 
allograft bone. A copy may be main­
tained in the patient chart. If not, 
the unique donor number is record­
ed in the surgical report. The origi­
nal recipient form is maintained in 
confidence by the bone bank. The 
bone bank also retains any reports 
of adverse reactions or problems.
Only femoral heads that have not 
been used and are promptly re­
turned to the bone bank are consid­
ered acceptable for reuse. Any bone 
that has been exposed to the recipi­
ent operating field but not used, or 
has been used in part, is unaccept­
able.
An unused, returned bone graft 
is accompanied by a statement as to 
the course of the graft and the 
reason for return. Acceptance of 
this graft is determined by the 
bone-bank medical director.
Discussion
Donor Screening
Donors are typically patients who 
undergo total joint replacement for 
osteoarthritis or femoral-head frac­
ture. They are otherwise healthy 
individuals, free of malignant dis­
ease (with the exception of primary 
basal cell tumour of skin following 
excision), absence of infection or 
history of communicable disease 
(Table I). Diseases of unknown eti­
ology (rheumatoid arthritis, autoim­
mune diseases, systemic lupus ery­
thematosus) and life-styles consid­
ered to be at high risk (intravenous 
drug abuse, recipients of clotting 
factor concentrate, sexual activity
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at risk for AIDS) are also contrain­
dications to donation.18 26
Complete screening of social and 
medical history cannot be overem­
phasized. A small but definite rate 
of false-negative results is possible 
with serologic testing, indicating 
that use of bone from patients in 
high-risk groups is not acceptable 
despite negative serologic results 
for HIV-1 and hepatitis B.27 Sero­
logic tests for many viruses that 
slowly affect nerves are not avail­
able; only a clinical observation of 
rapid dementia may indicate the 
presence of disease.28 Age does not 
preclude the usefulness of the bone- 
graft material, but may make it 
more difficult to obtain an accept­
able medical history and rule out 
disease-related dementia (e.g., 
Creutzfeldt-Jakob disease, Alz­
heimer’s disease, rabies). No con­
fused or demented patient should 
be accepted as an organ, blood or 
tissue donor.29
Currently there are no approved 
serologic tests for screening blood 
and tissue donors for non-A, non-B 
hepatitis (NANB).30 Nonspecific 
means of screening against NANB 
include surrogate testing for 
HBcAb and screening with respect 
to the medical and social histo­
ries.3031 The American Red Cross 
now screens all blood donors for 
human T-cell lymphotrophic virus 
type I (HTLV-1).32 This is not cur­
rent practice in Canada since 
HTLV-1 has a lower prevalence in 
the general population, so that 
there is a greater chance of a 
false-positive result; also, the speci­
ficity of the test is low in Canadian 
subjects. A summary of current 
serologic tests and acceptable re­
sults is presented in Table II.
Screening for contraindications 
should be continued at the postop­
erative follow-up examination. Any 
clinical observations of swollen 
lymph nodes, prolonged high body 
temperature, infection or high leu-
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kocyte count should be noted. 
These may not be absolute con­
traindications but could be evidence 
of potential disease or infection.
Cultures
Swabs for culture are of minimal 
or no value.33 Biopsy or curettage 
are better procedures. Specimens 
are transferred to the microbiology 
laboratory in dry sterile containers 
with appropriately marked requisi­
tions. They should not be placed 
into liquid media. Specimens taken 
at time of procurement are labelled 
“Donor.” A second specimen ob­
tained at the time of implantation is 
labelled “Graft.”
The bone chips or soft-tissue bi­
opsy specimens are cultured in 
cooked meat broth at 37°C for 6 
days. They are observed for growth 
over the incubation period. If 
growth is observed, or at day 6, the 
specimen is subcultured onto blood 
agar aerobically and BHI agar an­
aerobically at 37°C for 48 hours. 
All isolates from these specimens 
are considered pathogens, including 
diptheroids and coagulase-negative 
staphylococci. If growth is from the 
“Donor” specimen, only identifica­
tion is required. If the growth is 
from the “Graft” specimen identifi­
cation and susceptibility testing are 
carried out on each isolate. Records 
of culture results from all graft 
specimens are maintained to help 
provide a view to quality assurance 
of the bone-bank program.
Quarantine
The AATB standards18 state that 
“tissues from all living donors shall 
be held in quarantine for at least 
90-days at which time the donor 
shall be tested for human im­
munodeficiency virus (HIV) anti­
body. Only if tests are negative for
HIV shall tissue be released for 
distribution.” This quarantine is 
considered necessary in order to 
accommodate the window of time 
between exposure to the virus and 
production of antibodies.3435 Most 
published reports suggest that the 
majority of cases show positive se­
rologic results for the HIV-1 anti­
body by 9 weeks.36"40 Cohen and 
associates41 estimated the risk of 
HIV-1 transmission by transfusion 
at 0.003% (30 per million). Ward 
and colleagues34 estimated the risk 
of transmission of HIV-1 at 26 per 
million transfusions. A recent re­
port by the American Red Cross42 
stated that the probability of expo­
sure to the AIDS virus from the 
screened blood supply in the United 
States in 1987 was 1:156 000 (6 in 
1 million). Our protocol calls for 
rescreening of the social and medi­
cal histories and review of the post­
operative follow-up at the clinical 
interview at least 90 days after 
procurement of the femoral head. 
By providing a quarantine of 12 or 
more weeks before testing for the 
HIV-1 antibody, it should be possi­
ble to reduce the risk a further 
99%.37 The risk by comparison 
would be less than 30 in 100 mil­
lion.
We believe that an increase of the 
quarantine period from 12 weeks to 
24 weeks as is the case for repro­
ductive tissues19-26-43 is unwarranted 
when a documented protocol for 
screening of medical and social his-
Table II. S u m m a ry  o f A cce p ta b le  R esu lts  
o f  S e ro lo g ic  T e s ts
Test Acceptable result
H IV-1 a n tib o d y  (E IA
sc re e n ) N egative
H BsAg N egative
H B cA b N egative
V D R L  (s y p h ilis ) N o n -re a c tive
Rh fa c to r P o s it iv e /n e g a tiv e
B lood  typ e A /B /A B /0
EIA =  E n z ym e -lin ke d im m u n o s o rb e n t as-
say , H BsAG  =  h e p a tit is  B su rface  an tigen ,
H B cA b =  h e p a tit is  B co re  a n tib o d y .
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tory accompanies HIV-1 antibody 
testing more than 90 days after 
surgical procurement. This ratio­
nale is supported by the Federal 
Centre for AIDS and the Working 
Group on HIV Infection in Organ 
and Tissue Transplantation, Health 
and Welfare Canada (A.J. Clayton, 
W. Schlech: Personal communica­
tion 1990).
“Flag” Method
Our experience has shown that 
most surgeons forget to obtain 
written consent for donation of har­
vested bone before surgery. They 
usually remember during the course 
of the hip replacement. This prob­
lem, combined with the 90-day 
quarantine for postoperative HIV 
testing, has led us to the protocol 
of obtaining written consent and 
doing all serologic testing at least 
90 days postoperatively at the clini­
cal follow-up.
A large red sticker or “flag” (Fig. 
2) was designed to be attached to 
the outer jacket of the patient file 
or chart and serves to remind the 
surgeon that the patient’s femoral 
head has been stored in the freezer 
and that consent for use and for 
serologic testing must be obtained.
Each consent form is accompa­
nied by stepwise instructions for the 
review of the donor’s history and 
clinical follow-up against possible 
contraindications, by instructions to 
obtain consent and details of sero­
logic tests to be obtained and by a 
note instructing the laboratory to 
send the results to the bone bank.
We believe this method of flag­
ging can also be applied to patients 
followed in a private office or an 
outside clinic, if staff notification 
and instructions are appropriate. 
Our own clinic is now adapting this 
to the hospital computer system. 
When the patient comes to the 
clinic, the data sheet automatically
includes a flag to request donation 
and perform screening.
Consent
Femoral head bone banks should 
adhere strictly to established guide­
lines for testing, reporting and con­
fidentiality.44-45 There should be no 
testing for the HIV antibody with­
out informed, written consent.32-37-46 
The patient should be apprised of 
the nature of bone banking and the 
need for screening and serologic 
testing.
Consent must include permission 
for donation of the bone for trans­
plant and for serologic testing. It 
must be obtained in writing and 
must name all the tests to be per­
formed (AIDS, hepatitis, syphilis). It 
should also state that all results are 
kept confidential and that any ab­
normal results are forwarded to the 
patient’s physician. It is the respon­
sibility of the physician to interpret 
the results of the test for the pa­
tient.38
We have instituted a system of 
obtaining consent after the 90-day 
quarantine period. The patient usu­
ally does not have to consent to the 
removal of the femoral head, since 
this is implicit in the surgical proce­
dure. After the 90-day quarantine is 
the most appropriate time for 
screening for HIV-1 antibody, and 
this test is pivotal to the use of the 
femoral head for bone grafting. 
Asking patients at this stage is 
ethical because the treatment has 
not changed as a result of taking 
the femoral head and will not 
change whether consent is given or 
not. We find that few patients re­
fuse consent at this stage.
The result of our protocol is a 
one-step procedure providing the 
90-day quarantine for AIDS testing 
with written consent. There is no 
potential complication of dilution 
due to transfusion of blood pro­
ducts during surgery.47 This proto­
col has the advantage of providing 
review of the medical history 
against contraindications at two 
stages and allowing a review of the 
postoperative clinical course.
Packaging
Packaging of the femoral head in 
a plastic container and three freezer 
bags has a number of advantages: 
an aseptic barrier is provided; water 
loss due to cold storage is eliminat­
ed; the disposable plastic container 
allows easy handling and removal of 
the frozen bone at implantation; the 
bone may also be thawed in warm 
antibiotics and damage to the outer 
wrap from the sometimes sharp 
bony edges of the graft is prevent­
ed; at the time of use, the outer bag 
is opened by the circulating nurse 
and the bone, still packaged in the 
two inner bags, is presented to the 
scrub nurse. The extra inner bag 
allows for the possibility of error in 
opening the package.
The patient addressograph label 
placed on the package at the time 
of procurement contains all immedi­
ate information required for bone- 
bank processing. When the allo­
graft is considered acceptable for 
implantation (after all results are 
reported) this label is removed and 
the individual donor number is at­
tached.
A label (or accompanying leaflet) 
is also attached, stating that the 
serologic results of graft specimens 
were negative for HIV-1 antibody, 
HBsAg, HBcAb and syphilis. It also 
gives information about the blood 
type and Rh factor and use of 
Proviodine at time of procurement.
Bone-Graft Storage
Long-term storage of allograft 
bone requires cold storage at tem-
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peratures below — 60 °C. This cold 
environment is below the eutectic 
point of bone48 and is cold enough 
to inhibit the degradative enzyme 
activity of collagenases.49 The freez­
er should be equipped with high- 
temperature alarm sensors and a 
chart recorder to verify mainte­
nance of environment.26 This sys­
tem should be checked and the 
temperature documented weekly 
with a manual alcohol thermometer. 
Access is limited to bone-bank per­
sonnel to prevent loss of banked 
bone and potential use of bone that 
has not been released for trans­
plant.
By providing a second smaller 
refrigerator or freezer for tempo­
rary storage, it is possible to main­
tain limited access to the bone 
freezer and allow bone to be stored 
in a holding location until the re­
sults of the initial 48-hour cultures 
are known. This system helps re­
duce the possibility of contamina­
tion of the bone freezer and allows 
retrieved femoral heads to be depos­
ited by operating-room staff.
It is important to place accept­
able bone grafts in a physically 
separated part of the freezer and to 
document the placement systemati­
cally; this reduces the possibility of 
removing a graft that has not been 
approved and facilitates inventory 
checks of available allograft bone.
Antibiotic Prophylaxis
The 10% Proviodine solution, in 
which the bone is soaked at the 
time of procurement, is used as an 
antiseptic, because antibiotics re­
quire an incubation period before 
they are effective. The bone is 
thawed with a solution of bacitracin 
with an aminoglycoside (to­
bramycin) and cephalosporin (Kef- 
zol). It provides wide-spectrum anti­
biotic prophylaxis50-53 against the 
major aerobic and anaerobic patho­
gens. This protocol is similar to 
that used with large, open, surgical 
wound procedures54-56 and allograft 
bone applications.57 Thawing of 
bone before use provides an effec­
tive incubation period for the antibi­
otics and also allows the washing 
out of the residual Proviodine from 
the graft. The antibiotic solution 
may be substituted for the initial 
soaking in Proviodine, if desired.
The patient should also be main­
tained on an appropriate antibiotic 
prophylactic regimen, directed 
against the common pathogens as­
sociated with all orthopedic proce­
dures.57 We currently use a third- 
generation cephalosporin.
Rh Status o f Donor Bone
The Rh status of donor bone 
must be documented and the recipi­
ent’s surgeon made aware.58 This is 
most important with allograft pro­
cedures to Rh-negative women with 
potential childbearing years remain­
ing, although anti-Rh(D) immuno­
globulin therapy is possible.59
Record Keeping
A surprisingly large number of 
forms have to be completed to 
maintain quality control of surgical 
bone grafts (see Table III). Instruc­
tions for screening, procurement, 
consent, serologic testing and use 
of graft are required to standardize 
these procedures, especially when a
variety of medical and nursing staff 
may be involved.
Documentation of screening, pro­
curement, consent, culture and se­
rology results are also necessary for 
complete and accurate records (Ta­
ble III).18-23-26 A section in the sero­
logic and culture results form 
should also include documented ap­
proval for release of tissue by the 
bone-bank director.
Also required is a recipient form. 
This form may combine graft infor­
mation (Rh factor, date of procure­
ment, serologic tests) as well as a 
section to be completed at the time 
of grafting, documenting recipient 
information, use of the graft, the 
surgeon’s name and a notice stating 
that any adverse reactions should 
be reported to the bone bank.60 The 
recipient form may be in duplicate, 
one copy to remain in the patient’s 
chart and the other returned to the 
bone bank.
If the recipient form cannot be 
included with the patient chart, the 
unique donor number is recorded 
on the operative report.
Use of a personal computer for 
database, inventory and word pro­
cessing is ideal61 to maintain accu­
rate physical records, help with in­
ventory, produce forms and tabu­
late incomplete serology and micro­
biology reports.
Personnel
Daily operations, record keeping 
and distribution of allografts may
Table III. Standardized Form s o f Instruc tion  and D ocum entation Required fo r Banking Bone From
Surgical Donors
Form Type Description
FH1 Instruction Screening and procurem ent ins tructions
FH2 Instruction 90 -day postoperative screening, consent and sero log ic 
ins tructions
FH3 Instruction Instruc tions fo r clin ica l application
FH4 Docum ent P rocurem ent and screening docum entation
FH5 Docum ent W itnessed consent fo rm
FH6 Docum ent Record o f testing and release signature
FH7 D ocum ent Graft statem ent, recip ient data and adverse reaction fo rm
<
A.
XX
-4.
4  *
A
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be performed by a designated tech­
nologist or operating-room staff 
member. Overall operation of the 
bone bank, release of acceptable 
tissues and verification of docu­
mented policies is the responsibility 
of the bone-bank medical director.18
Protocols are written and updat­
ed from recommendations made by 
clinicians, operating-room nursing 
staff and the departments of pathol­
ogy and microbiology.
Conclusions
Standards for banking bone from 
surgical donors now include a 
90-day quarantine, at which time 
the donor is tested for the HIV-1 
antibody. This quarantine empha­
sizes the need for dedicated equip­
ment and documented standards in 
donor selection, tissue recovery, 
preservation techniques, storage, 
record keeping and distribution.
The screening of medical and 
social histories, and serologic test­
ing for HIV-1 antibody, HBsAg, 
HBcAb and syphilis after a 90-day 
quarantine minimize the risks of 
transmitting disease through the 
graft. This is a safe and effective 
program, which streamlines the pa­
perwork and handling of banked 
surgical bone. The methodology de­
scribed meets or exceeds criteria set 
by the Centers for Disease Control 
in Atlanta, the US Food and Drug 
Administration and the AATB.
The authors gratefully acknowledge the 
operating-room nursing staff and the 
staff in the Department of Microbiolo­
gy, Department of Immunology and 
Department of Orthopedics at the Victo­
ria General Hospital, Halifax, for their 
assistance and suggestions.
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Addendum
Effective Aug. 1, 1990, The Ameri­
can Association of Tissue Banks 
(AATB) (as stated in its newsletter 
volume 13, number 3) requires that 
all tissue donors be screened for the 
antibody to the hepatitis C virus 
(HCV). Although questions have 
been raised as to the sensitivity and 
specificity of current tests, they are 
being applied in the screening of all 
volunteer blood donors by the 
American and Canadian Red Cross 
societies. A positive result from an 
HCV test would require that the
banked tissue be discarded. Absence 
of a confirmatory antigen test ne­
cessitates the counselling of living 
donors about the possibility of 
being positive for HCV.
Future test kits may be of better 
benefit in screening HCV from 
those in non-high-risk groups. 
Meanwhile, this test will replace the 
hepatitis B core antibody (HBcAb) 
test described in our paper.
In a recent newsletter (volume 
13, no. 4, 1990) the AATB stated 
that, effective Apr. 1, 1991, an 
increase in the quarantine will be 
required for surgical bone donors, 
from 90 to 180 days. After that 
time the donor is to be screened for 
human immunodeficiency (HIV-1) 
and HCV antibodies.
This increase in the quarantine 
appears to be in response to the 
possibility of long-delayed serocon­
version and brings surgical bone 
donation in line with banking of 
reproductive tissues from living do­
nors. In our view, as described in 
detail in our paper, this increase in 
quarantine may not add any sub­
stantial benefit in terms of reducing 
the risk of HIV-1 transmission. It 
may even make the banking of 
surgical bone less feasible and re­
sult in more orthopedic practices 
opting for cadaveric bone banking, 
for which there is no option for 
quarantine and no way of account­
ing for the window of time between 
exposure and seroconversion.
In the banking of human tissue 
for clinical transplantation there 
will always be improvements to pro­
tocols and screening criteria. The 
value of these new applications 
should be weighed with consider­
ation given to the prevalence of 
cases at risk in the donor popula­
tion and the increased costs of 
application.*
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When choosing an antibiotic for nosocomial infections,
LOOK BEYOND 
THE PRICE TAG.
Look at the safety profile and total cost of treatment.
Significant biliary excretion of antibiotics can have a very disruptive effect on 
intestinal flora, which may promote the emergence of resistant strains of bacteria and 
cause diarrhea.12 This can add substantially to the cost of treatment.3
CLAFORAN (cefotaxime sodium) has an excellent safety profile. With only 5% biliary 
excretion, Claforan has little effect on intestinal flora, thus reducing the risk of 
diarrhea and bacterial resistance.14 And Claforan provides excellent coverage of 
major nosocomial pathogens.
Over a complete course of therapy, if one looks at the average cost per patient, 
Claforan makes good sense.5
1. GuggenbichlerJP et al. J Antimicrob Chemother 1984;14(Suppl B):pg. 67-70.
2. Hooker KD, Dipiro JT. Clin Pharm 1988;Vol 7:pg. 878-888.
3. Gladen HE et al. Infect Surg 1986;5 (10) :559-572.
4. Alcock SR, Update in Intensive Care and Emergency Medicine 1989;7:102-108.
5. Bivens BA et al. Diag Microbiol Infect Dis 1989;12:113-118.
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P R E S C R IB IN G  IN F O R M A T IO N  
Action
In vitro studies indicate that the bacterial action of Claforan (cefotaxime sodium) a semi-synthetic cephalosporin 
antibiotic, results from inhibition of cell wall synthesis.
Indications and Clinical Uses
Treatm ent: Claforan (cefotaxime sodium) may be indicated for the treatment of infections caused by susceptible 
strains of the designated micro organisms in the diseases listed below.
Lower resp ira to ry  tract in fe c tio n s : pneumonia and lung abscess caused by Streptococcus pneumoniae 
(formerly Diplococcus pneumoniae), other streptococci (excluding enterocci, e.g. S. faecalis), Straphylococcus 
aureus (penicillinase and non-penicillinase producing), Escherichia coli, Hemophilus influenzae, (including 
ampicillin resistant strains) and unspecified Klebsiella species.
Urinary tra c t in fec tions : caused by Escherichia coli, unspecified Klebsiella species (including K. pneumoniae), 
Proteus mirabilis, indole positive Proteus, Serratia marcescens and Staphylococcus epidermidis. Also, uncomplicated 
gonorrhea caused by N. gonorrhoeae including penicillin resistant strains.
Bacteremia /  Septicem ia: caused by Escherichia coli, unspecified Klebsiella strains and Serratia marcescens. 
Skin in fe c tio n s : caused by Staphylococcus aureus (penicillinase and non-penicillinase producing, S. epidermidis, 
Group A streptococci, Escherichia coli, Proteus mirabilis and indole positive Proteus.
In tra -abdom inal in fec tions: caused by Escherichia coli, and unspecified Klebsiella species.
Gynecologica l in fec tions: including pelvic inflammatory disease, endometritis and pelvic cellulitis caused by 
E. coli, Group A streptococci and Staphylococcus epidermidis; anaerobic bacteria including unspecified Peptococcus 
and Peptostreptococcus strains and some strains of Bacteroides fragilis. In several cases, although clinical cures 
were achieved, bacteriological follow-up was not available.
Central nervous system in fe c tio n s : meningitis and ventriculitis caused by Haemophilus influenzae, Neisseria 
meningitidis, Streptococcus pneumoniae, Klebsiella pneumoniae and Escherichia coli. Claforan is not active 
against Listeria monocytogenes.
Clinical experience with Claforan in anaerobic infections is limited. Claforan has been used with some success in 
wound and intra-abdominal infections against some strains of unidentified Bacteroides and anaerobic cocci. 
Claforan has been shown to be active against some strains of Pseudomonas.
In the treatment of infections encountered in immunosuppressed and granulocytopenic patients, results of therapy 
with Claforan have not been impressive.
Claforan should not be considered in the treatment of enterococcal infections, i.e. Streptococcus faecalis. 
Specimens for bacteriologic culture should be obtained prior to therapy in order to isolate and identify the causative 
organisms and to determine their susceptibilities to Claforan. Therapy may be instituted before results of susceptibility 
studies are known; antibiotic treatment should be re evaluated once these results become available.
Prophylactic U s e : The administration of Claforan perioperatively (preoperatively. intraoperatively and postoperatively) 
may reduce the incidence of certain infections in patients undergoing elective surgical procedures (e.g. abdominal 
or vaginal hysterectomy, gastrointestinal and genitourinary tract surgery) that may be classified as contaminated or 
potentially contaminated.
In patients undergoing caesarian section who are considered to be at increased risk of infection, intraoperative 
(after clamping the umbilical cord) and postoperative use of Claforan may also reduce the incidence of certain 
postoperative infections.
Effective use for elective surgery depends on the time of administration (see Dosage and Administration).
For patients undergoing gastrointestinal surgery, preoperative bowel preparation by mechanical cleansing as well as 
with a non absorbable antibiotic (e.g. neomycin) is recommended.
If there are signs of infection, specimens for culture should be obtained for identification of the causative organism 
so that appropriate therapy may be instituted.
Contraindications
Claforan is contraindicated in patients who have shown hypersensitivity to cefotaxime sodium, the cephalosporin 
or the penicillin groups of antibiotics.
Warnings
Before therapy with Claforan is instituted, it must be carefully determined whether the patient has had previous 
hypersensitivity reactions to cefotaxime, cephalosporins, penicillins or other drugs. Claforan should be given with 
caution to patients with Type 1 hypersensitivity reactions to penicillin. Antibiotics, including Claforan should be 
administered with caution to any patient who has demonstrated some form of allergy, particularly to drugs. If an 
allergic reaction to Claforan occurs, the drug should be discontinued and the patient treated with the usual agents 
(e.g. epinephrine, antihistamine, pressor-amines or corticosteroids).
Pseudom em branous colitis has been reported w ith  the use of cephalosporins (and other broad spectrum 
antib io tics); therefore, it is im portan t to consider its diagnosis in patients who develop diarrhea during 
the adm in is tra tion  o f Claforan. This co litis  can range from  m ild to life-threatening in severity.
Treatment with broad spectrum antibiotics, such as Claforan, alters the normal flora of the colon and may permit 
overgrowth of Clostridium difficile or other Clostridia. It has been established that a toxin produced by Clostridium 
difficile is one primary cause of antibiotic-associated colitis.
Mild cases of colitis may respond to discontinuation of Claforan and replacement with a suitable specific antibiotic. 
Moderate to severe cases should be managed with fluid, electrolyte and protein supplemntation as indicated.
When the colitis is not relieved by discontinuance of Claforan administration or when it is severe, an antibiotic 
specifically effective in antibiotic-associated pseudomembranous colitis (eg. vancomycin) or other suitable therapy 
may be indicated. Other possible causes of colitis should also be considered (see Adverse Reactions). 
Precautions
Claforan (cefotaxime sodium) should be prescribed with cauton in individuals with a history of lower gastro­
intestinal disease, particularly colitis.
The safety of Claforan in pregnancy has not been established. Consequently, use of the drug in pregnant women 
requires that the likely benefit from the drug be weighed against the possible risk to the mother and fetus.
Use of Claforan in women of child-bearing potential requires that the anticipated benefits be weighed against the 
possible risks.
Cefotaxime is excreted in human milk in low concentrations. Caution should be exercised when the drug is 
administered to nursing mothers.
Prolonged use of Claforan may result in the overgrowth of nonsusceptible organisms. Constant evaluation of the 
patient’s condition is essential. If super-infection occurs, therapy should be discontinued and appropriate measures 
taken.
Although Claforan rarely produces alterations in kidney function, evaluation of renal status is recommended, 
especially in severely ill patients receiving high doses.
Patients with markedly impaired renal function should be placed on the special dosage schedule recommended 
under Dosage and Administration, because normal dosage in these individuals is likely to produce excessive and 
prolonged serum antibiotic concentrations.
Positive direct Coomb’s test is known to develop in individuals during treatment with the cephalosporin group of 
antibiotics, including cefotaxime sodium.
In laboratory tests a fatso positive reaction to glucose may occur with reducing substances but not with the use 
of specific glucose oxidase methods.
Adverse Reactions
The most frequent adverse reactions with their frequency of occurrence are:
H ypersensitiv ity  (1.8%): Rash, pruritus, fever. Local (5%): Injection site inflammation with intravenous 
administration. Pain, induration and tenderness after intramuscular injection. Gastrointestinal (1.7%): Colitis, 
diarrhea, nausea and vomiting. Symptoms of pseudomembranous colitis can appear during or after Claforan 
treatment. H em ic and Lymphatic System ( <  1%): Mild, reversible leukopenia, granulocytopenia and thrombo­
cytopenia have been reported. Some patients developed positive direct Coomb’s test during treatment with 
Claforan. G en itourinary System ( <  1%): Moniliasis, vaginitis. Liver ( <  1%): Transient elevations in SGOT, SGFT,
serum LDH and serum alkaline phsphatase levels have been reported. Kidney ( <  1%): Increased serum creatinine 
and BUN have occasionally been observed. Central Nervous System (0.2%): Headache.
Symptoms and Treatment of Overdosage
Since no case of overdosage has been reported to date with Claforan, no specific information on symptoms or 
treatment is available. Treatment of overdosage should be symptomatic.
Dosage and Administration
Claforan (cefotaxime sodium) may be administered intramuscularly or intravenously after reconstitution (see Table 
with recommended mode of reconstitution according to route of administration).
Adults
The dosage of Claforan should be determined by susceptibility of the causative organisms, severity of the infection 
and condition of the patient.
Guidelines for Dosage of Claforan (cefotaxime sodium)
Type of Infection
Daily Dose 
(9) Frequency and Route
Uncomplicated Gonorrhea 1 1 g IM (single dose)
Uncomplicated infections 2 1 g every 12 hours IM or IV
Moderately severe to severe infections 3-6 1-2g every 8 hours IM or IV
Very severe infections (e.g. septicemia, CNS) 6-8 2g every 6-8 hours IV
Life-threatening infections up to 12 2g every 4 hours IV
To prevent postoperative infection in contaminated or potentially contaminated surgery, recommended doses are 
as follows.
(a) 1 g IM or IV administered 1/2 to 1-1/2 hours prior to the initial surgical incision to ensure that adequate 
antibiotic levels are present in the serum and tissues at the start of surgery
(b) 1 g IM or IV administered 1-1/2 to 2 hours following the first dose; for lengthy operative procedures, additional 
intraoperative doses may be administered, if necessary, at appropriate intervals (1-1/2 to 2 hours) during surgery
(c) 1 g IM or IV administered within 2 hours following completion of surgery 
The total cumulative prophylactic dose should not exceed 6 g in a 12 hour period.
Caesarian Section Patients
The first dose of 1 g is administered IV as soon as the umbilical cord is clamped. The second and third doses 
should be given as 1 g IM or IV at 6 and 12 hours after the first dose.
Neonates, Infants, and Children
The following dosage schedule is recommended:
Neonates: 0-1 week of age 50 mg / kg IV q 12 h
1-4 weeks of age 50 mg / kg IV q 8 h
Infants and children (1 month to 12 years): For body weights less than 50 kg, the recommended daily dose is 
50 to 100 mg / kg IM or IV of body weight divided into 4 to 6 equal doses, or up to 180 mg / kg / day for severe 
infections (including central nervous system infections).
For body weights 50 kg or more, the usual adult dosage should be used.
The maximum daily dosage should not exceed 12 grams.
Administration of Claforan should be continued for a minimum of 48 to 72 hours after the patient defervesces or 
after evidence of bacterial eradication has been obtained; a minimum of 10 days of treatment is recommended for 
infections caused by Group A beta-hemolytic streptococci in order to guard against the risk of rheumatic fever or 
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Comparison Between Patellar Resurfacing 
With an Inset Plastic Button 
and Patelloplasty
H.U. Cameron, MB, ChB, FRCSC*
Of 101 patients who underwent knee replacement with the Tricon P prosthesis and 
were followed up for 2 or more years, 68 had patellar resurfacing with a recessed 
press-fit plastic button and 43 patients had patelloplasty (shaving of the patella and 
removal of osteophytes). All patients were followed up for more than 2 years.
Three percent of the patients who had patellar resurfacing, later had patellar 
fractures; 4.6% of the patients who had patelloplasty initially, subsequently required 
patellar replacement. There were no instances of loosening of the patellar 
replacement.
Patellofemoral aching was experienced by 7.6% of the patients who had patellar 
resurfacing and by 17.6% of those who did not. Of the patients who had patellar 
resurfacing, 61.5% could climb stairs without aids using the replaced side as the 
lead leg compared with 37.2% of the patients who had patelloplasty. Overall ratings 
of the surgical results were similar for the two groups.
The author concludes that patellar resurfacing improves the quality of the result 
and that there are few drawbacks to the use of an inset patellar button.
Sur 101 patients qui re^urent une prothese du genou de type Tricon P et qui furent 
suivis pendant 2 ans ou plus, 68 avaient eu une mise a neuf de la surface rotulienne 
a l’aide d’un bouton de plastique appareille par pression alors que les 43 autres 
avaient subi une plastie de la rotule (planage de la rotule et enlevement des 
osteophytes).
Trois pourcent des patients qui avaient eu une remise a neuf de la surface 
rotulienne, subirent plus tard une fracture; 4.6% des patients qui avaient eu une 
plastie de la rotule necessiterent par la suite le remplacement de celle-ci. On n’a 
constate aucun detachement de prothese.
Des douleurs rotulo-femorales ont ete rapportees par 7.6% des patients qui 
avaient eu une remise a neuf de la surface et par 17.6% de ceux qui n’en avaient pas 
eu. Des patients qui avaient eu une remise a neuf de la surface rotulienne, 61.5% 
pouvaient monter un escalier sans aide en utilisant le cote opere comme jambe 
d’appui, comparativement a 37.2% pour ceux qui avaient une plastie rotulienne. 
L’evaluation globale des resultats chirurgicaux a ete la meme pour les deux 
groupes.
L’auteur condut que la remise a neuf de la surface rotulienne ameliore la qualite 
des resultats et qu’il y a peu d’inconvenients a utiliser un bouton de plastique 
incruste dans la rotule.
From the Department o f  Surgery, The Orthopaedic and A rth ritic  Hospital, University o f 
Toronto, Toronto
*Assistant professor, Department o f Surgery, Department o f  Pathology and Department o f  
Engineering, University o f Toronto. Staff orthopedic surgeon. The Orthopaedic and A rth ritic  
Hospital, Toronto
Accepted for publication Mar. 15, 1990
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P roblems resulting from the use o f metal-backed patellar pros- 
theses12 have led to doubt about 
the value of patellar replacement. In 
an attempt to define the advantages 
and disadvantages of patellar re­
placement, I compared two groups 
of patients who received a Tricon P 
knee replacement; one group had 
patellar resurfacing, the other did 
not.
The Tricon P knee prosthesis 
(Richards Manufacturing Co., Mem­
phis, Tenn.) was introduced in 
1982. A refinement of the RMC 
knee prosthesis,3 it consisted o f a 
cemented femoral component and 
uncemented tibial and patellar com ­
ponents. The tibial component was 
held in place by ridged plastic pegs4 
driven into undersized holes drilled 
into the centre of the medial and 
lateral tibial plateaus. Although 
these plastic pegs lasted reasonably 
well,5 for long-term fixation, under­
cut grooves were machined into the 
undersurface o f the tibial com po­
nent to allow for possible bone 
upgrowth (Fig. 1).
The Tricon P patellar component 
is a plastic button with a central 
peg. It is inserted by reaming an 
exact-sized hole into the centre o f 
the patella and press-fitting the 
component without cement (Fig. 2). 
Recession of this component allows 
the shear loads on the patella to be 
absorbed by the side walls o f the 
component and not the central peg. 
The component is load-sharing in 
the sense that most of the contact 
between the patella and the metallic
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trochlear groove occurs on the plas­
tic insert, but some bony contact 
around the periphery is possible.
At first the advantages of a patel­
lar component were not obvious 
and it was seldom used. Later, 
however, it was used universally. 
All patellar components were insert­
ed without cement.
Methods
One hundred and one patients
who underwent knee replacement 
with the Tricon P prosthesis be­
tween 1982 and 1987 at the Ortho­
paedic and Arthritic Hospital in To­
ronto, and who were followed up 
for 2 or more years, were reviewed 
prospectively according to the Hos­
pital for Special Surgery rating sys­
tem.6 Follow-up was at 3 months 
and 6 months after placement and 
annually thereafter. At each visit, 
1-m standing anteroposterior, later­
al and skyline x-ray films were 
obtained.
FIG. 1. Tricon P replacement knee, showing grooves and flanges in two Freeman 
pegs that hold implant in place. Undercut grooves have filled with bone and have 
upside-down triangular shape, indicating that this bone is not produced by sinkage. 
Patella has not been replaced in this case.
Technique
In all cases a midline skin inci­
sion was made. Early in the series 
the knee was opened with a lateral 
parapatellar capsular incision to 
avoid patellar avascular necrosis.7 
Later a medial parapatellar capsular 
incision was used if the patella was 
located centrally, and a lateral ap­
proach was used only if the patella 
was in a laterally subluxed position 
preoperatively.
The upper surface of the tibia 
was cut off at right angles to the 
floor using an extramedullary 
guide, and holes were drilled in the 
centre of the lateral and medial 
tibial plateaus to receive the pegs. 
Ligaments were balanced by means 
of lamina spreaders. The distal fem­
oral condyles were cut with an 
intramedullary guide set at 7° of 
valgus. The amount of distal femo­
ral resection matched the thickness 
of the metal component so as to 
prevent proximal shift of the joint 
line.3 The anterior and posterior 
femoral condyles were resected, re­
moving the same minimal amount 
of bone from both posterior femoral 
condyles to ensure that the knee 
would be tight in flexion.8 Initially 
the posterior cruciate ligament was 
completely resected, but later in the 
series it was simply left, or, if it was 
tight, a midsubstance step cut was 
made. Initially the patella was
FIG. 2. (Left) Patella is grasped in holder and central hole reamed out. (Middle) Close-up view shows outline of recessed patella 
and fixation peg. Walls of plastic patella are surrounded by bone. (Right) Typical fibrous meniscus that surrounds and 
overgrows patellar button.
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shaved and the osteophytes were 
removed; later in the series routine 
patellar replacement was carried out 
using the press-fit patellar compo­
nent already described.
All femoral components were ce­
mented in place. Cement was used 
to hold the tibial component in 
place only if the bone was unusual­
ly soft (if it could readily be indent­
ed by finger pressure) or if substan­
tial bone loss had occurred; these 
conditions were more common in 
patients who underwent revisions of 
previous surgical procedures. Apart 
from these indications, all tibial 
components were inserted without 
cement. Later in the series tibial 
defects were repaired by bone graft­
ing.9 Unless the tibial bone grafts 
were large, all patients were allowed 
immediate full weight bearing. The 
patients considered in this study all 
had noncemented tibial compo­
nents.
Findings
Patellar Resurfacing
Sixty-eight patients (9 men 59 
women, mean age 71 years) under­
went patellar resurfacing. The fol­
low-up ranged from 2 to 5 years 
(mean 3.5 years). Three of these 
patients underwent revision of pre­
vious surgery and are considered 
separately.
The results in 39 (60%) patients 
were rated as excellent, in 23 
(35.4%) as good and in 3 (4.6%) as 
fair. Only five (7.6%) patients com­
plained of aching in the patellofem- 
oral joint during use. Forty (61.5%) 
patients could climb stairs with no 
aids using the operated leg as the 
lead leg; 15 (24%) patients needed 
the assistance of a handrail to use 
the operated leg as the lead leg 
when climbing stairs and 10 (15%) 
used the other leg.
One of the three patients who
required revision of a previous sur­
gical procedure experienced a su­
pracondylar fracture 2 years after 
operation. Open reduction and in­
ternal fixation were carried out. The 
femoral component subsequently 
loosened and required revision. The 
second patient had loosening of the 
femoral component at 3 years. At 
revision the tibial component was 
found to be tight. The third patient 
required a revision operation at 3 
years to repair a sunken tibial com­
ponent. The medial tibial plateau 
had fractured before surgery and 
had been inadequately reconstruct­
ed.
One man continued to have patel- 
lofemoral pain. His patella was re­
vised to a metal-backed patella at 1 
year. He continued to have some 
patellar aching, and his patella was 
again revised, 4 years later, to a 
custom-made patellar component 
that covered the whole surface of 
the patella. Currently he is doing 
well. Two patients had neuroma of 
the infrapatellar branch of the sa­
phenous nerve, which took 18 
months to settle, and three patients 
had a minor wound dehiscence of 
no particular significance. Two pa­
tients (3%) had a patellar fracture. 
One fracture occurred at 10 months 
in a patient in whom a lateral 
parapatellar approach had been 
used. The fracture, which was 
transverse with no separation, 
healed with a fibrous nonunion. 
The other, a longitudinal fracture at 
18 months, occurred in a patient 
who had had a medial incision with 
no lateral release. Both patients 
were treated simply by bracing for 4 
weeks.
Patelloplasty
This group comprised 43 patients 
(6 men 37 women, mean age 72 
years). The follow-up ranged from 2 
to 7 years (mean 4.5 years). Twen­
ty-seven patients had the opposite
knee replaced with some other type 
of prosthesis, and 5 patients had 
other joints replaced.
In this group the results were 
rated as excellent in 25 (58.1%) 
patients, good in 15 (34.9%) pa­
tients and fair in 3 (7%) patients. 
Seven (16.2%) patients complained 
of patellofemoral aching. Sixteen 
(37.2%) patients could use the oper­
ated leg as the lead leg when climb­
ing stairs without using aids. Nine 
patients (20.9%) could use the oper­
ated leg as the lead leg if they used 
the handrail and 18 (41.9%) pa­
tients used the opposite leg as the 
lead leg for stair-climbing.
None of the patients in this 
group required surgical revision. 
Two patients required patellar re­
surfacing to relieve significant pa­
tellofemoral pain, one at 14 months 
and one at 19 months.
Discussion
In this study group the only 
patellar problems potentially related 
to patellar resurfacing were two 
fractures (3%). Of those who did 
not have their patellas resurfaced, 
4.6% subsequently required resur­
facing. Patellofemoral ache was 
present in 16.2% of those with no 
resurfacing and in 7.6% of those 
who had resurfacing. When climb­
ing stairs, 61.5% of the patients 
who underwent patellar resurfacing 
could ascend without aids, using 
the leg with the replaced knee as 
the lead leg, compared with 37.2% 
of those who did not undergo resur­
facing. There were minimal differ­
ences in the ratings between the 
two groups: the results of 95.4% of 
the group with patellar resurfacing 
were rated as good or excellent 
compared with 93% of the group 
with patelloplasty.
It is obvious therefore that resur­
facing the patella seldom influences 
the overall result but does affect the
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quality of the results. The knee 
rating systems are coarse instru­
ments at best and are not capable of 
reflecting subtle differences, al­
though stair-climbing ability dif­
fered markedly between the two 
groups.
The recessed plastic press-fit pa­
tella has functioned well. The knees 
that have been revised have general­
ly shown wear only on a single 
central facet, in spite of an average 
range of motion greater than 100°. 
The recession coupled with the de­
velopment of a fibrous patellar me­
niscus10 presumably protects the 
components. No loosening and no 
subsidence into the patella have 
been noted, all components being 
surrounded by a peri-implant bone 
plate. There must be some concern 
that, with time, there will be a 
build-up of polyethylene debris from 
this interface, possibly leading to 
late bone resorption and loosen­
ing,11 but this has yet to be seen.
Use of a lateral or medial parapatel­
lar approach does not seem to influ­
ence the result, and at our institu­
tion we continue to use a medial 
parapatellar incision when the patel­
la is situated centrally before sur­
gery and a lateral approach when it 
is subluxed laterally.
The results of this study indicate 
that the drawbacks to resurfacing 
the patella are minimal and that the 
improvement in “quality of life” for 
patients who undergo this proce­
dure is significant.
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Etiology of Prosthetic Anastomotic False 
Aneurysms: Pathologic and Structural 
Evaluation in 26 Cases
A.R. Downs, MD;*t R. Guzman, MD;*t M. Formichi, MD;* R. Courbier, MD;J J.M. Jausseran, MD;:}: 
A. Branchereau, MD;H C. Juhan, MD;§ N. Chakfe, MD;* M. King, PEng;** R. Guidoin, PhD*
To determine the etiology of anastomotic false aneurysms (AFAs), 26 textile graft 
specimens, removed because of AFA, were studied morphologically, histologically 
and by scanning electron microscopy. No cases of suture-related failures leading to 
AFA were found. Nine cases of frayed grafts were documented but were not the 
cause of AFA formation. In three cases, chemical degradation of the fibres, which 
may have been secondary to lipid infiltration, may have contributed to AFA 
formation. There were no cases of overt clinical infection, but the presence of 
bacteria was documented by scanning electron microscopy in 20 cases. The role of 
bacteria is not well defined, but they may be a factor in host arterial-wall 
degeneration as a cause for AFA formation.
L’etiologie des faux anevrismes a ete etudiee a l’aide de 26 segments prothetiques 
en polyester, explantes pour resection de faux anevrismes et analyses macroscopi- 
quement, en microscopie optique et en microscopie electronique a balayage. Aucun 
cas de rupture de suture n’a ete note. Neuf segments prothetiques presentaient un 
effilochage a leur extremite, mais celui-ci n’etait pas responsable de la formation des 
faux anevrismes. Cependant, parmi les defaillances prothetiques ayant pu contribuer 
a la formation des faux anevrismes, nous avons observe trois cas de degradation 
chimique des fibres vraisemblablement secondaire a une infiltration de lipides. Parmi 
les specimens etudies, nous n’avions aucun cas d’infection clinique, cependant une 
colonisation bacterienne a ete observee en microscopie electronique a balayage dans 
20 cas. Le role des bacteries doit etre elucide et il pourrait agir comme facteur de 
degenerescence de la paroi arterielle responsable de la formation de faux 
anevrismes.
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Laval University, Quebec
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Anastomotic false aneurysms (AFAs) at the junction of pros­
thetic arterial anastomoses continue 
to be a relatively common late com­
plication of grafting.1 The etiology 
of AFA is multifactorial. The recog­
nized causes include suture dissolu­
tion or fracture, overt infection at 
the anastomosis, dilatation of the 
graft, rupture of the prosthesis and 
fraying of the prosthesis at the 
suture line. Predisposing factors 
considered to play a role are endar­
terectomy near the anastomotic 
site, compliance mismatch between 
the prosthesis and the artery, inap­
propriate graft-arterial diameter ra­
tio, repeated mechanical traction at 
the anastomosis and shortening of 
the graft.2 The most common find­
ing at the site of the anastomosis in 
the noninfected false aneurysm is 
an intact suture line in the prosthe­
sis pulled out from the arterial wall, 
usually at the toe of the graft. 
Sometimes the graft is completely 
separated from the artery. This 
finding has been attributed to the 
degeneration of the arterial wall at 
the anastomotic site,3 but the cause 
or nature of the arterial-wall degen­
eration has not been elucidated. In 
an attempt to understand further 
the etiology of AFAs, 26 grafts that 
were resected at operation for AFA 
were submitted for gross morpho­
logic and histologic investigation 
and scanning electron microscopy 
(SEM).
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Patient Data and Methods
Twenty-six grafts, resected be­
cause of AFA over an 8-year period 
(1978 to 1986), were submitted for 
pathological investigation. All were 
removed by vascular surgeons in 
Marseille, France. An accompanying 
patient questionnaire, filled out by 
the attending surgeon, provided the 
relevant patient data. At the time of 
graft implantation the 23 men and 
3 women ranged in age from 28 to 
74 years (average 56.2 years). Indi­
cations for implantation were aortic 
occlusive disease in 23 patients and 
abdominal aortic aneurysm in 3 
patients. The initial operative proce­
dures performed are listed in Table 
I. Twenty-four repeat operations 
were performed because of a pulsa­
tile mass in the groin (Table II) and 
the remaining 2 because of throm­
bosis of the graft. There was no 
clinical evidence of graft infection. 
At operation, a segment of graft 
was removed, and a short interposi­
tion graft was used to restore blood 
flow. No recurrences or infections 
were noted postoperatively at fol­
low-up.
Processing o f Graft Specimens
After excision, the grafts were 
opened longitudinally, carefully 
rinsed with heparinized saline, fixed 
in a buffered solution of 1.5% glu- 
taraldehyde and shipped to the Bi­
omaterials Institute at the St-Fran- 
?ois d’Assise Hospital in Quebec.
As part of the ongoing graft 
retrieval program, each specimen 
was processed through a series of 
pathological investigations. The 
graft specimen, including suture, 
was examined and photographed 
with a Tessovar macrophotography 
optical system (Carl Zeiss, Oberkoc- 
hen, Germany). An appropriate rep­
resentative segment was then se­
lected for the pathological studies. 
Each segment was divided into two.
The first piece was post-fixed in 
Perfix solution, dehydrated with 
ethanol and clarified with toluene 
before being mounted in paraffin. 
Sections 4 p.m thick were then 
stained for light microscopy using 
Weigert’s, Masson’s trichrome and 
Gram’s stains.
The second piece was post-fixed 
in thiocarbohydrazide and osmium 
tetroxide for examination by SEM. 
Dehydration was obtained by im­
mersion in a series of ethanol solu­
tions of increasing concentrations, 
culminating in pure ethanol, fol­
lowed by critical-point drying with 
liquid carbon dioxide as the transfer 
medium. The specimen was then 
coated with gold-palladium and ex­
amined in a JSM 35CF scanning 
electron microscope (Jeol [USA] 
Inc., Peabody, Mass.) at 15 to 20 
kV of accelerating voltage. The re­
maining graft specimens were 
cleaned for assessment of the textile 
material through a series of 5% 
sodium bicarbonate baths; this was 
followed by rinsing with distilled 
water.
Assessment Criteria
The sutures were assessed for 
type and for evidence of fractures or 
dissolution. The grafts were as­
sessed for the following: type (mac- 
roscopically and by SEM), fraying 
(macroscopically and by SEM), fibre 
degradation (macroscopically and 
by SEM), lipid infiltration (macro­
scopically and by SEM), endothelial- 
ization (by SEM), integrity of the 
inner capsule and fibrin deposition 
(by SEM) and the presence of bacte­
ria (histologically and by SEM).
Findings
The duration of implantation av­
eraged 6.7 years (range from 1 to 
10 years). Only five aneurysms were 
diagnosed within 5 years of implan­
tation; the remaining 21 appeared
between 5 and 10 years (Fig. 1).
The suture material used for the 
anastomosis was identified in all but 
four specimens. In 17 specimens, 
monofilament suture (Prolene) had 
been used, and in the remaining 5 
specimens multifilament braided su­
ture had been used. No suture 
fractures or dissolution was identi­
fied.
With respect to the types of 
grafts recovered at reoperation (Ta­
ble III), no clustering of a single 
graft type within a given time peri­
od was demonstrated.
Fraying, seen in nine grafts, was 
most marked in the single woven 
graft submitted (Fig. 2). The pres­
ence of fraying did not seem to 
contribute to the formation of AFA 
in any case of this series.
Defects in the graft wall associat­
ed with chemical fibre degradation 
were seen in three grafts (Figs. 3 to 
5). Lipid infiltration was seen in 17 
grafts, the most marked being in a 
patient with hyperlipidemia.
Only one specimen had some evi­
dence of endothelial cell growth, 
which was found near the anasto­
mosis. In only 3 specimens was the 
integrity of the inner capsule com­
posed of packed fibrin found to be
Tab le  1. Types of Revascularization 
Procedures Performed on 26 Patients Who 
Had Grafts Removed Because of Aortic 
False Aneurysms
Procedure
N um ber  
ot patients
Aortofemoral bypass 14
Unilateral aortofemoral or 6
ileofemoral bypass 
Femoropopliteal bypass 3
Axillofemoral bypass 1
Patch grafts (1 aortic, 1 2
iliac)
Tab le  II. Site of Aortic False Aneurysms in 
26 Patients
Site N um ber of patients
Femoral 20
Popliteal 2
Aortic 3
Iliac 1
- A
- n -
A
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*
54 JCC, VOL. 34, NO 1, FEVRIER 1991
ANASTOMOTIC FALSE ANEURYSMS
intact and confluent; in the remain­
ing 23 specimens disrupted surfaces 
were demonstrated with patchy (15) 
or absent (8) internal capsules. Con­
fluent and disrupted internal cap­
sules are compared in Figs. 6 and 7 
respectively.
In 18 specimens stained with
Gram’s stain, bacteria were not 
demonstrated; however, SEM dem­
onstrated bacteria in 15 of these 18 
specimens (Fig. 8). Overall, the 
presence of a discrete bacteremic 
colonization was demonstrated by 
SEM in 20 of 26 patients. No 
infection was detected clinically.
Discussion
The etiology of AFA is multifac­
torial and can generally be classified 
into three major groups: suture 
fractures or dissolution, graft-relat­
ed defects and factors related to the 
host artery or arterial-prosthetic 
junction.45
Currently, suture-related defects 
account for only a small proportion 
of all AFAs.1"3 With the elimination 
of silk sutures and the more wide­
spread use of nonabsorbable mono- 
or multifilament suture, reports of 
AFAs secondary to this group have 
diminished but have not been com­
pletely eliminated.2'36 There were 
no suture-related failures leading to 
AFA formation in our series, which 
is consistent with this diminished 
trend.4-5
Graft-related defects again ac­
counted for a relatively minor pro­
portion of recognized causes of
T a b le  I I I .  T y p e s  o f G ra fts  U sed
G ra ft typ e
N u m b er  
of pa tien ts
W e ft k n it  f la t  f ib re 7
W e ft  k n it  te x tu r iz e d  f ib re 9
W e ft  k n it  lig h tw e ig h t 3
W a rp  k n it 5
W o v e n 1
D o u b le  v e lo u r 1
► >
►
r* -
FIG. 2. (A) Cleaned graft specimen demonstrating fraying at edges of woven graft. (B) Scanning electron micrograph of frayed 
edges of graft (original magnification X 20).
CJS, VOL. 34. NO. 1. FEBRUARY 1991 55
DOWNS ET AL
AFA.23-5 In this series, nine cases of 
fraying and three cases of fibre 
degradation were documented. 
Fraying did not lead to AFA in any
case. However, the three cases of 
fibre degradation are of particular 
concern and likely contributed to 
AFA formation in two instances.
Lipids may contribute to the de- 
gradative process, but the exact 
mechanism and natural history of 
this chemical degradative process is
FIG. 3. (A) Marked lipid deposition in portion of graft removed from 73-year-old patient with femoral AFA that appeared 8 years 
after implantation. (B) Cleaned graft specimen showing area of fibre degradation at site separate from anastomosis. (C) Scanning 
electron micrograph demonstrating both fraying and rounded ends of trilobar fibres, reflecting chronic degradative process 
(original magnification X 720).
A
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FIG. 4. (A) Cleaned graft specimen from 58-year-old patient who required reoperation for aortic AFA 6 years and 4 months after 
implantation. Note frayed edges on right and adjacent graft tear just proximal to bifurcation. (B) Scanning electron micrograph 
of area of graft tear (original magnification X 20). (C) Scanning electron micrograph showing evidence of degradation at ends of 
fibres (original magnification X 720).
FIG. 5. (A) Cleaned graft specimen removed from 58-year-old patient who had aortobifemoral bypass performed 6 years earlier 
and was found to have right femoral thrombosis. Linear tear was evident just proximal to intact suture line. (B) Scanning 
electron micrograph demonstrating extensive residual lipid infiltration after cleansing in sodium bicarbonate baths (original 
magnification X 20).
*
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not known.4-7 Furthermore, the rel­
ative roles of lipids, bacteria and 
macrophages are not well defined, 
and further research needs to be 
done in this area.
The remaining group of factors 
related to the host artery or ar­
terial-prosthetic junction accounted 
for the majority of AFAs in most 
recent series.2-3-8 Compliance mis­
match, stress at the anastomosis, 
adherence to the inguinal ligament 
causing traction at the anastomosis, 
associated hypertension or previous
endarterectomy are examples of 
such factors and are the focus of 
other reports.9-13 The most common 
factor reported is that of degenera­
tion of the arterial wall, but the 
exact pathogenesis is not clear. The 
arterial wall may undergo necrosis, 
and subsequently fibrosis, during 
the healing process. This fibrosed 
wall gradually gives way to mechan­
ical forces, enlarges and eventually 
may be detected clinically or may 
become symptomatic. Arterial ne­
crosis may be secondary to suture
placement combined with repeated 
mechanical stresses with or without 
overt clinical infection. Although no 
cases of overt infection were seen in 
this series, the presence of bacteria 
was documented by SEM in 20 of 
the 26 patients. Gram’s staining 
was negative in all 18 specimens so 
stained, yet bacteria were seen in 15 
of the specimens on SEM. This 
high rate of bacterial invasion is 
consistent with findings in the re­
ports of Kaebnick and col­
leagues,14-15 who obtained positive
FIG. 6. Graft removed from 74-year-old patient whose aortobifemoral bypass lasted 10 years before left AFA appeared. (A) 
Scanning electron micrograph of internal capsule showing relatively smooth surface (original magnification X 200). (B) Note 
the confluence of fibrin strands at higher magnification (original magnification X 2000).
FIG. 7. Graft removed from 65-year-old patient with right 
femoral AFA in aortobifemoral bypass performed 6 years 
previously. Internal capsule shows loose fibrin strands (com­
pare with Fig. 6B) (original magnification X 200).
FIG. 8. Scanning electron micrograph of luminal surface of 
graft removed from 79-year-old patient who had undergone 
patch iliac angioplasty for iliac stenosis 1 year earlier. Note 
presence of bacteria, often seen in clumps (arrows) (original 
magnification X 2000).
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cultures in 90% of AFAs after ul- 
trasonification of the specimens. Al­
though samples were not taken for 
culture in this series and the bacte­
ria seen by SEM cannot be typed, 
the most likely organism is Sta- 
phyloccoccus epidermidis, which 
may reflect contamination at the 
time of surgery.1617 The exact role 
of these bacteria in the pathogene­
sis of AFAs is unclear, and the lack 
of case-control grafts removed ei­
ther at autopsy or for reasons other 
than AFA in this study makes it 
difficult to associate the presence of 
bacteria solely with AFAs. Recently, 
however, Martin and colleagues18 
produced anastomotic disruption in 
9 (56%) of 16 dogs implanted with 
a graft exposed to a biofilm-produc­
ing strain of S. epidermidis. The 
additional observation of an intact 
and confluent internal capsule in 
only 3 of our 26 specimens may 
implicate a fibrinolytic process, 
which could contribute to the even­
tual breakdown of the fibrous wall 
and dehiscence of the anastomosis 
with formation of the AFA.
Conclusions
The etiology of AFAs is multifac­
torial. Factors relating to the host 
artery and arterial-prosthetic junc­
tion are the major ones. Bacteria 
were documented in 20 out of 26
specimens and may play a role in 
degeneration of the arterial wall 
leading to necrosis. Chemical fibre 
degradation, possibly secondary to 
lipid infiltration, was seen in three 
cases. There were no cases of su­
ture-related failure leading to AFA 
formation.
The authors are indebted to the operat­
ing-room technicians and hospital at­
tendants charged with the collection 
and expedition of the specimens. The 
technical assistance of Marielle Cor- 
riveau, Nicole Massicotte, Suzanne 
Bourassa, Karen Horth, Richard Cou­
ture and Gilles Mongrain is greatly 
appreciated.
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Parathyroid Cyst: Diagnosis
and Treatment of an Unusual Surgical
Problem
B. Mitmaker, MD, PhD, FRCSC;* S. Lerman, MD, CSPQ;f E. Lamoureux, MD, FRCPCjf 
L. Begin, MD, FRCPC$
A case of parathyroid cyst is reported in which the diagnosis was suggested when 
watery, clear fluid was aspirated from a mass found in the anterior region of the 
neck of a 34-year-old woman on routine medical examination. The diagnosis was 
confirmed by measurement of the parathormone content in the cyst fluid and by 
histologic examination of the cyst wall. Although rare, parathyroid cyst should be 
considered in the differential diagnosis of cysts in the anterior compartment of the 
neck.
Surgery has been the usual treatment of such cysts, but several reports have been 
published in which repeated aspiration resulted in the disappearance of the cyst. If 
conservative treatment of a parathyroid cyst is unsuccessful, the cyst should be 
removed surgically.
Un cas de kyste de la parathyroide est signale oil le diagnostique a ete suggere 
lorsqu’un liquide aqueux, limpide a ete aspire d’une masse decouverte a la region 
anterieure du cou d’une femme de 34 ans au cours d’un examen medical de routine. 
Le diagnostique a ete confirme par la mesure de la teneur en parathormone du 
liquide du kyste et a l’examen histologique de la paroi du kyste. Bien que rares, les 
kystes de la parathyroide devraient etre consideres dans le diagnostique differentiel 
des kystes du compartiment anterieur du cou.
La chirurgie a ete utilisee comme traitement habituel de ces kystes, mais 
plusieurs rapports ont ete publies oil l’aspiration repetee a provoque la disparution 
du kyste. Si le traitement conservateur du kyste de la parathyroide echoue, le kyste 
devrait etre excise.
A lthough microscopic cysts are common in both normal and 
abnormal parathyroid glands, a sin­
gle parathyroid cyst, large enough 
to assume clinical and surgical im­
portance, is rare.1-4 Since the initial 
case report by Goris in 1905,5 162 
such cases have been published.
Despite this, the condition is hardly 
mentioned in modern surgical text­
books and is rarely considered in 
the differential diagnosis of anterior 
neck masses. However, awareness 
of this condition is worthwhile, 
since fine-needle aspiration of cystic 
masses in the neck permits the
preoperative diagnosis of these le­
sions by determining the parathy­
roid hormone (PTH) levels of the 
cyst fluid.6-8
In this paper we describe a case 
that illustrates the value of PTH 
determination on the fluid aspirate 
of an anterior neck mass.
Case Report
An anterior neck mass was dis­
covered during routine medical ex­
amination of a 34-year-old woman. 
There were no symptoms of thyroid 
dysfunction or local compression. 
There was no history of nephroli­
thiasis, pancreatitis or peptic ulcer 
disease. The family history was neg­
ative for disorders of the thyroid 
gland and for calcium homeostasis.
Physical examination revealed a 2 
X 3-cm nodule in the region of the 
left lobe of the thyroid gland. The 
nodule was soft, mobile and non­
tender, and there was no regional 
lymphadenopathy. The clinical im­
pression was consistent with a thy­
roid nodule. The initial results of 
tests of thyroid function were nor­
mal. Thyroid scanning with io­
dine-131 revealed a hypofunction­
ing nodule, measuring 2 X 2  cm, in 
the lower pole of the left lobe of the 
thyroid, and ultrasonography dem­
onstrated a 4.3 X 5-cm cystic struc­
ture in the anterior compartment of 
the neck (Fig. 1). Fine-needle aspi-
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ration biopsy yielded 10 mL of clear 
watery fluid and resulted in com­
plete disappearance of the mass.
Despite repeated fine-needle aspi­
rations the cyst recurred. Each re­
currence was heralded by pain and 
discomfort on the left side of the 
neck. The watery, clear appearance 
of the fluid at the first aspiration 
had prompted the treating physi­
cian (S.L.) to measure the PTH 
content of the cyst fluid (Table I). 
The patient’s serum calcium and 
PTH levels measured at the time of 
the first recurrence were normal. 
After the fifth recurrence of the 
cyst surgical exploration of the 
neck was carried out.
A cystic mass, 5 cm in diameter, 
was found. It bulged anteriorly after 
separation of the strap muscles 
overlying the left lobe of the thyroid
FIG. 1. Ultrasonogram shows cystic 
mass in left lobe of thyroid gland.
gland. The cyst was tense and had a 
translucent opaque wall (Fig. 2). 
Dissection of the cyst from the 
inferior aspect of the atrophic left 
thyroid lobe was impossible. Conse­
quently the entire cyst, including 
its attached thyroid lobe and isth­
mus, was excised. The parathyroid 
glands on the contralateral side 
were essentially normal. The re­
maining fourth parathyroid gland 
on the side of the cyst was not 
located and was assumed to be 
present in the resected specimen. 
The patient had a smooth recovery 
and was able to leave the hospital 
on postoperative day 4.
Gross examination of the speci­
men revealed a cyst 5 cm in diame­
ter, attached to an atrophic left 
thyroid lobe. Aspiration of the cyst 
yielded 5 mL of clear fluid. The 
concentration of PTH in the aspi­
rate was 10 000 ng/L.
Microscopic examination of mul-
FIG. 2. Operative appearance of para­
thyroid cyst occupying left lobe of 
thyroid gland. Note translucent ap­
pearance of cyst wall.
tiple sections of the cyst wall re­
vealed a fibrous shell in which was 
embedded in normally appearing 
parathyroid tissue as well as some 
thymic rests. The cyst wall was 
lined by a continuous, single layer 
of cuboidal wasserhelle and chief 
cells, each with a prominent, dense 
nucleus. The adjacent thyroid tissue 
was histologically normal. The lin­
ing epithelium of the cyst wall 
showed a strong cytoplasmic reac­
tion for PTH, using an im- 
munoperoxidase technique for this 
antigen (Dakopatts Corp., Missis­
sauga, Ont.).
Discussion
The presence of a clear, colour­
less fluid obtained from an anterior 
neck cyst should suggest the diag­
nosis of a parathyroid cyst. The 
performance of a PTH assay on the 
cyst fluid not only has enhanced the 
accuracy of the preoperative diag­
nosis, but also has influenced the 
treatment of 678 of these rare 
cases. The PTH levels of the cyst 
fluid reported in the literature7-910 
were generally extremely elevated, 
as in the present case. Although the 
majority of these clinically palpable 
parathyroid cysts are nonfunctional, 
a small number have been associat­
ed with hyperparathyroidism.1112 
Pathologic changes in the walls of 
these cysts or adenomas, such as 
hemorrhage or necrosis, are be-
T a b le  1.  R esu lts  o f  M ea s u re m e n ts  M ade  on A s p ira te  o f  P a ra th y ro id  C ys t and S erum  M ea su re m e n ts  o f P a ra th y ro id  H o rm o n e  (P TH ) and C a lc ium
D ate  of 
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ca lc iu m , m m o l/L tV o lum e , m L Colour C e llu larity
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d isap p earan ce PTH, ng /L
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lieved to be responsible for the 
hyperparathyroid crisis reported in 
some cases.2'1314
The pathogenesis of parathyroid 
microcysts is uncertain. Several hy­
potheses have been advanced. The 
most common explanation for the 
formation of microscopic cysts os­
tensibly arising in normal parathy­
roid glands is that they result from 
degeneration or hemorrhage.1315 
Other hypotheses include the reten­
tion of parathyroid secretions with­
in colloid vesicles, developmental 
anomalies and the persistence of 
Kursteiner canals, normally found 
in fetal parathyroid glands.16
Ultimately the coalescence of 
these microcysts or the progressive 
enlargement of a single microcyst is 
believed to give rise to a macroscop­
ic cyst. Others1718 have suggested 
that parathyroid cysts may be the 
result of infarction of parathyroid 
adenomas.
Clinically these rare lesions occur 
most commonly in the fourth and 
fifth decades of life. The female to 
male ratio is 2.5:1. Less than 10% 
of the cysts are associated with 
hyperparathyroidism. For unknown 
reasons, functioning parathyroid 
cysts are 1.6 times more common in 
men.111'1214'19 Most commonly the 
inferior parathyroid glands are in­
volved, predominantly on the left 
side, as in this case. The mass is 
generally related to the inferior 
poles of the thyroid gland with 
most patients complaining of mild 
discomfort and pain in the cervical 
region. A cystic mass in the lower 
neck palpable on physical examina­
tion is usually considered to be 
thyroidal or branchial in ori­
gin.2'3'8'2021 Given the ease of fine- 
needle aspiration of these lesions 
for diagnostic purposes, the pres­
ence of a clear watery fluid should 
suggest this diagnosis, which can 
be verified by PTH assay.6 7'910
At present the initial treatment of 
these large parathyroid cysts is nee­
dle aspiration, since some have been 
known to disappear completely.2910 
No reports in the literature have 
described the use of sclerotherapy, 
a method frequently used in the 
treatment of large thyroid cysts. 
Those parathyroid cysts that tend 
to recur after repeated aspirations 
are treated definitively by surgical 
removal.
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Spinal Injuries in Ice Hockey Players, 
1966-1987
Charles H. Tator, MD, PhD, FRCSC; Virginia E. Edmonds, RN, BA; Lillian Lapczak, BSc;
Ira B. Tator, BA, MSc
A registry, established by the Committee on Prevention of Spinal Cord Injuries Due 
to Hockey, of major injuries to the spine or spinal cord sustained while playing ice 
hockey contains 117 cases entered between January 1966 and March 1987; 112 of 
these injuries were sustained in Canada. Between 1981 and 1986 up to 15 hockey 
related major spinal injuries were reported in Canada each year. Most injuries 
occurred in teenagers and players under 30 years of age who were playing in 
supervised games. The most common cause of injury was a push or check from 
behind, which caused the player to be catapulted head first into the boards.
The authors describe the programs currently being implemented to prevent the 
occurrence of major spinal injuries. Unfortunately, these programs have not 
decreased the number of injuries reported annually.
Un registre des blessures serieuses de la moelle epiniere subies par les joueurs de 
hockey sur glace a ete etabli par le Comite pour la prevention des blessures de la 
moelle epiniere dues au hockey. Celui-ci renferme maintenent 117 cas repertories 
entre janvier 1966 et mars 1987; 112 de ces blessures ont ete subies au Canada. De 
1981 a 1986, jusqu’a 15 blessures serieuses de la moelle ont ete associees au 
hockey, chaque annee, au Canada. La plupart des lesions sont survenues chez des 
adolescents ou chez des joueurs de moins de 30 ans qui evoluaient dans des circuits 
organises. La cause de blessures la plus frequente etait une poussee ou un echec 
venant de l’arriere qui avait pour effet de catapulter le joueur, tete premiere, dans la 
bande.
Les auteurs decrivent les programmes actuellement mis en vigueur pour prevenir 
les blessures serieuses de la moelle epiniere. Malheureusement, ces programmes 
n’ont pas fait diminuer le nombre de lesions signalees annuellement.
A round the world, participa­tion in sports and recreational 
activities has resulted in acute 
injury to the spinal cord,1 although 
the types of activities leading to 
these catastrophic injuries differ be-
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tween countries. In Canada diving 
has always been the leading cause 
of spinal-cord injury in the sports- 
recreation category;2-4 until recently 
such injuries were rarely related to 
hockey. In a review o f 55 patients
who sustained acute spinal-cord in­
juries while participating in sports 
or recreational activities and were 
treated in two Toronto hospitals 
between 1948 and 1973, not a 
single case was hockey related.2 
The first report o f spinal-cord inju­
ry associated with hockey in the 
Canadian literature was published 
in 1984.5 No spinal-cord injuries 
were mentioned in reports o f hock­
ey related injuries in the English 
literature before 1984,6-n although 
Feriencik7 in 1979 reported hockey 
related injuries to the lumbar spine 
in Czechoslovakia.
In 1981 the Committee on Pre­
vention of Spinal Cord Injuries Due 
to Hockey was formed. Since then 
it has conducted research into the 
causes of these injuries and has 
developed preventive programs. The 
committee conducted its first Cana­
dian national survey in 1982 to 
document the extent of the prob­
lem; since then, two additional sur­
veys have been done. By March 
1987, 117 hockey related spinal 
injuries had been reported to the 
registry. It should be noted that the 
registry is strongly supported by 
the Canadian Amateur Hockey As­
sociation and the Canadian Paraple­
gic Association.
This article provides demograph­
ic details o f these 117 injuries, 
discusses the possible causal mech­
anisms and outlines the preventive
From the Canadian Sports Spine and Head Injuries Research Centre and the Division o f 
Neurosurgery, Toronto Western Hospital, University o f  Toronto, Toronto
Reprint requests to: Dr. C.H. Tator, Toronto Western Hospital, Rm. 2 -003  Edith Caveli Wing, 
399 Bathurst St., Toronto, ON M 5T 2S8
CJS, VOL. 34. NO. 1, FEBRUARY 1991 63
TATOR ET AL
programs introduced by the Canadi­
an Sports Spine and Head Injuries 
Research Centre to reduce the inci­
dence of these tragic injuries. It is 
the committee’s belief that collect­
ing data on spinal injuries in hock­
ey is an essential part of the effort 
to eliminate these injuries.
Methods
The Committee on Prevention of 
Spinal Cord Injuries Due to Hockey 
conducted national surveys in 
1982, 1984 and 1986. Question­
naires, in English and French, were 
sent to approximately 1000 neuro­
surgeons, orthopedic surgeons and 
physical medicine and rehabilitation 
specialists practising in Canada, 
asking them to report all major 
spinal injuries seen in their prac­
tices. Information was collected on 
all patients with hockey related 
major injuries to the spine, with or 
without injuries to the nerve roots 
or spinal cord. Excluded were minor 
spinal injuries such as sprains, 
strains, flexion-extension injuries 
and whiplash. In addition, case re­
ports published in the media were 
collected to augment the cases re­
ported by the physicians, although 
virtually every case was eventually 
reported by a physician. In approxi­
mately half of the cases, the infor­
mation provided by the physician 
was augmented by information from 
the players, coaches and league 
officials. The data on the six cases 
occurring in the United States were 
submitted by physicians in the Unit­
ed States who became aware of the 
work of the committee.
For the purpose of this report, 
the data from the first 42 cases 
reported in 198412 have been added 
to the more recent cases. Thus, the 
present report spans the period 
from 1966, when the first reported 
case occurred, to March 1987, the 
date of occurrence of the last case
included in this report. The data 
were accumulated at the Canadian 
Sports Spine and Head Injuries Re­
search Centre, Toronto Western 
Hospital, University of Toronto, 
which is the research facility of the 
Committee on Prevention of Spinal 
and Head Injuries Due to Hockey. 
The March 1987 cut-off date was 
based on a report made at that time 
to the Canadian Amateur Hockey 
Association, one of the sponsors of 
the registry.
Results
Geographic Location
Except for the six injuries that 
occurred in the United States and 
were reported by US physicians, all 
injuries reported to the Committee 
occurred in Canada (Table I). Fifty- 
seven (49%) injuries occurred in 
Ontario; only 12 injuries (10%) oc­
curred in Quebec. The rest of the 
Canadian cases were distributed 
across the country in proportion to 
the population.
Annual Incidence
The injuries occurred rarely in 
the 1960s and 1970s (Table II). 
Beginning in 1980, the number of
Table 1. Geographic Location of Hockey 
Related Spinal Injuries Sustained by 117 
Patients Between January 1966 and March 
1987
Location
Frequency, no.
( % )
Ontario 57 (49)
Quebec 12 (10)
Alberta 9 ( 8 )
British Columbia 9 ( 8 )
Nova Scotia 5 ( 4 )
Saskatchewan 5 ( 4)
Manitoba 4 ( 3)
Prince Edward Island 3 ( 3 )
Yukon Territories 3 ( 3 )
Newfoundland 2 ( 2 )
New Brunswick 1 ( 0.5)
United States 6 ( 5 )
Unknown 1 ( 0.5)
major spinal injuries occurring an­
nually increased markedly, and be­
tween 1982 and 1986 they num­
bered approximately 15/yr.
Sex and Age
Of the 117 injuries, 112 (96%) 
occurred in boys and men and 5 
(4%) occurred in girls and women. 
Sixty-four percent of the players 
were between 11 and 20 years of 
age, and only 19% were between 21 
and 30 years of age (Table III). The 
youngest player to sustain a major 
spinal injury was 11 years old and 
the oldest 47 years (median 18 
years, mean 21 years).
Level of Injury
Almost 80% of the injuries in-
Table II. The Number of Spinal Injuries 
Occurring Annually,* Reported to the 
Committee on Prevention of Spinal and 
Head Injuries Due to Hockey, From January 
1966 to March 1987t
Year Number ot injuries
1966 1
1975 1
1976 2
1977 2
1978 4
1979 2
1980 8
1981 12
1982 15
1983 15
1984 15
1985 12
1986 15
1987 (to March) 6
‘ The injuries are recorded for the year in 
which they occurred rather than the year
when they were reported to the committee. 
tData are missing for seven injuries.
Table III. Age of Injured Players*
Age, yr+ Frequency, no. (%)
1 1 - 2 0 75 (64)
21 - 3 0 22(19)
31 - 4 0 7 ( 6)
4 1 - 5 0 3 ( 3)
'Data are missing for 10 cases (8%).
tAge range 11 
median 18 yr.
to 47 yr, mean 21 yr,
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volved the cervical spine (Table IV); 
approximately 48% of the injuries 
affected C4-5, C5 and C5-6. Tho­
racic, thoracolumbar and lumbosa­
cral injuries were relatively rare. 
The most common site of injury 
(15.6%) was C5-6.
Neurologic Deficit
As noted above, the registry ex­
cluded minor injuries such as verte­
bral strains, although fractures or 
dislocations of the spine were in­
cluded even if they did not cause 
neurologic injuries. The spinal cord 
was affected in 52.1% of the inju­
ries, and damage to one or more 
nerve roots occurred in 10.3% of 
the injuries (Table V). Of those 
whose spinal cord was injured, 29 
patients sustained complete perma­
nent spinal-cord injuries with no 
preservation of motor or sensory 
function below the level of injury,
T a b le  IV . Vertebral Level of Spinal Injury*
V erte b ra l level
Frequency, no.
(%)
Cervical, C1 -  C7, T1 93 (79.5)
Thoracic, T1 — T11 3 ( 9.2)
Thoracolumbar, T11/12 -  
L1 /2 7 ( 6.0)
Lumbosacral, L2 -  S5 6 ( 5.1)
’ Data are missing for 8 cases (6.8%).
T a b le  V. Neurologic Type of Injury 
(n =  73)*
T ype  of injury
Frequency, no.
(°/»)
Spinal cord injury 
Complete motor and 
complete sensory loss 29 (24.8)
Complete m otor and 
incomplete sensory 
loss 9 ( 7.7)
Incomplete motor loss 
and incomplete 
sensory loss 21 (17.9)
Incomplete sensory loss 2 (  1.7)
Root injury only 12(10.3)
*No neurologic injury in 28 cases (23.9%).
Data were missing or incomplete in 16
cases (13.7%).
which was cervical in all cases. Of 
the 117 injured players, 5 were 
known to have died as a result of 
their injuries at the time of prepar­
ing this report. Most deaths were 
attributed to respiratory failure.
Type o f Athletic Event
The largest number of injuries 
occurred in supervised, scheduled 
games within an organized hockey 
league (Table VI): 85 players (73%) 
were known to have sustained their 
injuries in organized games. Only a 
small number of injuries occurred 
during practices or unstructured or 
unsupervised events (shinny).
Mechanism of Injury
Axial loading was found to be the 
most common mechanism causing 
cervical-spine and cervical-cord in­
jury. Axial loading was applied to 
the head when the helmeted head 
struck another object, especially the 
boards. The event that precipitated 
the injury was usually a push or
T a b le  V I. Type of Hockey Played When 
Spinal Injury Occurred*
Type of p lay
Frequency, no.
(% )
Organized games 85 (73)
Practices 4 (  3)
Unstructured play (shinny) 1 (  1)
Unknown 27 (23)
T a b le  V II. Type of Collision*
Frequency, no.
Type of collis ion (% )
Boards 70 (59.8)
Other players 12(10.3)
Ice 3 ( 2.6)
Goal post 1 ( 0.9)
Boards and playerst 5 ( 4.3)
Players and ice t 1 ( 0.9)
Players and goal po s tt 1 ( 0.9)
Boards and ice t 1 ( 0.9)
*Data were incomplete or missing in 23 
cases (19.7%).
tM o re  than one type of collision.
check from behind (31 injuries, 
26.5%). In most instances the play­
er was completely unsuspecting of 
the impact and was hurled horizon­
tally into the boards; the cervical 
spine was crushed between the 
abruptly halted, helmeted head and 
the torso. In most instances the 
axial loading was applied with the 
head in neutral alignment with the 
neck and torso or in slight flexion. 
Major degrees of flexion or exten­
sion were much less common. Im­
pact with the boards accounted for 
76 injuries (65%) (Table VII). Im­
pact between players was the cause 
of injury in 10.3%; injuries caused 
by impact with the ice (2.6%) or 
goal post (0.9%) occurred less fre­
quently. In most cases the player 
collided with the boards (Table 
VIII). Other frequent causes of inju­
ry were pushes and checks from the 
front and from the sides, especially 
into the boards. In many of these 
injuries, impact with the boards 
produced the spinal injury.
T a b le  V II I .  Mode of In jury*
M o d e  of in jury
F re q u e n c y , no.
(% )
Single mechanisms 
Pushed or checked from 
behind 26 (22.2)
Pushed or checked 15 (12 .8 )
Slide 6 ( 5.1)
Tripped on ice 10 ( 8.5)
Trip or fall 3 ( 2.6)
Tripped by player 3 ( 2.6)
Slide w ith player 1 ( 0.9)
Lost balance 2 ( 1 7 )
Missed check 2 ( 1.7)
Multiple mechanisms 
Tripped on ice +  slide 3 ( 2.6)
Tripped on ice +  slide 
w ith player 1 ( 0.9)
Trip +  fall 1 ( 0.9)
Slide +  pushed or 
checked 2 ( 1.7)
Slide +  pushed or 
checked from  behind 5 ( 4.3)
Trip or fall +  pushed or 
checked 1 ( 0.9)
Slide +  tripped by player 1 ( 0.9)
*Data incomplete or missing in 35 cases
(29.9%).
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O ther Features
Burst fractures and fracture-dis­
locations were the most frequent 
types of vertebral injuries. There 
was one case of a ruptured cervical 
disc that caused an incomplete spi­
nal-cord injury. Cases were reported 
of hockey players who had cervical- 
spine stenosis with neurapraxia and 
transient traumatic quadriparesis, 
which was described in football 
players by Torg, Pavlov and Ge- 
nuario.1314 However, spinal stenosis 
in hockey players was not accurate­
ly documented in this study.
Almost all the players in this 
series were wearing helmets, and 
more than two-thirds were wearing 
face masks. Only three cases of 
serious hockey related head injury 
were reported to the Committee 
between 1981 and 1987.
Discussion
Unfortunately, hockey related 
spinal-cord injuries have not de­
clined during the interval since 
1984 when we reported the results 
of the first national survey. From 
1966 to March 1987, we recorded 
117 cases of hockey related spinal 
injury, including five deaths. The 
Committee received reports of 12 to 
15 such injuries occurring each 
year in Canada between 1981 and 
1986. In 1985 the Canadian Ama­
teur Hockey Association instituted 
a rule prohibiting pushing or check­
ing from behind. Either the rule has 
not been enforced as vigorously as 
it should be, or the time required 
for the referees, coaches and play­
ers to adjust their behaviour has 
not been sufficient. A push or 
check, causing the top of the hel- 
meted head to strike the boards was 
the most common mechanism. 
Young men in their teens and early 
20s playing organized hockey were 
at greatest risk of spinal injury;
nearly three-quarters of the injuries 
occurred during organized games. 
Only 4% of the known cases in­
volved injuries incurred during 
practice or shinny. This finding is 
fundamental in terms of injury pre­
vention. It also is reflected in some 
of the recent American literature. 
For example, Gerberich and col­
leagues15 also found that the major­
ity of injuries occurred during orga­
nized games, and in their study 
from Minnesota,15 82.3% of all 
hockey injuries ’occurred during 
games.
Efforts to prevent spinal-cord in­
jury in hockey must address the 
rudimentary problem of aggression 
during the game. In the Minnesota 
study, players were asked to rank 
their reasons for playing the game. 
Extraordinarily, those players who 
noted in their first or second rank­
ing that playing hockey was a 
means of ridding tension and ag­
gression ran a fourfold risk of con­
cussion.15 Recognition of this atti­
tude may be important in isolating 
the causes and developing preven­
tive strategies.
As in the initial analysis of the 
first 42 cases,12 there was a sharp 
contrast between the numbers of 
reported cases from Quebec and 
Ontario — 10% versus 49% (Table 
I). Although Ontario has more 
hockey players than Quebec, the 
number of injuries exceeds an ex­
planation on this basis. Indeed, the 
authors believe that differences in 
organization and player attitude 
may account for this major dispari­
ty. The correlation between meth­
ods of coaching and refereeing and 
the incidence of injuries needs to be 
carefully scrutinized.
From an epidemiologic viewpoint 
it is worthwhile to review some of 
the conclusions drawn from the 
literature on American football. Al­
though the incidence of head inju­
ries was markedly reduced during 
the 1960s and 1970s due to the use
of helmets, the incidence of spinal- 
cord injuries may have increased,16 
according to the results of excellent 
epidemiologic studies of injuries 
documented by two athletic injury 
reporting systems.1617 It was con­
cluded that the helmeted head was 
being used as an offensive weapon 
to spear the opponent. Head-first 
tackling and blocking were disal­
lowed, and since then there has 
been a marked reduction in the 
incidence of spinal-cord injuries in 
football.18 In the late 1970s and 
early 1980s, the annual number of 
cases of quadriplegia in football 
players decreased from about 30 to 
10.17 There are approximately four 
cases of quadriplegia a year in Can­
ada due to hockey. Thus, on a per 
capita basis, hockey in Canada 
causes approximately three times as 
many cases of quadriplegia annually 
as does football in the United 
States. In terms of the risk of 
spinal-cord injury, participation in 
hockey appears to be much riskier 
than participation in football, espe­
cially in Ontario, although we have 
not been able to obtain exact data 
on the numbers of participants.
Analysis of Etiologic Factors
Hockey related spinal injury is a 
recent phenomenon; the Canadian 
Sports Spine and Head Injuries Re­
search Centre has identified several 
causal factors. In our opinion, no 
single factor is responsible for these 
tragic accidents, but rather the ori­
gin is multifactorial.
It should be noted that hockey 
has also been associated with a 
high incidence of non-spinal inju­
ries. For example, a survey in 1986 
found that hockey caused the high­
est number of major injuries of all 
types in sports or recreational activ­
ities in the Province of Ontario. 
Indeed, 79 of the 530 major inju­
ries sustained while participating in 
all types of sports and recreational
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activities during 1986 were hockey 
related; the next most frequent 
causes of injury were water and 
motor sports.19
Head injuries, including face, 
scalp and brain injuries comprised 
40% to 50% of all injuries in ice 
hockey before the introduction of 
helmets and face masks.20-23 But, 
even with the use of helmets, head 
injuries still constitute about one- 
quarter of hockey injuries.24 Most 
of the remaining injuries are to the 
limbs, especially the lower limbs.25
The following factors appear to 
be significant to the current high 
incidence of spinal-cord injuries in 
ice hockey:
•  Physical factors related to cur­
rent players. Hockey players are 
now taller and heavier and skate 
faster than players in former years. 
The increased weight and speed 
raise the forces generated by colli­
sions.
•  Social and psychologic factors 
among young hockey players. 
There is an increased willingness to 
take risks as youthful players try to 
emulate the violence and aggression 
of professional players. Unfortu­
nately, most of these young players 
have neither the physical fitness nor 
the conditioning of professionals. 
There is a feeling of invincibility 
among young players, most likely 
related to the large amount of pro­
tective equipment worn. Indeed, 
many of the victims interviewed 
were completely unaware of the 
possibility of spinal injury in hock­
ey.
•  Rules and refereeing. Fre­
quently the rules were not enforced. 
Many of the victims were injured 
during illegal play, especially push­
ing or checking from behind.
•  Coaching. There was insuffi­
cient emphasis on physical condi­
tioning, especially of the neck mus­
cles. The players did not receive 
sufficient instruction about the 
risks of hockey and the methods of
protecting the spine from injury. 
Some coaches overemphasized body 
contact and underemphasized pro­
tective manoeuvres, especially 
avoiding impact with the boards 
and strategies for impacting safely. 
The marked disparity in the inci­
dence of these injuries between On­
tario and Quebec suggests that atti­
tude and coaching techniques were 
extremely important etiologic fac­
tors. It is of major importance that 
there have been no recent reports of 
hockey related spinal injuries from 
Europe, where hockey is played 
extensively in several northern 
countries.
•  Hockey rinks and equipment. 
Small rinks have been considered a 
possible factor because collisions 
may be more frequent in smaller 
rinks. The lack of shock absorption 
of the boards in most rinks has 
been questioned as a possible etio­
logic factor. The use of helmets 
became widespread in Canadian 
hockey in the 1970s and preceded 
by several years the marked in­
crease in neck injuries. However, 
biomechanical studies have not sup­
ported the notion that the helmet is 
an important factor.26 It should be 
noted that helmets have been ex­
tremely effective in reducing the 
incidence of brain injuries in hockey 
players. Before the widespread use 
of helmets approved by the Canadi­
an Standards Association, fatal 
brain injuries were not uncommon 
in hockey.27-28 We registered only 
three cases of severe brain injury 
between 1981 and 1987. Neverthe­
less, we would encourage further 
research into helmet design. Sim 
and Simonet25 have recently com­
mented with respect to head and 
neck injuries in hockey that “Hel­
met design has been improved, but 
few researchers have specifically 
studied how well newer helmets 
absorb impact and prevent injury.” 
We do not know if poorly fitting 
helmets contributed to any of the
injuries in this series, but we do not 
believe this was a significant factor. 
There is little evidence that a neck 
protector such as a roll-type collar 
will prevent any of these injuries 
and will not substitute for the ex­
tensive neck conditioning exercises 
we have called for. Face masks have 
produced a remarkable reduction of 
eye and dental injuries in hock­
ey.29-30 We found no evidence that 
face masks are related to the in­
crease in spinal-cord injuries, as has 
been suggested.31
Prevention Programs
The Committee on Prevention of 
Spinal and Head Injuries Due to 
Hockey has developed several spe­
cific preventive programs to reduce 
the incidence of these tragic spinal 
injuries.
Player education and condition­
ing. Canadian hockey leagues and 
organizations have accepted the re­
sponsibility for reducing the inci­
dence of these injuries by improving 
player awareness and coaching 
techniques, and by changing and 
enforcing rules. Players are being 
made aware of the risks of certain 
aspects of play, especially going 
into the boards face first and 
“blindly.” Several defensive tactics 
for avoiding spinal injuries are 
being taught, especially avoiding 
impact of the helmeted head with 
the boards, the ice surface or other 
players. A videotape entitled “Smart 
Hockey” was produced in 1988 by 
the Committee, and is being distrib­
uted widely to leagues and schools. 
Coaches and league officials are 
encouraging players to perform spe­
cific exercises to strengthen the 
neck muscles; these are detailed in 
a brochure Neck and Spine Condi­
tioning fo r Hockey Players, which 
has been distributed to all hockey 
players since 1984 and is also in­
cluded with the videotape.
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Rules and refereeing. The hockey 
leagues have taken a leading role in 
encouraging positive attitudes to­
ward injury reduction and safe 
hockey. In 1985 the Canadian Ama­
teur Hockey Association introduced 
specific rules against pushing or 
checking from behind, and the as­
sociation has resolved to reduce 
violence in the game by enforcing 
the rules.
Equipment manufacturers and 
rink contractors. Further research 
is required to improve the safety of 
hockey equipment. Although some 
excellent research has been 
done,26-32 further research on hel­
mets must be done on shape, fric­
tion and shock absorption. Re­
search into the shock absorption of 
the boards should be conducted. 
Placement of unyielding backing, 
such as concrete blocks, behind the 
boards should be discouraged. The 
leagues have adopted other safety 
measures, including the use of mag­
netic goalposts, and are promoting 
increasing the size of rinks to inter­
national standards. Perhaps low- 
interest federal or provincial loans 
could be made available to ease the 
burden of changing to the larger, 
European-size rinks.
Sports medicine experts. Special­
ists in sports medicine and other 
recreation researchers should be en­
couraged to continue research into 
spinal injuries. It is essential to 
continue an organized reporting 
system to assess the effectiveness of 
the preventive programs.33 Further 
epidemiologic and biomechanical re­
search should be strongly encour­
aged and supported by the hockey 
associations and by provincial, state 
and federal governments.
We hope that hockey will follow 
the excellent example set by the US 
football program, which reduced 
the incidence of major spinal-cord 
injuries by improving awareness 
and attitude and by effecting rule 
changes.16' 1834
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Summary
Major spinal injuries have been 
recognized as a common problem in 
Canadian ice hockey only during 
the 1980s. The causes of these 
injuries have been found to be mul­
tifactorial. The increased weight, 
height, speed and aggressiveness of 
hockey players are important fac­
tors. Lack of awareness of the haz­
ards of small rinks and of certain 
high-risk manoeuvres such as 
checking or pushing from behind 
are also important factors. Until 
1985 there were no specific rules 
against checking or pushing from 
behind. Lack of neck-muscle 
strengthening and the player’s feel­
ing of invincibility when outfitted in 
modern equipment have set the 
stage for these tragic injuries. After 
these factors were identified, specif­
ic measures were taken to correct 
them, and a reporting system was 
established in Canada so that the 
effects of the preventive programs 
could be monitored. Greater aware­
ness of the risk factors by players, 
coaches, leagues officials, referees 
and parents promises to be an effec­
tive prophylactic measure. The cur­
rent, specific preventive programs 
involve the hockey associations, 
players, equipment manufacturers, 
health care professionals, research­
ers and governments.
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SESAP VI Critique
Item 145
The incidence of pneumococcal sepsis is higher among patients who have had splenectomy than in the general 
population. Patients with otherwise normal reticuloendothelial systems are largely able to compensate for the 
loss of their spleen. In otherwise normal patients, the incidence of overwhelming sepsis after splenectomy varies 
in several large series from approximately 1.5% (with a 50% mortality) to 3% (with a 30% mortality). Thus, the 
risk of dying from overwhelming sepsis in otherwise normal patients after splenectomy approximates 1%. The 
probability of sepsis rises significantly (to 20% to 30%) in patients with certain hematologic diseases such as 
thalassemia and other abnormalities of the reticuloendothelial system. Polyvalent pneumococcal vaccines can 
reduce this risk somewhat. Because these vaccines do not protect against all serotypes of pneumococci, 
however, and because sepsis can be produced by other organisms, the protection is approximately 30%.
[a
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^PRIMAXIN®
(imipenem and cilastatin sodium 
for injection)
Antibiotic
CNS adverse experiences such as myoclonic 
activity, confusional states, or seizures have 
been reported with PRIMAXIN® especially when 
recommended dosages based on renal function 
and body weight were exceeded. These expe­
riences have occurred most commonly in patients 
with CNS disorders (e.g., brain lesions or 
history of seizures) and/or who have compro­
mised renal function. However, there were rare 
reports in which there was no recognized or 
documented underlying CNS disorder. Close 
adherence to recommended dosage schedules 
is urged, especially in patients with known 
factors that predispose to seizures.
•  Morganella morganii
•  Neisseria
•  Proteus (indole positive and indole negative 
strains)
•  Providencia
•  Pseudomonas aeruginosa
•  Serratia marcescens
Gram-positive Anaerobes
•  Clostridium (excluding C. difficile)
•  Peptococcus
•  Peptostreptoccus
Gram-negative Anaerobes
•  Bacteroides fragilis
•  Bacteroides (non-fragilis)
CONTRAINDICATIONS
PRIMAXIN® (imipenem and cilastatin sodium for 
injection) is contraindicated in patients who have 
shown hypersensitivity to either component of this 
product.
ACTION
Imipenem exerts a bactericidal action by inhibiting 
cell wall synthesis in aerobic and anaerobic gram­
positive and gram-negative bacteria.
PRIMAXIN® consis ts  o f tw o com ponents: 
(1) imipenem, a derivative o f th ienamycin, a 
carbapenem antibiotic; and (2) cilastatin sodium, a 
specific inhibitor of dehydropeptidase-l a renal 
enzyme w hich metabolizes and inactivates 
imipenem. Cilastatin blocks the metabolism of 
imipenem in the kidney, so that concomitant 
administration of imipenem and cilastatin allows 
antibacterial levels of imipenem to be attained in the 
urine.
Inhibition of cell-wall synthesis is achieved in gram­
negative bacteria by the binding of imipenem to 
penicillin binding proteins (PBPs). In the case of 
E sch e r ic h ia  c o li and se le c te d  s tra in s  of 
Pseudomonas aeruginosa, imipenem has been 
shown to have highest affinity for PBP-2, PBP-1a 
and PBP-1 b, with lower activity against PBP-3. The 
preferential binding of imipenem on PBP-2 and 
PBP-1 b leads to direct conversion of the individual 
cell to a spheroplast resulting in rapid lysis and cell 
death without filament formation. When imipenem 
is removed prior to complete k illing of gram­
negative species, the remaining viable cells show a 
measurable lag, termed a "post-antibiotic effect" 
(PAE), prior to resumption of new growth.
INDICATIONS AND CLINICAL USE
PRIMAXIN® (imipenem and cilastatin sodium for 
injection) may be indicated in the treatment of 
serious infections when caused by sensitive strains 
of bacteria. Where considered necessary, therapy 
may be initiated on the basis of clinical judgment 
before results of sensitivity testings are available. 
Continuation of therapy should be reevaluated on 
the basis of bacteriological findings and of the 
patient’s clinical condition.
Imipenem is active in vitro against a wide range of 
gram-positive and gram-negative aerobic and 
anaerobic bacteria, including most strains which 
are beta-lactamase producing. Patients have 
responded while under treatment with PRIMAXIN® 
for single or mixed infections of the following body 
systems, when they were associated with a number 
of pathogenic species and strains of the genera 
listed:
1. Lower Respiratory Tract Infections
2. Urinary Tract Infections
3. Intra-Abdominal Infections
4. Gynecological Infections
5. Septicemia
6. Endocarditis caused by Staphylococcus 
aureus
7. Bone and Joint Infections
8. Skin Structure Infections
Gram-positive Aerobes
•  Listeria monocytogenes
•  Nocardia asteroides
•  Staphylococcus (excluding many strains 
which are methicillin resistant)
•  Streptococcus (excluding S. faecium)
Gram-negative Aerobes
•  Acinetobacter
•  Citrobacter
•  Enterobacter
•  Escherichia coli
•  Haemophilus influenzae
•  Haemophilus parainfluenzae
•  Klebsiella
WARNINGS
PRIMAXIN® (imipenem and cilastatin sodium for 
in jection) SHOULD BE ADMINISTERED WITH 
CAUTION TO ANY PATIENT WHO HAS DEMONS­
TRATED SOME FORM OF ALLERGY, PARTICULARLY 
TO STRUCTURALLY-RELATED DRUGS. IF AN 
ALLERGIC REACTION TO PRIMAXIN® OCCURS, 
DISCONTINUE THE DRUG. SERIOUS HYPER­
SENSITIVITY REACTIONS MAY REQUIRE 
EPINEPHRINE AND OTHER EMERGENCY 
MEASURES.
Pseudomembranous colitis
Pseudomembranous colitis has been reported with 
the use of PRIMAXIN®. Therefore it is important to 
consider this diagnosis in patients who develop 
diarrhea during or after therapy. This colitis may 
range from mild to life threatening in severity.
Mild cases of pseudomembranous colitis may 
respond to drug discontinuance alone. In more 
severe cases, m anagem ent may in c lu d e  
sigm oidoscopy, appropria te  bacte rio log ica l 
studies, fluid, electrolyte and protein supple­
mentation, and the use of a drug such as oral 
vancomycin, as indicated. Other causes of colitis 
should also be considered.
PRECAUTIONS
General
Prolonged use of PRIMAXIN® (imipenem and 
cilastatin sodium for in jection) may result in 
overgrowth of resistant organisms. Repeated 
evaluation of the patient's condition is essential. If 
superinfection occurs during therapy, appropriate 
measures should be taken.
CNS adverse experiences such as myoclonic 
activity, confusional states, or seizures have been 
reported with PRIMAXIN® especially when recom­
mended dosages based on renal function and body 
weight were exceeded. These experiences have 
occurred most commonly in patients with CNS 
disorders (e.g., brain lesions or history of seizures) 
and/or who have compromised renal function. 
However, there were rare reports in which there was 
no recognized or documented underlying CNS 
disorder. Close adherence to recommended dosage 
schedules is urged especially in patients with 
known factors that predispose to seizures (see 
DOSAGE AND A D M IN IS TR A TIO N ). A n ti­
convulsant therapy should be continued in patients 
with a known seizure disorder. If focal tremors, 
myoclonus, or seizures occur, patients should be 
evaluated neurologically and placed on anti­
convulsant therapy if not already instituted. If CNS 
symptoms continue, the dosage of PRIMAXIN® 
should be decreased or discontinued.
Use in Patients with Impaired Renal Function
Dosage in patients with impaired renal function is 
based on the severity of infection but the maximum 
daily dose varies with the degree of renal functional 
im pairm ent (see DOSAGE AND AD M IN IS­
TRATION - Dosage in Patients w ith Renal 
Insufficiency).
Use in Pregnancy
The use of PRIMAXIN® in pregnant women has not 
been studied, therefore, PRIMAXIN® should be 
used during pregnancy only if clearly needed. Use 
of this drug in women of childbearing potential 
requires that the anticipated benefits be weighed 
against possible hazards.
Reproduction studies with bolus I.V. doses suggest 
an apparent intolerance to PRIMAXIN® (including
emesis, inappetence, body weight loss, diarrhea 
and death) at doses equivalent to the average 
human dose in pregnant rabbits and cynomolgus 
monkeys that is not seen in non-pregnant animals in 
theseorother species. In other studies, PRIMAXIN® 
was well tolerated in equivalent or higher doses (up 
to 11 times the average human dose) in pregnant 
rats and mice (see REPRODUCTION STUDIES 
under TOXICOLOGY in the complete monograph).
Nursing Mothers
It is not known whether PRIMAXIN® is excreted in 
milk. If the use of PRIMAXIN® is deemed essential, 
the patient should stop nursing.
Pediatric Use
Efficacy and tolerability in infants under the age of 
3 months have not yet been established; therefore, 
PRIMAXIN® is not recommended in the pediatric 
age group below the age of 3 months.
Drug Interactions
Concomitant administration of PRIMAXIN® and 
probenecid results in only minimal increases in 
plasma levels of imipenem and plasma half-life. It is 
not recommended that probenecid be given with 
PRIMAXIN®.
PRIMAXIN® should not be mixed with or physically 
added to other antibiotics. PRIMAXIN® has been 
administered concomitantly with some antibiotics, 
such as aminoglycosides.
There is no evidence to suggest that association of 
PRIMAXIN® with any other beta-lactam antibiotics 
has any therapeutic advantage.
ADVERSE REACTIONS
PRIMAXIN® (imipenem and cilastatin sodium for 
injection) is generally well tolerated. The following 
adverse reactions were reported on 1,723 patients 
treated in clinical trials. Many of these patients were 
severely ill and had multiple background diseases 
and physiological impairments, making it difficult to 
determine causal relationship of adverse ex­
periences to therapy with PRIMAXIN®.
Local Adverse Reactions
Adverse local clinical reactions that were reported 
as possibly, probably or definitely related to therapy 
with PRIMAXIN® were:
Incidence (%)
Phlebitis/thrombophlebitis 1.7
Infused vein pain 0.6
Vein induration 0.2
Infused vein infection 0.1
Systemic Adverse Reactions
Adverse clinical reactions that were reported as 
possib ly, probably, or d e fin ite ly  related to 
PRIMAXIN® were:
Incidence (%)
Gastrointestinal
nausea 2.0
diarrhea 1.7
vomiting 1.6
tongue papillar hypertrophy 0.2
pseudomembranous colitis 
(see WARNINGS) 0.1
hemorrhagic colitis <0.1
gastroenteritis <0.1
abdominal pain <0.1
glossitis <01
heartburn <0.1
pharyngeal pain <0.1
increased salivation <0.1
CNS
fever 0.4
dizziness 0.3
seizures 0.2
(see PRECAUTIONS)
somnolence 0.2
confusion 0.2
myoclonus 0.1
vertigo 0.1
headache 0.1
encephalopathy <0.1
paresthesia <0.1
Special Senses
transient hearing loss in 
patients with impaired hearing <0.1
tinnitus <0.1
Respiratory
dyspnea 0.1
hyperventilation <0.1
thoracic spine pain <0.1
Cardiovascular
hypotension 0.4
palpitations 0.1
tachycardia < 0.1
Renal
oliguria/anuria <0.1
polyuria < 0.1
Skin
rash 0.9
pruritus 0.3
urticaria 0.2
skin texture changes 0.1
candidiasis 0.1
erythema multiforme <0.1
facial edema < 0.1
flushing < 0.1
cyanosis < 0.1
hyperhidrosis < 0.1
pruritus vulvae <0.1
Body as a whole
polyarthralgia <0.1
asthenia/weakness <0.1
Adverse Laboratory Changes
Adverse laboratory changes, without regard to drug 
relationship, that were reported during clinical trials 
were:
The maximum daily dose should not exceed 4 g or 
50 mg/kg, which ever is less.
Dosage in Elderly Patients
The recommended dosage of PRIMAXIN® in elderly 
patients with normal renal function is the same as 
given for adults above. Renal status of elderly 
patients may not be accurately portrayed by 
measurement of BUN or creatinine alone. Deter­
mination of creatinine clearance is suggested to 
provide guidance for dosing in such patients.
Dosage in Patients with Renal Insufficiency
P a tie n ts  w ith  c re a t in in e  c le a ra n c e s  o f 
<5 mL/min/1.73m2 (=S0.08 mL/s/1.73m2) should 
not receive PRIMAXIN® unless hemodialysis is 
instituted within 48 hours. Both imipenem and 
cilastatin are cleared from the circulation during 
hem odia lys is . The pa tien t should  rece ive 
PRIMAXIN® after hemodialysis and at 12 hour 
intervals timed from the end of that hemodialysis 
session. Dialysis patients, especially those with 
background CNS disease, should be carefully 
m o n ito re d ; fo r pa tien ts  on hem od ia lys is , 
PRIMAXIN® is recommended only when the benefit 
outweighs the potential risk of seizures (see 
PRECAUTIONS). Currently, there are inadequate 
data to recommend the use of PRIMAXIN® in 
patients undergoing peritoneal dialysis.
TABLE 2
Hepatic: IncreasedSGPT.SGOT,alkalinephospha- MAXIMUM DOSAGE OF PRIMAXIN®
tase, bilirubin and LDH. IN RELATION TO RENAL FUNCTION
Hemic: Increased eosinophils, positive Coombs 
test, decreased WBC and neutrophils, increased 
WBC, increased platelets, decreased platelets, 
decreased hemoglobin and hematocrit, increased 
monocytes, abnormal prothrombin time, increased 
lymphocytes, increased basophils.
Electrolytes: Decreased serum sodium, indreased 
potassium, increased chloride.
Renal: Increased BUN, creatinine.
Urinalysis: Presence of urine protein, urine red 
blood cells, urine white blood cells, urine casts, 
urine bilirubin, and urine urobilinogen.
TREATMENT OF OVERDOSAGE
There are no data available on overdosage.
PRIMAXIN® (imipenem and cilastatin sodium for 
injection) is cleared by hemodialysis.
DOSAGE AND ADMINISTRATION
The dosage recommendations for PRIMAXIN® 
(imipenem and cilastatin sodium for injection) 
represent the quantity of imipenem to be ad­
ministered by I.V. infusion only. An equivalent 
amount of cilastatin is also present in the solution.
The dosage of PRIMAXIN® should be determined 
by the severity of the infection, renal function, body 
weight, the antibiotic susceptibility of the causative 
organism(s) and the condition of the patient. Doses 
cited are based on body weight of 70 kilos.
The median duration of treatment with PRIMAXIN® 
in clinical trials for infections of the various body 
systems ranged from 6 to 10 days except for 
endocarditis and bone and joint infections for which 
the median duration of treatment was 4 weeks.
Dosage in Adults
The recommended daily dose is 1 to 2 g adminis­
tered in equally divided doses every 6 to 8 hours 
(see Table 1).
TABLE 1
ADULT DOSAGE OF PRIMAXIN®
I.V. Administration
Severity 
of infection
Dose
(mg of imipenem)
Dosage
Interval
Daily
Dose
Mild 250 mg 6 h 1.0 g
Moderate 500 mg 8 h 1.5 g
Severe (fully 
susceptible)
500 mg 6 h 2.0 g
Severe* infections 
due to less 
susceptible 
organisms 
or life threatening 
conditions
1000 mg 
1000 mg
8 h 
6 h
3.0 g
4.0 g
* Primarily some strains of Ps. aeruginosa.
RENAL
FUNCTION
CREATININE  
CLEARANCE 
mL/m in/1.73 m2 
(m L/s/1.73 m 2)
DOSE
(g)
DOSAGE
INTERVAL
(h)
M AXIM UM
TOTAL
DAILY
DOSAGE
(g)
Mild
impairment 3 1 -7 0
(0 .5 2-1 .17 )
0.5 6 - 8 1 .5 - 2
Moderate
impairment 2 1 -3 0  
(0.35 -  0.50)
0.5 8 -1 2 1 - 1 .5
Severe*
impairment 0 - 2 0
(0 -0 .3 3 )
0 .2 5 -0 .5 12 0 .5 - 1 .0 * *
x P a tie n ts  w ith  c re a t in in e  c le a ra n c e  o f  6 to  
20 m L/m in /1 .73 m2 (0.1 - 0.3 m L/s/1.73 m2) should 
be treated with 250 mg (or 3.5 mg/kg w h ichever is 
owerl every 12 hours fo r most pathogens. When 
the 500 mg dose is used in these patients, there may 
be an increased risk of seizures.
x * T he  h ig h e s t dose is o n ly  recom m en ded  fo r 
in fe c tio n s  due to  less suscep tib le  o rgan ism s 
prim arily some strains of Ps. aeruginosa.
When only the serum creatinine level is available, 
the following formula (based on sex, weight, and 
age of the patient) may be used to convert this value 
into creatinine clearance (mL/min). The serum 
creatinine should represent a steady state of renal 
function.
Males: Weight (kg) x (140 - age)
72 x serum creatinine (mg/100 mL) 
Females: 0.85 x above value.
When using the International System of units (SI), 
the estimated creatinine clearance (mL/s) in males 
can be calculated as follows:
(lean body weight, kg) x (140 - age, years) x 1.4736 
(72) x (serum creatinine concentration, pmol/L)
and in females the estimated creatinine clearance 
(mL/s) is:
(lean body weight, kg) x (140 - age, years) x 1.2526 
(72) x (serum creatinine concentration, pmol/L)
PRIMAXIN® is cleared by hemodialysis. After each 
dialysis session the dosage schedule should be 
restarted.
Dosage In Infants and Children
The recom m ended to ta l d a ily  dosage of 
PRIMAXIN® in children and infants 3 months of age 
and older is 60 to 100 mg/kg of body weight divided 
into 4 equal doses given at six hour intervals. The 
higher dosages should be used for infants and 
young children. The total daily dosage should not 
exceed 2 grams. Clinical data are insufficient to 
recommend an optimum dose for infants and 
children with impaired renal function.
Administration
CAUTION: CONTENTS OF VIALS NOT FOR 
DIRECT INFUSION.
Each reconstituted 250 mg or 500 mg dose should 
be given by intravenous infusion over twenty to 
th irty  minutes. Each 1000 mg dose should be 
infused over 40 to 60 minutes. In patients who 
develop nausea during the infusion, the rate of 
infusion may be slowed.
RECONSTITUTION
Contents of the vials must be suspended and 
transferred to 100 mL of an appropriate infusion 
solution.
A suggested procedure is to transfer approximately 
10 mL from the 100 mL of the appropriate infusion 
solution to the vial (see list of diluents under 
COMPATIBILITY AND STABILITY). Shake well. 
Return the resulting 10 mL of suspension to the 
remaining 90 mL of the infusion solution.
Repeat, using 10 mL of the diluted suspension, to 
ensure complete transfer of the contents of the vial 
to the infusion solution.
CAUTION: CONTENTS OF VIALS NOT FOR 
DIRECT INFUSION.
COMPATIBILITY AND STABILITY
List of diluents
0.9% Sodium Chloride Injection 
5% or 10% Dextrose Injection 
5% Dextrose Injection with 0.02% sodium 
bicarbonate solution
5% Dextrose and 0.9% Sodium C h loride  
Injection
5% Dextrose Injection with 0.225% or 0.45% 
saline solution 
NORMOSOL-M in D5-W 
5% Dextrose Injection with 0.15% potassium 
chloride solution 
Mannitol 2.5%, 5% and 10%
Reconstituted solutions
Solutions of PRIMAXIN® range from colourless to 
yellow. Variations of colour within this range do not 
affect the potency of the product.
PRIMAXIN®, as supplied in vials and reconstituted 
as above maintains satisfactory potency for four 
hours at room temperature and for 24 hours under 
refrigeration (4°C). PRIMAXIN® has been found to 
be stable in 0.9% Sodium Chloride Injection for 
10 hours at room temperature and 48 hours under 
refrigeration.
DOSAGE FORMS
AVAILABILITY
PRIMAXIN® is supplied as a sterile powder mixture 
in vials containing im ipenem anhydrous and 
cilastatin sodium as follows:
3514Ca - 250mgimipenemequivalentand250mg 
cilastatin equivalent in vials.
3516 Ca - 500 mg imipenem equivalent and 500 mg 
cilastatin equivalent in vials.
STORAGE
The dry powder should be stored at a temperature 
below 30° C.
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PRESCRIBING INFORMATION
Rocephin;
CEFTRIAXONE I  SODIUM
Sterile Ceftriaxone Sodium 
For Injection
Therapeutic Classification 
Antibiotic
INDICATIONS AND CLINICAL USES The treatment of the following infections when caused by susceptible strains of the 
designated micro-organisms: Lower respiratory tract inlections caused by £  coli, H. influenzae, K. pneumoniae and species, 
Staph, aureus, Strep, pneumoniae and species (excluding enterococci). Urinary tract inlections (complicated and 
uncomplicated) caused by £. coli. Klebsiella species, P, mirabilis and P. vulgaris. Bacterial septicemia caused by £  coli,
H. influenzae. K. pneumoniae. Staph, aureus and Strep, pneumoniae (excluding enterococci). Skin and skin structure 
inlections caused by K. pneumoniae and species, P  mirabilis, Staph aureus, Staph, epidermidis and Streptococcus 
species (excluding enterococci). Bone and joint infections caused by Staph, aureus, Strep, pneumoniaeani Streptococcus 
species (excluding enterococci). Meningitis caused by H. influenzae, N. meningitidis, and Strep, pneumoniae. Rocephin1, 
should not be used tor the treatment of meningitis caused by L. monocytogenes. Uncomplicated gonorrhea (cervical/ 
urethral and recta l) caused by H. gonorrhoeae (penicillinase and nonpenicillinase producing strains).
Prophylaxis: The preoperative administration of a single 1 g dose of Rocephin® (sterile ceftriaxone sodium) may reduce 
the incidence of postoperative infections in patients undergoing vaginal or abdominal hysterectomy, coronary artery 
bypass surgery, or in patients at risk of infection undergoing biliary tract surgery. If signs of post surgical infection should 
appear, specimens fo r culture should be obtained for identification of the causative organism(s) so that the appropriate 
therapy may be instituted. CONTRAINDICATIONS Rocephin® (sterile ceftriaxone sodium) is contraindicated in patients 
with known allergy to ceftriaxone, other cephalosporins or penicillins. WARNINGS Before therapy with Rocephin® (sterile 
ceftriaxone sodium) is instituted, careful inquiry should be made concerning previous hypersensitivity reactions to 
ceftriaxone, other cephalosporins, penicillins or other allergens. Rocephin® should only be administered with caution to 
any patient who has demonstrated any form of allergy particularly to drugs. Serious, and occasionally fatal hypersensitivity 
(anaphylactoid) reactions have been reported in patients receiving cephalosporins. The reactions are more likely to occur 
in persons with a history of sensitivity to multiple allergens. Rocephin® should be administered with caution to patients 
with type I hypersensitivity reaction to penicillin. If an allergic reaction occurs, the administration of Rocephin® should be 
discontinued and appropriate therapy instituted. Pseudomembranous colitis has been reported with the use of Rocephin®, 
(and with broad-spectrum and other antibiotics). Therefore, it is important to consider its diagnosis in patients 
administered Rocephin- who dev^opdiarrhea. Treatment with broad-spectrum antibiotics, including Rocephin®, alters 
the normal flora of ttie colon and may permltovergrowth of Clostridia. Studies indicate that a toxin produced by C/osfr/rf/um 
difficile is one primary cause of antibiotic-associated colitis. Mild cases of colitis may respond to drug discontinuation 
alone. Moderate to severe cases should be managed with fluid, electrolyte, and protein supplementation as indicated. 
When the colitis is not relieved by discontinuation of Rocephin® administration or when it is severe, consideration shouid 
be given to the administration of vancomycin or other suitable therapy. Other possible pauses ot the colitis should also 
be considered, Rocephin® therapy shouid be discontinued in patients who develop signs or symptoms suggestive of
gallbladderdiseaseandconservativemanagementcorisidered.Theeffectofpre-existinggallbladderdiseaseisnot known.
In a few patients administered Rocephin®, shadows suggesting “sludge" have been -detected by sonograms of the 
gallbladder in those who remained asymptomatic andin those who became symptomatic. This condition appeared to  be 
reversible on discontinuation ot RocepWn®therapy. inafew symptomatic patients receivmgdgof Ftapf*Y»W ho underwent 
cholecystectomy, "sludge” containing traces of ceftriaxone was recovered from surgical specimens. Concretions 
consisting o( the predipitated calcium salt ot ceftriaxone have been found in the gallbladder bile bf dogs and baboons 
treated with high doses of ceftriaxone. PRECAUTIONS General Hypoprothrombinemia and alterations in prothrombin time 
have occurred rarely in patients treated with Rocephin® (sterile ceftriaxone sodium) (see ADVERSE REACTIONS). Patients 
with impaired vitamin K synthesis or low vitamin K stores (e.g. chronic hepatic disease and malnutrition) may require 
monitoring ol hematology and coagulation parameters during Rocephin* treatment. Vitamin K administration (10 mg 
weekly) may be necessary it the prothrombin time is prolonged before or during treatment. Prolonged treatment with 
Rocephin* may result in overgrowth of non-susceptible organisms and organisms initially sensitive to the drug. If 
superinfection ox^turs, appropriate measures should be taken. Rocephin® should be administered with caution to individuals 
with a history o f gastrointestinal disease, particularly colitis. Renal and Hepatic Impairment Although transient elevations 
of BUN and serum creatinine have been observed in clinical studies, there is no other evidence that Rocephin®, when 
administered alone, is nephrotoxic. In severe renal impairment (creatinine clearance of less than 10 mL/min), periodic 
monitoring of serum ceftriaxone concentrations is recommended. The maximum daily dose should not exceed 2 g. In 
severe renal impairment associated with clinically significant hepatic impairment, close monitoring of serum ceftriaxone 
concentrations, at regular intervals, is recommended. If there is evidence of accumulation, dosage should be decreased 
accordingly. Interactions Interactions between Rocephin® and other drugs have not been fully evaluated. Pregnancy The 
safety of Rocephin® in the treatment of infections during pregnancy has not been established. Rocephin® should only be 
used during pregnancy it the likely benefit outweighs the potential risk to the fetus and/or the mother. Ceftriaxone has been 
detected in the umbilical cord blood, amniotic fluid and placenta. Nursing Mothers Ceftriaxone is excreted in human milk 
at low concentrations. The clinical significance of this is unknown; therefore, caution should be exercised when Rocephin® 
is administered to a nursing mother. Neonates The safety of Rocephin* in neonates (birth to one month of age) has not 
been established. In vitro studies have shown that ceftriaxone can displace bilirubin from serum albumin. Caution should 
be exercised when considering Rocephin® treatmentforhyperbilirubinemic neonates especially if premature. Elderly Patients 
The elimination of ceftriaxone may be reduced in elderly patients possibly due to impairment of both renal and hepatic 
function. Drug-Laboratory Test Interactions Ceftriaxone may interfere with urine glucose determinations utilizing the 
copper-reduction test (CLINITEST), but not utilizing the glucose-oxidase test (DIASTtX or TES-TAPE) ADVERSE REACTIONS 
During clinical trials with Rocephin® (sterile ceftriaxone sodium) the following adverse reactions have been observed: 
Clinical Adverse Experiences: Dermatological: Rash (1.3%); exanthema, allergic dermatitis and pruritis (0.1 -1.0%). 
Hematological: Anemia (0.1-1.0% ); auto-immune hemolytic anemia and serum sickness (<0.1%). Hepatic: Jaundice, 
reports (in asymptomatic and symptomatic patients) of ultrasonographic shadows suggesting precipitations in the 
gallbladder and reports of gallbladder sludge (<0.1 %) Urogenital: Moniliasis and vaginitis (0.1 -1.0%). Gastrointestinal: 
Diarrhea (3.3%); nausea, vomiting, dysgeusiaand gastric pain (0.1-1.0%); abdominal pain, colitis, flatulence, dyspepsia, 
pseudomembranous colitis and stomatitis (<0.1%). Neurological: Dizziness and headache (0.1 -1 .0% ); ataxia and 
paresthesia (<0.1 %). Miscellaneous: Fever, chills, diaphoresis, malaise, burning tongue, flushing, edema and anaphylactic 
shock (0.1 -1.0% ); bronchospasm, palpitations and epistaxis (<0.1%) Local Reactions al Injection Site: Pain (9.4%), 
induration and tenderness (1 -2%); phlebitic reactions (0.1-1.0%); thrombophlebitis (<0.1 %). Laboratory Abnormalities: 
Hematologic: Eosinophilia (4.6%), thrombocytosis (5.1%), leukopenia (2.0%); neutropenia, lymphophenia, 
thrombocytopenia, increase or decrease in hematocrit, prolongation of prothrombin time and decrease in hemoglobin (0.1 
-1.0%); leukocytosis, lymphocytosis, monocytosis, basophiliaand decrease in prothrombin time (<0.1%). Hepatic: Increase 
in AST (SGOT) (4.0%)*, ALT (SGPT) (4.8%)', increase in alkaline phosphatase (1.0%); increase in bilirubin (0.1 -1.0%). 
Urinary: Increase in BUN (1.1 %)‘ ; increase in creatinine, erythrocyturia, proteinuria and presence of casts in urine (0.1 
-1.0%); glycosuria (<0.1 % ).1 Incidence is more frequent in patients less than one year old.1 Incidence is more frequent 
in patients less than oneyear old and over 50 years old. SYMPTOMS AND TREATMENTOFOVERDOSAGE Ultrasonographic 
shadows suggesting precipitations in the kidneys accompanied by calcium ceftriaxone precipitate in the urine was 
observed in one patient dosed with Rocephin® (sterile ceftriaxone sodium) at 10 g/day (2.5times the maximum recommended 
dose). No other case of overdosage has been reported to date with Rocephin®. No specific information on symptoms or 
treatment is available. Excessive serum concentration ot ceftriaxone cannot be reduced by hemodialysis or peritoneal 
dialysis. Treatment should be symptomatic. DOSAGE AND ADMINISTRATION Rocephin® (sterile ceftriaxone sodium) may 
be administered intravenously or intramuscularly after reconstitution. Dosage and route of administration should be 
determined by the severity of intection, susceptibility of the causative organisms, and condition of the patient. The 
intravenous route is preferable tor patients with septicemia or other severe or life-threatening infections. DOSAGE Adults: 
Moderate and Severe Intentions: Total daily I.M. or I.V dose 1 or 2 g daily. The daily dose may be given as 0.5 or 1 g q12h, 
or 1 or 2 g q24h. There is limited experience with daily doses of 3-4 g administered as a single dose or two equally divided 
doses. The total daily dose should not exceed 4 o. Uncomplicated Gonorrhea: Single dose of 250 mg I.M. IntantsaM 
Children (one month to 12 years of age) Serious Miscellaneous Inlections: Total daily I.M. or I.V. dose 50 or 75 mg/kg 
administered as 25 or 37.5 mg/kg g12h. The total daily dose should not exceed 2 g. If body weight is 50 kg or more the 
adult dose should be used Meninnitis: Total daily I.M. or I.V. dose -100 mg/kg administered as 50 mg/kg* q12h. * With 
or without a loading dose of 75 mg/kg. The total daily dose should not exceed 4 g. With the exception of gonorrhea, which 
is treated with a single dose, the administration ot Rocephin® should be continued for a minimum ot 48 to 72 hours after 
the patient defervesces or after evidence of bacterial eradication has been obtained, usually 4 to 14 days. In bone and joint
infections the average duration of treatment during clinical trials was 6 weeks, with a range of 1 to 13 weeks, depending 
on the severity of the infection. When treating infections caused by beta-hemolytic Streptococcus, it is recommended that 
therapy be continued for at least 10 days. The average duration of therapy for infections associated with beta-hemolytic 
Streptococcus during clinical trials was 2 weeks, with a range of 1 to 5 weeks, depending on the site and severity ot the 
infection. Prophylaxis (Vaginal or Abdominal Hysterectomy, Coronary Artery Bypass Surgery, Biliary Tract Surgery): 
For preoperative use as prophylaxis before vaginal or abdominal hysterectomy, coronary artery bypass surgery, or biliary 
tractsurgery in patients at risk of infection, asingle dose of 1 g administered 1/2 to2 hours before surgery is recommended. 
Impairment ot Renal and/or Hepatic Function In patients with mild to moderate renal impairment, changes in the dosage 
regimen are not required, provided liver function is intact. In cases of preterminal renal failure (creatinine clearance less 
than 10 mUmin), periodic monitoring of serum ceftriaxone concentrations is recommended. The daily dosage should be 
limited to 2 g or less. In patients with liver damage, there is no need for the dosage to be reduced provided renal function 
is intact. In cases of coexistent renal and clinically significant hepatic insufficiency, close monitoring ol serum ceftriaxone 
concentrations, at regular intervals, is recommended. If there is evidence of accumulation, dosage should be decreased 
accordingly. ADMINISTRATION Intramuscular: The reconstituted solution of Rocephin®should be administered by deep 
intragluteai injection. It is recommended that not more than 1 g beinjected ata single site. Pain on intramuscular injection 
is usually mild and less frequent when Rocephin® is administered in sterile 1% Lidocaine solution. Intravenous (bolus) 
Injection: The reconstituted solution should be administered over approximately 5 minutes. Short Intravenous Infusion: 
The further diluted intravenous solution should be given over a period of 10 to 15 minutes in infants and children and 20 
to 30 minutes in adults. NOTE: Rocephin® solution should not be physically mixed with aminoglycoside antibiotics nor 
administered at the same site because of possible chemical incompatibility.
PHARMACEUTICAL INFORMATION
Reconstitution
For Intramuscular Use
Reconstitute Rocephin® powder with the appropriate diluent:
• Sterile Water for Injection • Bacteriostatic Water for Injection
•  0.9% Sodium Chloride Injection • 1 % Lidocaine Solution
• 5% Dextrose Injection 
Reconstitute as follows:
Reconstitution Table (IM)
Vial
Size
Volume to be 
added to vial 
mL
Approximate available 
volume 
mL
Approximate average 
concentration 
g/mL
0.25 g 0.9 1 m 0.25
0.5 g 1 4 ; 2 mm 0.25
10 g 3.6 ; 4 0.25
2 0 0 7.2 ■ ■  8 I 0.25
b-akeweii until dissolved. W H W W  
NOTE- SOLUTIONS"PREPARED FOR INTRAMUSCULAR USEiOR ANY SOLUTION.CONTAINING LIDOCAINE OR 
BACTERIOSTATIC WATER FOR INJECTION SHOULO NEVER BE ADMINISTERED INTRAVENOUSLY. .-h-,;/:
For Intravenous Use
Reconstitute only with Sterile Water for Injection.
Reconstitute aS W m fR
Reconstitution Table (IV)
Vial
Size
Volume to be 
added to vial 
mL
Approximate available 
volume 
mL
Approximate average 
concentration 
g/mL
0.25 g 2.4 2.5 0.1
0.5 g 4.8 5.0 0.1
1.0 g 9.6 10.0 0.1
2.0 g 19.2 20.0 0.1
Shake well until dissolved. The prepared solution may be further diluted to the desired volume with any of the “ Solutions 
for IV Infusion”  listed below.
Solutions for IV Infusion
0.9% Sodium Chloride Injection
5% Dextrose Injection
Dextrose and Sodium Chloride Injection
0.9% Sodium Chloride Injection in ADD-VANTAGE (Abbott) flexible diluent container, 50 mL and 100 mL 
5% Dextrose Injection in ADD-VANTAGE (Abbott) flexible diluent container, 50 mL and 100 mL.
Pharmacy Bulk Package Reconstitution for Preparation of Intravenous Infusion Solutions
The closure of the pharmacy bulk vial shall be penetrated only one time after reconstitution, using a suitable sterile transfer 
device or dispensing set which allows measured dispensing for the contents.
Volume to be Approximate Approximate
Vial added to vial available volume average concentration
size mL mL g/mL
10 g 95 100.0 0.1
Shake well until dissolved. Withdraw the required amount and dilute with one of the “Solutions for IV Infusion” . Any 
unused solution remaining within a period of 8 hours should be discarded.
Stability of Solutions - Storage
For complete stability and storage information, consult the Product Monograph.
Incompatibility:
Rocephin® should not be physically mixed with other antimicrobial agents.
Rocephin® should not be added to blood products, protein hydrolysates or amino acids.
Rocephin® should not be added to solutions containing calcium.
DOSAGE FORM 
Availability:
1 .Rocephin® Vials containing sterile powder equivalent to 0.25 g, 1 g and 2 g of ceftriaxone.
2. Rocephin® Vials containing sterile powder equivalent to 1 g and 2 g of ceftriaxone for use only with Abbott Laboratories 
Limited ADD-VANTAGE (Abbott) 0.9% Sodium Chloride Injection U.S.P. or 5% Dextrose Injection U.S.P. in 50 mL and 
100 mL containers.
3. Rocephin® Pharmacy Bulk Vials containing sterile powder equivalent to 10 g ceftriaxone (not for direct administration). 
The availability o f the pharmacy bulk vial is restricted to hospitals with a recognized intravenous admixture programme. 
Storage:
Rocephin® sterile powder should be stored at a controlled room temperature (between 15°and 30°C) and protected from 
light.
Product Monograph available on request.
References:
1. Hell K. Chemotherapy 1989;35:228-235.2. Rocephin® Product Monograph.
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Bilateral Central Dislocation of the Hip: 
a Case Report
Patrick Kinnard, MD, FRCSC; Richard Lirette, MD, FRCSC
Bilateral central dislocation of the hip occurs rarely. The authors report a case in 
which the patient was treated successfully by one-stage, bilateral, total hip 
arthroplasty.
Une dislocation centrale simultanee des deux hanches est rare. Les auteurs 
presentent un cas traite par prothese de hanches bilaterale en une seance 
chirurgicale avec un excellent resultat.
S imultaneous bilateral central dislocation of the hip, which 
occurs rarely, may be caused by 
electric or convulsive therapy,1-4 
epileptic seizures, convulsions sec­
ondary to hyponatremia or low 
magnesium and calcium levels after
parathyroidectomy5-7 and cere­
brovascular accident.8
Case Report
A 70-year-old woman was admit­
ted to the Centre Hospitalier de
l’Universite Laval with pain in both 
legs following severe convulsions 
that occurred 2 weeks after she 
underwent a hysterectomy. The 
convulsions were caused by hypona­
tremia, which was induced by inap­
propriate secretion of the antidiu­
retic hormone.
Radiography demonstrated bilat­
eral, central, hip dislocation. The 
pelvic rings were intact on the right 
side and disrupted on the left.
The severity of the pain, despite 
bilateral traction, necessitated a 
one-stage, bilateral, total hip ar­
throplasty under general anesthe­
sia. After reduction and fixation of 
the left pelvic ring, a screw-ring 
acetabular prosthesis and a stan­
dard cemented femoral stem were 
inserted on each side (Fig. 1).
During the 3.5-hour operation 
blood loss was 850 mL. There were 
no postoperative complications, and 
the patient was allowed to walk 
with crutches, with no weight bear­
ing on the left side for 6 weeks.
Eighteen months after surgery, 
the patient was able to walk with­
out pain or limp; she occasionally 
used a cane when she experienced 
discomfort but had resumed all her 
preoperative activities.
Discussion
The mechanism of injury in bilat­
eral central hip dislocation is both 
complex and controversial.57 It 
seems likely that the uncontrolled, 
simultaneous, violent contraction of 
the pelvitrochanteric muscles gener­
ates sufficient force to fracture the 
acetabular floor and dislocate the 
femoral head centrally.57 The sym-
FIG. 1. Pelvis 1 year postoperatively.
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metric nature of the contractions 
may account for the bilaterality of 
the injury.
All patients with this injury re­
ported in the literature were treated 
by traction and bed rest2' 7 to 
achieve bone union, which ensued 
successfully in most cases. If post- 
traumatic arthritis developed, elec­
tive total hip replacement was per­
formed.
In patients with subacute or 
chronic fracture-dislocation of the 
hip, a two-stage operation may be 
preferable, first creating an ade­
quate acetabulum.9
For our patient, a one-stage, bi­
lateral, total hip arthroplasty was 
indicated because she was in severe 
pain. The one-stage procedure alle­
viated much of her pain, allowing a 
more comfortable recovery without 
complications.
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ANTIBIOTIC
ACTION
In vitro studies demonstrate that the bactericidal 
action of cefoxitin, a cephamycin derived from 
cephamycin C, results from the inhibition of 
bacterial cell wall synthesis. Evidence suggests 
that the methoxy group in the la  position is 
responsible for the resistance of cefoxitin to 
degradation by bacterial beta-lactamases.
IND ICATIO NS AND CLINICAL USES
TREATMENT
The treatment of the following infections when 
due to susceptible organisms:
1 - Intra-abdominal infections such as peritonitis
and intra-abdominal abscess
2 - Gynecological infections such as endo­
metritis and pelvic cellulitis
3 - Septicemia
4 - Urinary tract infections (including those
caused by Serratia marcescens and Serratia 
spp.)
5 - Lower respiratory tract infections
6 - Bone and jo in t in fections caused by
Staphylococcus aureus
7 - Soft tissue infections such as cellulitis,
abscesses and wound infections 
Appropriate culture and susceptibility studies 
should be performed to determine the suscepti- 
b i l i t y  of the causa tive  o rgan ism (s) to 
MEFOXIN®. Therapy may be started while 
awaiting the results of these tests, however, 
modification of the treatment may be required 
once these results become available.
Organisms particularly appropriate for therapy 
with MEFOXIN® are:
Gram positive
Staphylococci, penicillinase producing and 
non-producing
Streptococci excluding enterococci 
Gram negative (beta-lactamase producing and 
non-producing strains)
Escherichia coli
Klebsiella species (including K. pneumoniae) 
Proteus, indole positive and negative 
Haemophilus influenzae 
Providencia species
Anaerobes
Bacteroides fragilis
MEFOXIN® may also be appropriate for the 
treatment of infections involving susceptible 
strains of both aerobic and anaerobic bacteria.
MEFOXIN® is not active against Pseudomonas 
spp., most strains of enterococci, many strains 
of Enterobacter cloacae, and m ethicillin- 
re s is ta n t s ta p h y lo c o c c i and L is te r i a  
monocytogenes.
Clinical experience has demonstrated that 
MEFOXIN® can be administered to patients who 
are also receiving carbenicillin, gentamicin, 
tobramycin, or amikacin (see PRECAUTIONS 
and ADMINISTRATION).
PROPHYLACTIC USE
MEFOXIN® may be administered periopera- 
tively (preoperatively, intraoperatively and post- 
operatively) to patients undergoing vaginal or 
abdominal hysterectomy and abdominal surgery 
when there is a significant risk of postoperative 
infection or where the occurrence of post­
operative infection is considered to be especially 
serious.
In patients undergoing cesarean section, intra­
operative (after clamping the umbilical cord) 
and postoperative use of MEFOXIN® may 
reduce the incidence of surgery related post­
operative infections.
®Trademark Merck & Co., Inc. 
Merck Frosst Canada Inc., R.U.
Effective prophylactic use depends on the time 
of administration. MEFOXIN® usually should be 
given one-half to one hour before the operation. 
Prophylactic administration should usually be 
stopped within 12 hours. It has been generally 
reported that continuing administration of any 
antibiotic beyond 24 hours following surgery 
increases the possibility of adverse reactions 
but, in the majority of surgical procedures, does 
not reduce the incidence of subsequent 
infection.
If signs of postsurgical infection should appear, 
specimens for culture should be obtained for 
identification of the causative organism(s) so 
that appropriate treatment may be instituted.
CONTRAINDICATIONS
MEFOXIN® is contraindicated in persons who 
have shown hypersensitivity to cefoxitin or to 
the cephalosporin group of antibiotics.
W ARNINGS
Before therapy with MEFOXIN® is instituted, 
careful inquiry should Be made to determine 
whether the patient has had previous hyper­
sensitivity reactions to MEFOXIN®, cepha­
losporins, penicillins or otherdrugs. MEFOXIN® 
should be given with caution to penicillin- 
sensitive patients.
There is some clinical and laboratory evidence 
of partial cross-allergenicity between cepha- 
mycins and the other beta-lactam antibiotics, 
penicillins and cephalosporins. Severe reactions 
(including anaphylaxis) have been reported 
with most beta-lactam antibiotics. 
Pseudomembranous colitis has been reported 
w ith  v ir tu a lly  all a n tib io tic s  in c lu d in g  
MEFOXIN®. This colitis can range from mild to 
life threatening in severity. Antibiotics should 
therefore be prescribed with caution in indi­
viduals with a historyof gastrointestinal disease, 
particularly colitis. It is important to consider a 
diagnosis of pseudomembranous colitis in 
patients who develop diarrhea in association 
with antibiotic use. While studies indicate that a 
toxin produced by Clostridium difliciie is one 
primary cause of antibiotic-associated colitis, 
other causes should also be considered.
Any patient who has demonstrated some form of 
allergy, particularly to drugs, should receive 
antibiotics including MEFOXIN® with caution.
If an allergic reaction to MEFOXIN® occurs, 
administration of the drug should be dis­
continued. Serious hypersensitivity reactions 
may require treatment with epinephrine and 
other emergency measures.
PRECAUTIONS
The total daily dosage should be reduced when 
MEFOXIN® is administered to patients with 
transient or persistent reduction of urinary 
output due to renal insufficiency (see DOSAGE 
AND ADMINISTRATION) because high and 
prolonged serum antibiotic concentrations can 
occur from usual doses.
In patients treated with MEFOXIN® a false­
positive reaction to glucose in the urine may 
occur with Benedict’s or Fehling's solutions but 
not with the use of specific glucose oxidase 
methods.
Using the Jaffe Method, falsely high creatinine 
values in serum may occur if serum concen­
trations of cefoxitin exceed 100 pg/mL. Serum 
samples from patients treated with MEFOXIN® 
should not be analyzed for creatinine if with­
drawn within two hours of drug administration. 
High concentrations of cefoxitin in the urine 
may interfere with measurement of urinary 17- 
hydroxy-corticosteroids by the Porter-Silber 
reaction, and produce false increases of modest 
degree in the levels reported.
Increased nephrotoxicity has been reported 
fo llow ing  concom itant adm in istra tion of 
cephalosporins and aminoglycoside antibiotics.
Prolonged use of MEFOXIN® may result in the 
overgrowth of non-susceptible organisms. 
Repeated evaluation of the patient's condition is 
essential and if super-infection occurs during 
therapy, appropriate measures should be taken. 
Should an organism become resistant during 
antibiotic therapy, another antibiotic should be 
substituted.
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Use in Pregnancy
The safety of MEFOXIN® in the treatment of 
infections during pregnancy has not been 
established. If the administration of MEFOXIN® 
during pregnancy is considered necessary, its 
use requires that the anticipated benefits be 
weighed against possible hazards to the fetus. 
Reproductive and teratogenic studies have been 
performed in mice and rats and have revealed no 
evidence of impaired fertility or harm to the fetus 
due to MEFOXIN®.
There are no controlled studies in pregnant 
women.
Nursing Mothers
Cefoxitin is excreted in human milk. Caution 
should be exercised if use is indicated.
Children
In children 3 months of age or older, higher 
doses of MEFOXIN® (100 m g/kg/day and 
above) have been associated with an increased 
incidence of eosinophilia and elevated SGOT.
ADVERSE REACTIONS
MEFOXIN® is generally well tolerated. Adverse 
reactions rarely required cessation of treatment 
and usually have been mild and transient.
Local Reactions
Thrombophlebitis has occurred with intra­
venous administration. Some degree of pain and 
tenderness is usually experienced after intra­
muscular injections using water. Induration has 
occasionally been reported.
Allergic
M aculopapular rash, u rtica ria , pru ritus, 
eosinophilia, fever and other allergic reactions 
including anaphylaxis have been noted. 
Gastrointestinal
Symptoms of pseudomembranous colitis can 
appear during or after antibiotic treatment. 
Nausea and vomiting have been reported rarely. 
Blood
Eosinophilia, leukopenia, neutropenia, hemo­
lytic anemia, and thrombocytopenia and bone 
marrow depression have been reported. Some 
individuals, particularly those with azotemia, 
may develop positive direct Coombs tests 
during therapy with MEFOXIN®.
Liver Function
Transient elevations in SGOT, SGPT, serum 
LDH, and serum alkaline phosphatase and 
jaundice have been reported.
Cardiovascular Function
Flypotension.
Renal Function
Elevations in serum creatinine and/or blood 
urea nitrogen levels have been observed. As 
with the cephalosporins, acute renal failure has 
been reported rarely. The role of MEFOXIN® in 
changes in renal function tests is difficult to 
assess, since factors predisposing to prerenal 
azotemia or to impaired renal function have 
often been present.
TREATMENT OF OVERDOSE
Other than general supportive treatment, no 
specific antidote is known. MEFOXIN® can be 
eliminated by dialysis in patients with renal 
insufficiency.
DOSAGE AND ADMINISTRATION
MEFOXIN® may be administered intravenously 
or intramuscularly as required. (See complete 
m onograph on ADM IN ISTRATIO N and 
RECONSTITUTION.)
Intravenous Administration
The intravenous route is preferable for patients 
with bacteremia, bacterial septicemia, or other 
severe or life-threatening infections, or for 
patients who may be poor risks because of 
lowered resistance resulting from such debili­
tating conditions as m alnutrition, trauma, 
surgery, diabetes, heart failure, or malignancy, 
particularly if shock is present or impending.
TREATMENT DOSAGE 
Adults
The usual adult dosage is 1 g or 2 g of 
MEFOXIN® every 6 to 8 hours. Dosage and 
route of administration should be determined by
severity of infection, susceptibility of the 
causative organisms, and condition of the 
patient. The usual adult dosages are shown in 
the Table below.
Usual Adult Dosage
Type of Daily Frequency
infection Dosage and Route
Uncomplicated 3-4 g 1 g every 6-8 h
forms* of in- I.V. or I.M.
fections such as
pneumonia,
urinary tract
infection, soft
tissue infection
Moderately 6-8 g 1 g every 4 h
severe or severe or
infections 2 g every 6-8 h I.V.
Infections 12 g 2 g every 4 h
commonly or
needing anti- 3geve h I.V.
biotics in higher
dosage (e.g. gas
gangrene)
'Including patients in whom bacteremia is absent or 
unlikely
Therapy may be started while awaiting the 
results of susceptibility testing.
Antibiotic therapy for group A beta-hemolytic 
streptococcal infections should be maintained 
for at least 10 days to guard against the risk of 
rheumatic fever or glomerulonephritis. In 
staphylococcal and other infections involving a 
collection of pus, surgical drainage should be 
carried out where indicated.
Adults with Impaired Renal Function
MEFOXIN® may be used in patients with 
reduced renal function but a reduced dosage 
should be employed and it is advisable to 
monitor serum levels in patients with severe 
impairment.
In adults with renal insufficiency, an initial 
loading dose of 1 g to 2 g should be given. After 
a loading dose, the following recommendations 
for maintenance dosage may be used as a guide:
MAINTENANCE DOSAGE OF 
MEFOXIN® IN ADULTS 
WITH REDUCED RENAL FUNCTION
RENAL CREATININE
FUNCTION CLEARANCE
mL/min
Mild
impairment 50-30
Moderate
impairment 29-10
Severe
impairment 9-5
Essentially 
no function <5
DOSE FREQUENCY
1-2 g every 8-12 h
1-2 g every 12-24 h
0.5-1 g every 12-24 h
0.5-1 g every 24-48 h
In patients undergoing hemodialysis, the 
loading dose of 1 -2 g should be given after each 
hemodialysis, and the maintenance dose should 
be given as indicated in the Table above. 
Neonates (Including Premature Infants), Infants 
and Children (See WARNINGS for Neonates 
under ADMINISTRATION in the complete 
monograph.)
Premature Infants 
with Body Weights 
Above 1500 g 20-40 mg/kg every 12 h I.V.
Neonates
0- 1 week of age
1- 4 weeks of age
20-40 mg/kg every 12 h I.V. 
20-40 mg/kg every 8 h I.V.
Infants
1 month to 2 years 
of age
20-40 mg/kg every 6 h or 
every 8 h I.M. or I.V.
Children 20-40 mg/kg every 6 h or 
every 8 h I.M. or I.V.
In severe infections, the total daily dosage in 
infants and children may be increased to 
200 mg/kg, but not to exceed 12 g per day.
MEFOXIN® is not recommended for the therapy 
of meningitis. If meningitis is suspected, an 
appropriate antibiotic should be used.
At present there is in s u ff ic ie n t data to 
recommend a specific dosage for children with 
impaired renal function. However, if the adminis­
tration of MEFOXIN® is deemed to be essential 
the dosage should be modified consistent with 
the recommendations for adults (see Table 
above).
PROPHYLACTIC USE
For prophylactic use, a three-dose regimen of 
MEFOXIN® is recommended as follows:
Vaginal or abdominal hysterectomy and 
abdominal surgery
2 g  administered in tram uscu larly or in tra ­
venously just prior to surgery (approximately 
one-half to one hour before initial incision).
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Lymphatic Fistula After Vascular 
Reconstruction: a Case-Control Study
John L. Murphy, MD, FRCSC; C. William Cole, MD, FRCSC; Prudy M. White, RN;
Graeme G. Barber, MD, FRCSC; Adrien G. Bouchard, MD, FRCSC; Neil V. McPhail, MD, FRCSC; 
Walter G. Waddell, MD, FRCSC, FACS; James L. Wellington, MD, FRCSC, FACS
A retrospective case-control study was carried out to assess the importance of 
lymphatic fistulas that develop after vascular reconstruction and to determine the 
risk factors associated with them. The authors compared 35 patients who had 
lymphatic fistula after vascular reconstruction with 70 control patients, taken from 
the same database. They found a significant difference between the two groups only 
in age and indication for surgery: lymphatic fistulas were more likely to develop in 
older patients and in patients who underwent aortobifemoral bypass for limb salvage 
rather than for claudication (p < 0.05).
Une etude cas-temoins retrospective a ete menee pour etablir l’importance des 
fistules lymphatiques qui surviennent a la suite de reconstructions vasculaires et 
pour calculer les facteurs de risques qui en decoulent. Les auteurs ont compare 35 
patients avec fistules lymphatiques suite a une reconstruction vasculaire avec 70 
patients temoins, issus d’une meme banque de donnees. Ils n’ont trouve de 
difference significative entre les deux groupes que par rapport a l’age et l’indication 
pour la chirurgie: les fistules lymphatiques etaient plus frequentes chez les patients 
plus ages et ceux qui ont subi un contournement aortobifemoral pour recuperation 
d’un membre plutot que pour claudication (p < 0.05).
Lymphatic fistula is an uncom­mon complication of surgery in 
the groin but may be of importance 
in certain circumstances, such as 
after vascular reconstruction, par­
ticularly when prosthetic material is 
used. Lymphatic fistulas in this sit­
uation have been said to heighten 
the risk of graft infection,1 but, to 
our knowledge, this hypothesis has 
not been tested. The purpose of our 
study was to assess the importance
of lymphatic fistulas occurring after 
vascular reconstruction and to de­
termine the risk factors associated 
with them.
Methods
Review of a computerized data­
base of vascular surgery patients 
treated at the Ottawa Civic and 
Ottawa General hospitals between
1982 and 1987 was used to identify 
those with lymphatic fistula, de­
fined in this study as clear, watery 
drainage from a groin wound that 
was present 7 or more days postop- 
eratively. A control group was se­
lected from the same database by 
taking the nearest numbered record 
of a patient with a groin wound 
before and after each case of lym­
phatic fistula. The majority of study 
subjects were interviewed and ex­
amined by one of us (J.L.M.), and 
additional information was obtained 
by a review of the hospital records. 
Data were analysed by comparison 
of the two groups using the x2 test 
with Yates’ correction and Stu­
dent’s t-test when required.
Findings
Thirty-five patients satisfied the 
criteria for inclusion in the study. 
The demographic characteristics of 
the two groups were comparable. 
Patients with a lymphatic fistula 
differed from control patients in two 
important variables: age and indica­
tion for surgery. Those with a lym­
phatic fistula were older (Table I) 
and had undergone surgery more 
often for limb salvage than for 
claudication (Table II).
Throughout the follow-up there 
were no graft infections or pseudo-
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aneurysms in either group (Table 
III). During that time two graft 
occlusions occurred in the fistula 
group and six among the controls. 
The causes of death in the fistula 
group included myocardial infarc­
tion (four patients), carcinoma 
(four), stroke (three) and others 
(three); no death was attributed to a 
graft complication. Other factors 
that may have influenced wound 
healing and perhaps contributed to 
the development of a lymphatic fis­
tula were diabetes (seven patients), 
renal failure (two), steroid therapy
(two) and repeat surgery that in­
volved a previous groin incision 
(six).
Cultures of the lymphatic drain­
age were positive in 8 of the 35 
patients with a lymphatic fistula 
(Table IV). However, only two had 
clinically apparent superficial 
wound infections; one infection de­
veloped after a lymphocele was as­
pirated. These infections resolved 
with intravenous antibiotic therapy, 
and there were no long-term seque­
lae.
Drainage from the fistula persist­
Table 1.  Demographic Characteristics of 35 Patients With Lymphatic Fistula and 70 Control
Patients
Group
Patients Fistula Control p  value
Mean age, yr 69.9 63.4 < 0.05*
Sex, M:F 31:4 51:19 NS
Smokers, no. 31 57 NS
Diabetics, no. 7 (all men) 14 NS
*Two-tailed Student’s f-test.
Table II. Indication for Operation and Type of Reconstruction
Group
Indication/procedure Fistula Control p value
Aneurysm NS
Aortobifemoral bypass 13 14
Occlusive disease <0 .01*
Claudication
Aortobifemoral bypass 2 24
Limb salvaget
Aortobifemoral bypass 4 32
Femorofemoral bypass 1 —
Femoropopliteal bypass 8 —
Femorotibial bypass 2 —
Axillofemoral bypass 5 —
Other 1 —
*x 2 with Yates’ correction.
tOne patient had aortobifemoral and femoropopliteal bypass.
Table III. Outcome Over 5 Years
Group
Outcome Fistula Control
Follow-up, mo 
Mean 42.7 41.5
Range 6-84 12-84
Positive culture, no. 8 1
Superficial infection, no. 2 2
Graft infection, no. 0 0
Anastomotic aneurysm, no. 0 0
Graft occlusion, no. 2 6
Death, no. 14 10
Lost to follow-up, no. 5 14
ed for an average of 28 days and 
resulted in prolonged hospital stay 
in most cases, but no other prob­
lems arose over a follow-up that 
averaged more than 3 years. The 
management of all cases consisted 
of bed rest and scrupulous wound 
care together with continuous anti­
biotic therapy; none had surgical 
exploration.
Discussion
The findings from this study 
show that lymphatic fistulas compli­
cating vascular reconstructive sur­
gery in the groin do not frequently 
lead to graft infection. The impor­
tance of a postoperative lymphatic 
fistula in this group of patients may 
therefore depend upon other fac­
tors. It has been suggested that 
distal foot lesions may allow micro­
organisms to be transported to the 
groin by way of lymph channels, 
with resultant local contamination 
and infection in a prosthetic graft.2 
Graft infection was not seen in this 
series, but the significance of distal 
foot lesions can be appreciated 
when 20 of the 22 patients with 
occlusive disease had limb-threaten­
ing ischemia compared with 32 of 
the 56 control patients with occlu­
sive disease (p < 0.01). The type of 
reconstruction may also be a factor 
in the development of a lymphatic 
fistula: none of the control patients 
in this study had popliteal or tibial 
incisions compared with 10 patients
Table IV. Microorganisms Isolated From 
the Groin of Eight Patients With Lymphatic 
Fistula
Organism isolated Number of 
isolates
Staphylococcus
epidermidis 4
Pseudomonas aeruginosa 2
Enterococcus 3
Staphylococcus aureus 2
Escherichia coli 2
Mixed organisms 3
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with lymphatic fistula (Table II). 
When taken together, these data 
suggest that distal procedures asso­
ciated with severe ischemic changes 
are more likely to result in a lym­
phatic fistula at the groin than 
bypasses to the femoral artery for 
proximal occlusive disease.
The incidence of lymphatic fistula 
reported in the literature is incon­
sistent and often not accompanied 
by a clear definition of what is 
meant by the term. In many groin 
wounds lymph drainage occurs for 
a short time and is not always 
reported. In a recent multicentre, 
prospective study of aneurysm sur­
gery only three lymphatic fistulas 
were noted in 367 groin anastomo­
ses.3 This may represent under­
reporting since another report of 
423 groin wounds identified 27 
cases of lymphatic fistula.4 In that 
report, only 9 of 22 patients had 
lymph drainage for more than 5 
days.4 There is no widely accepted 
definition of a lymphatic fistula and 
little more agreement regarding its 
importance. When clear lymph 
drainage is abundant or when drain­
age persists beyond the usual time 
for a patient to be discharged from 
hospital, most would agree that a 
lymphatic fistula exists. The pres­
ent study included only fistulas that 
were present 7 or more days post- 
operatively, to distinguish them 
from minor wound drainage that 
may moisten a groin dressing in the 
early postoperative period.
The management of lymphatic 
fistula is the subject of considerable 
controversy. All patients in this 
series were treated nonoperatively, 
but others have recommended a 
more aggressive, surgical approach. 
Kwaan, Bernstein and Connolly5
compared operative and nonopera­
tive management in a small series. 
On the basis of one graft infection 
in seven nonoperative cases com­
pared with none in five managed 
surgically, they concluded that op­
erative treatment reduced hospital 
stay and the risk of graft infection. 
The present series is larger and the 
follow-up longer. Our findings sup­
port a contrary position: that non­
operative therapy has a low inci­
dence of infectious complications 
and most fistulas will respond with­
out operative intervention. Surgery 
may be required for fistulas drain­
ing very large volumes of lymph or 
those that fail to respond to nonop­
erative management. The nature of 
the microorganisms present in a 
groin wound infection largely deter­
mines the consequences. Arteries 
infected with Staphylococcus au­
reus or gram-negative organisms, 
or both, more often result in disrup­
tion than arteries infected with Sta­
phylococcus epidermidis.6 The or­
ganisms cultured from the draining 
lymph in the cases reported here 
were more often S. epidermidis than 
any other. It is possible that greater 
contamination with a more virulent 
organism such as Pseudomonas sp. 
would have resulted in a much 
different outcome. No correlation 
was noted between culture results 
and the presence of open or infected 
foot lesions. However, the observa­
tion that a lymphatic fistula oc­
curred more often in patients oper­
ated upon for limb salvage may be 
of more than passing importance. 
Many patients with severe ischemia 
present with edema in the affected 
part, which is due mainly to two 
causes: first, with severe ischemia 
patients keep the limb in a position
of dependency, even at rest, which 
results in clinically apparent edema; 
second, ischemic tissues lose the 
integrity of cell membranes and 
leak fluid into the interstitium. 
Postoperatively, this results in a 
greater volume of lymph flow 
through channels in the groin that 
have a reduced capacity as a result 
of the surgical procedure.
Important risk factors predispos­
ing to the development of a lym­
phatic fistula in the groin were 
advanced age and surgery for limb 
salvage. A consequence of this com­
plication was prolonged hospital 
stay, but the clinical course and 
outcome were not otherwise influ­
enced.
We thank David Moher, Department of 
Research, for statistical support and 
assistance with study design, and Lise 
Fournier for follow-up of patients.
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The Canadian Journal of Surgery will consider manuscripts of original articles, clinical research, surgical 
technique, clinical reviews, history of surgery, a limited number of case reports, editorials and letters. 
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examination in the standard clinical format. Negative findings and normal results of laboratory tests need be 
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diagnosis and the management. The clinical course should be described briefly and the significant observation or 
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4.2) and cannot edit from diskettes that are not IBM-compatible.
The process of initial consideration, peer review and editorial decision making of the manuscript usually takes 
about 8 weeks. The original copy of a rejected manuscript will be returned to the authors; all other copies will be 
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desires.*
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ATLAS OF ORTHOPAEDIC PA­
THOLOGY. Lester E. Wold, Richard 
A. McLeod, Franklin H. Sim et al. 
Atlases in Diagnostic Surgical Pathol­
ogy series; editor, Gerald M. Bordin. 
276 pp. Illust. W.B. Saunders Compa­
ny, London/Harcourt Brace Jovano- 
vich, Inc., Philadelphia; HBJ-Holt- 
Saunders Distribution Services, To­
ronto. 1990. Price not stated. ISBN 0 -  
7216-2911-3
This atlas is one of a proposed series 
relating to specific, well-defined areas of 
specialty pathology. It has been pre­
pared by four staff members of the 
Mayo Clinic — two pathologists, a 
radiologist and an orthopedic surgeon 
who has a specific interest in orthopedic 
oncology.
The book is well organized into 
seven sections, each section being clear­
ly defined by the common factor of the 
cell or origin of the lesions to be 
discussed. Thus, section one is on os­
teoid-forming lesions, section two on 
cartilage-forming lesions, section three 
on fibrous lesions, and so on. This 
allows for a speedy reference to lesions 
of similar origin. Each tumour or tu- 
mour-like condition within each section 
is given a short chapter, which begins 
with a brief discussion of the incidence 
of the lesion, signs and symptoms, 
major radiographic features, differential 
diagnosis and the histology. The intro­
duction is followed by lavishly illustrat­
ed examples of the gross and micro­
scopic appearances, including radio­
graphs and some clinical photographs. 
The illustrations are superb.
This textbook sets out admirably to 
accomplish its goal. For the practising 
surgeon, it is an excellent reference for 
the pathologic features of malignant 
and benign musculoskeletal tumours. 
Unfortunately, it is restricted in its 
scope to tumour pathology, so that 
many important pathological conditions 
affecting the musculoskeletal system 
are ignored. The text therefore is mis­
named — it is not an atlas of orthope­
dic pathology but an atlas of tumours 
and tumour-like conditions of bone and 
connective tissue.
Despite this shortcoming it remains 
an excellent reference text for practis­
ing surgeons and surgical trainees. It 
will prove invaluable for orthopedic sur­
geons in training in improving their 
understanding and knowledge of these 
relatively uncommon conditions and 
will greatly assist them in formulating 
differential diagnoses based upon the 
clinical and radiographic presentation of 
these lesions.
James P. Waddell, MD, FRCSC
Surgeon-in-chief 
Division of Orthopedics 
St. Michael’s Hospital 
Toronto, ON 
M5B 1W8
METABOLIC BONE DISEASE AND 
CLINICALLY RELATED DISOR­
DERS. 2nd ed. Edited by Louis V. 
Avioli and Stephen M. Krane. 912 pp. 
Illust. W.B. Saunders Co./Harcourt 
Brace Jovanovich, Inc. Philadelphia. 
1990. $240. ISBN 0-7216-2766-8
Readers should first be aware that the 
reviewer of this book is an orthopedic 
surgeon: this review is therefore from 
the point of view of an orthopedic 
surgeon, and a senior one at that.
This text first appeared in two vol­
umes in 1977 and 1979. This second 
edition, now one volume, attempts “to 
present a correlated view of metabolic 
bone disease and related topics, stress­
ing the relationship between genetics, 
molecular biology, biochemistry, pa­
thology, and clinical syndromes, in a 
single volume.” The editors appear to 
have accomplished their goals by pro­
ducing a relatively compact book of just 
under 1000 pages which, nevertheless, 
covers a frequently poorly understood 
group of bone diseases, including os­
teopetrosis, osteogenesis imperfecta, 
Gaucher’s disease and sarcoidosis, as 
well as female osteoporosis syndrome, 
osteomalacia, renal osteodystrophy and 
hyperparathyroidism. A chapter on met­
abolic bone disorders in children is a 
welcome addition, and one on tumours 
of bone is perhaps justified, at least on 
the basis of differential diagnosis.
The editors are professors of medi­
cine, in St. Louis and Boston respec­
tively, and they have put together con­
tributions from 40 authors, almost ex­
clusively North American. Interestingly, 
the only “foreign” authors are from 
Melbourne, Australia, and they have 
contributed the chapter on a Canadian 
discovery, calcitonin.
Two features are immediately evi­
dent: the relative paucity of illustrations 
(which presages a large amount of solid 
reading) and the very extensive refer­
ence lists for each chapter. A quick 
check for the least number of refer­
ences revealed the chapter on hypercal­
cemia of malignant disease (a useful one 
for orthopedic surgeons) with 87; sever­
al chapters contain over 500 references.
The index was put to the test on a 
number of occasions and responded 
consistently and with ease. Subjects 
dear to the hearts of orthopedic sur­
geons (alkaline phosphatase, myositis 
ossificans, fractures in Paget’s disease) 
were easily traced.
As a clinician, I found it difficult to 
adjust to the scientific terminology 
(dare I say jargon?), but after a chapter 
or two it came with greater ease. As a 
reader of English, I also had occasional 
difficulty with words. “Solubilization” 
tied my silent tongue, but it is in 
Webster’s dictionary.
The book, therefore, is judged to be 
an extensive compilation of current 
knowledge in its field, and as such 
should be a useful reference for those 
physicians and surgeons clinically active 
in the area of skeletal diseases and 
injuries. Its subtitle “and Clinically Re­
lated Disorders” is significant. It is not 
simply a large tome on osteoporosis 
with a number of exotic but rare diseas­
es added. It includes conditions encoun­
tered daily in orthopedic practice and is 
broadened by inclusion of a wide group 
of conditions as differential diagnoses.
At the list price of $240 it is unlikely 
to grace the shelves of many personal 
libraries but should be an essential 
addition to all group-practice and medi­
cal-centre libraries.
Kenneth S. Morton, MD, CM, FRCSC
Department of Orthopedics
3rd Floor
910 W 10th Ave.
Vancouver, BC 
V5Z 4E3
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BOOK REVIEWS
SHOULDER RECONSTRUCTION. 
Charles S. Neer II. Illustrated by Rob­
ert J. Demarest. 551 pp. Illust. W.B. 
Saunders Company, London/Harcourt 
Brace Jovanovich, Inc., Philadelphia; 
HBJ-Holt-Saunders Distribution Ser­
vices, Toronto. 1990. $165. ISBN 0 -  
7216-2832-X
Shoulder surgery has attracted the in­
terest of many orthopedic surgeons and 
allied health professionals in the last 
decade. Before then, this joint was 
rarely the focus of any major discus­
sion, and surgical treatment was offered 
by only a few who had special interest 
in that area. Dr. Neer became interested 
in this joint early in his career. Stimu­
lated by his teacher, Dr. Harrison 
McLaughlin, Neer makes his vast expe­
rience available to the reader in this 
extensive book. In it he combines an 
underlying pathologic condition with a
clear indication for a procedure and 
details the potential pitfalls.
The figures by Robert J. Demarest 
are of high quality and vividly illustrate 
Neer’s concepts from his earlier, well- 
known articles. The figures are accom­
panied by detailed anatomic drawings 
and radiographs, outlining the individu­
al pathologic conditions.
The anatomy of the shoulder region 
and related conditions are described in 
detail. A chapter on shoulder rehabilita­
tion will be of interest to the orthopedic 
surgeon and to all personnel involved in 
restoring shoulder-girdle function.
The remaining five chapters focus on 
all the common shoulder disorders. Cuff 
lesions and impingements as well as 
glenohumeral arthroplasty are covered, 
reflecting the author’s long-time inter­
ests. The chapter on fractures of the 
shoulder clearly outlines the pathologic 
concept and eventual outcome of any
fracture and its treatment. Neer de­
serves the credit for creating a classifi­
cation that has become the common 
knowledge base for the treatment of 
shoulder fractures.
An extensive collection of references 
reflects the volume of Neer’s work and 
will direct orthopedic surgeons to addi­
tional topics of interest.
This book is a pleasure to read and a 
necessity for any orthopedic surgeon 
working in this field. Its clear concept 
and excellent illustrations make it very 
attractive for professionals in related 
specialties such as rheumatology and 
physical medicine.
Joachim F. Lohr, MD, FRCSC
Assistant professor of surgery, 
University of Ottawa,
Ottawa General Hospital, 
Ottawa, ON 
K1H 8L6
0Anaprox® DS 550 mg 
^Anaprox® 275 mg
(naproxen sodium)
Indications:
Relief of mild to moderately severe pain, accompanied by 
inflammation such as musculoskeletal trauma, post­
dental extraction, relief of post-partum cramping and 
dysmenorrhea.
Contraindications:
Anaprox and Anaprox DS (naproxen sodium) are contrain­
dicated in patients, with active ulcers or active inflam­
matory diseases of the gastrointestinal tract. They are 
also contraindicated in patients who have shown hyper­
sensitivity to it or to naproxen. Since cross-sensitivity 
has been demonstrated, Anaprox or Anaprox DS should 
not be given to patients in whom ASA or other non­
steroidal anti-inflammatory drugs induce the syndrome 
of asthma, rhinitis, or uticaria. Sometimes severe and 
occasionally fatal anaphylactic reactions have occurred 
in such individuals.
Warnings:
Peptic ulceration, perforation and gastrointestinal bleed­
ing, sometimes severe and occasionally fatal, have been 
reported during therapy with non-steroidal anti-inflam­
matory drugs (NSAID's) including Anaprox and Anaprox 
DS. Anaprox and Anaprox DS should be given under 
close medical supervision to patients prone to gastroin­
testinal tract irritation particularly those with a history of 
peptic ulcer, diverticulosis or other inflammatory dis­
eases of the gastrointestinal tract.
Patients taking any NSAID including this drug should 
be instructed to contact a physician immediately if they 
experience symptoms or signs suggestive of peptic ulcer­
ation or gastrointestinal bleeding. These reactions can 
occur without warning at any time during the treatment. 
Elderly, frail and debilitated patients appear to be at 
higher risk from a variety of adverse reactions from 
NSAIDs. For such patients, consideration should be
given to a starting dose lower than usual. The safety 
of Anaprox and Anaprox DS in pregnancy and lactation 
has not been established and its use is therefore not 
recommended.
Precautions:
Anaprox or Anaprox DS (naproxen sodium) should not 
be used concomitantly with the related drug Naprosyn® 
(naproxen) since they circulate in plasma as the 
naproxen anion.
G.l. system: If peptic ulceration is suspected or con­
firmed, or if gastrointestinal bleeding or perforation occurs 
Anaprox or Anaprox DS should be discontinued, and 
appropriate treatment instituted. Renal effects: Patients 
with impaired renal function, extracellular volume deple­
tion, sodium restrictions, heart failure, liver dysfunction, 
those taking diuretics, and the elderly, are at greater risk 
of developing overt renal decompensation. Assessment 
of renal function in these patients before and during 
therapy is recommended. Naproxen sodium and its metab­
olites are eliminated primarily by the kidneys, and there­
fore, a reduction in daily dosage should be anticipated to 
avoid the possibility of drug accumulation in patients 
with significantly impaired renal function. Naproxen 
sodium should not be used chronically in patients having 
baseline creatinine clearance less than 20m l/m inute.
Peripheral edema has been observed, consequently, 
patients with compromised cardiac function should be 
kept under observation when taking Anaprox or Anaprox 
DS. Each Anaprox tablet contains approximately 25 mg 
of sodium and each Anaprox DS tablet contains approxi­
mately 50 mg of sodium. This should be considered in 
patients whose overall intake of sodium must be mark­
edly restricted. As with other drugs used in the elderly or 
those with impaired liver function it is prudent to use the 
lowest effective dose. Severe hepatic reactions includ­
ing jaundice and cases of fatal hepatitis have been 
reported with NSAIDs. The prescriber should be alert to 
the fact that the anti-inflammatory, analgesic and antipy­
retic effects of Anaprox or Anaprox DS (naproxen sodium) 
may mask the usual signs of infection. Periodic liver 
function tests and ophthalmic studies are recommended
for patients on chronic therapy. Caution should be exer­
cised by patients whose activities require alertness if 
they experience drowsiness, dizziness, vertigo or depres­
sion during therapy with the drug. The naproxen anion 
may displace other albumin-bound drugs from their bind­
ing sites and may lead to drug interactions or interfere 
with certain laboratory tests. See product monograph for 
specific examples. The safety and efficacy of th is drug in 
children has not been established and its use in children 
is therefore not recommended.
Adverse reactions:
Adverse reactions which occur in > 1 %  of patients 
include:
G.I.: heartburn, constipation, abdominal pain, nausea, 
diarrhea, dyspepsia, stom atitis and diverticulitis.
CNS: headache, dizziness, drowsiness, light-headed­
ness, vertigo, depression and fatigue.
Skin: pruritus, ecchymoses, skin eruptions, sweating 
and purpura.
CVS: dyspnea, peripheral edema and palpitations. 
Special Senses: tinnitus and hearing disturbances. 
Others: thirst.
For additional adverse reactions please refer to the 
product monograph.
Availability:
Anaprox® is available in OVAL-SHAPED, BLUE film - 
coated tablets of 275 mg in bottles of 100, 500 and 
1000 tablets.
Anaprox® DS is available in OVAL-SHAPED, BLUE 
film-coated tablets of 550 mg in bottles o f 100 tablets. 
Dosage:
Anaprox® 275m g: Two tablets (5 5 0 mg) followed by 
one tablet (275 mg) every 6 - 8  hours as required. 
Anaprox® DS: One tablet (550 mg) tw ice daily.
Maximum daily dose: 1375 mg.
Product monograph available on request.
SYNTEX
Syntex Inc* M ississauga, Ont./Montreal, Que. 
*Reg. user of all ®  trademarks.
CJS, VO L. 34. N O . 1, F E B R U A R Y  1991 83
NOTICES
Congres annuel de l’Association 
des chirurgiens genereux du Que­
bec
L’Association des chirurgiens genereux 
du Quebec tiendra son congres 
annuel les jeudi et vendredi, 2 et 3 mai 
1991 chez le Chateau Frontenac, Que­
bec. Pour renseignements s’adresser au 
secretariat de l’Association: (514) 393- 
9179.
Laparoscopic Cholecystectomy
The Department of Surgery, University 
of Toronto, will be holding postgradu­
ate courses in laparoscopic cholecystec­
tomy for general surgeons, at the 
Mount Sinai Hospital, Toronto, on the 
following dates: Mar. 20 and 21, 1991; 
Apr. 3 and 4, 1991; Apr. 17 and 18, 
1991; May 1 and 2, 1991; May 15 and 
16, 1991: May 29 and 30, 1991 and 
June 26 and 27, 1991. (These dates 
may be subject to change.) For further 
information please contact: Dr. S.M. 
Strasberg, Course director, Mount Sinai 
Hospital, Rm. 1225, 600 University 
Ave., Toronto, ON M5G 1X5; phone: 
(416) 586-8420; fax: (416) 586-8392.
Gastrointestinal Surgery for Se­
vere Obesity
A National Institutes of Health Consen­
sus Development Conference on gas­
trointestinal surgery for severe obesity 
will be held from Mar. 25 to 27, 1991 
in the Masur Auditorium, The Warren 
Grant Magnuson Clinical Center, Na­
tional Institutes of Health, Bethesda, 
Md. For further information contact: 
Conference registrar, Prospect Associ­
ates, 1801 Rockville Pike, Ste. 500, 
Rockville, MD 20852: phone: (301) 
468-MEET; fax: (301) 770-5164.
Histamine H2 Receptor Antagonist
ACTIONS AND 
CLINICAL PHARMACOLOGY
PEPCID* (famotidine) is a competitive inhibitor of 
histamine Hr receptors. The primary clinically 
important pharmacologic activity of PEPCID® is 
inhibition of gastric ju ice secretion. PEPCID® 
reduces the acid and pepsin content, as well as the 
volume, of basal, nocturnal, and stimulated gastric 
secretion.
INDICATIONS AND CLINICAL USE
PEPCID® (famotidine) is indicated in the treatment 
of the following conditions where a controlled 
reduction of gastric secretion is required for ulcer 
healing:
1. Treatment of acute duodenal ulcer;
2. Prophylactic use in duodenal ulcer;
3. Treatment of acute benign gastric ulcer;
4. Treatment of pathological hypersecretory 
conditions (e.g., Zollinger-Ellison syndrome).
PEPCID® I V. is indicated in some hospitalized 
patients with pathological hypersecretory con­
ditions or intractable ulcers, or as an alternative to 
the oral dosage forms for short-term use in patients 
who are unable to take oral medication.
CONTRAINDICATIONS
H ypersens itiv ity  to any com ponent of this 
medication.
PRECAUTIONS
Patients with Severe Renal Insufficiency
Dosing intervals may need to be prolonged in 
pa tients w ith  advanced renal insu ffic iency 
(creatinine clearance <10 mL/min.) to adjust for the 
longer elimination half-life of famotidine. (See 
CLINICAL PHARMACOLOGY and DOSAGE AND 
ADMINISTRATION.)
Drug Interactions
Studies with famotidine in man, in animal models, 
and in vitro have shown no significant interference 
with the disposition of compounds metabolized by 
the hepatic microsomal enzymes, e.g., cytochrome 
P450 system. Compounds tested in man have 
included w arfa rin , theophy lline , phenytoin, 
diazepam, am inopyrine and antipyrine. Indo­
cyanine green as an index of hepatic blood flow 
and/or hepatic drug extraction has been tested and 
no significant effects have been found.
Use in Gastric Ulcer
Gastric malignancy should be excluded prior to 
initiation of therapy of gastric ulcer with PEPCID®. 
Symptomatic response of gastric ulcer to PEPCID® 
therapy does not preclude the presence of gastric 
malignancy.
Use in Pregnancy
Reproductive studies have been performed in rats 
and rabbits at oral doses of up to 2000 and 
500 mg/kg/day, respectively (approximately 2500 
and 625 times the maximum recommended human 
dose, respectively), and have revealed no evidence 
of impaired fertility or harm to the fetus due to 
PEPCID®. There are, however, no adequate or well- 
controlled studies in pregnant women.
Since the safe use of PEPCID® in pregnant women 
has not been established, the benefits of treatment 
with PEPCID® should be weighed against potential 
risks.
Nursing Mothers
Studies performed in lactating rats have shown that 
PEPCID® is secreted in breast milk. It is not known 
whether this drug is secreted in human milk. 
Nursing mothers should either stop this drug or 
should stop nursing.
Pediatric Use
Safety and effectiveness in children have not been 
established.
Use In Elderly Patients
No dosage adjustment is required based on age (see 
HUMAN PHARMACOLOGY, Pharmacokinetics).
ADVERSE REACTIONS
PEPCID® (famotidine) is usually well tolerated; 
most adverse reactions have been mild and 
transient. The adverse reactions listed below have 
been reported during clinical trials in 2333 patients. 
In those controlled clinical trials in which PEPCID® 
was compared to placebo, the overall incidence of 
adverse experiences in the group which received 
PEPCID®, 40 mg at bedtime, was similar to the 
placebo group. No antiandrogenic or other adverse 
hormonal effects have been observed.
The following adverse reactions have been reported 
at a rate of greater than 1% in patients on therapy 
with PEPCID® in controlled clinical trials, and may 
be causally related to the drug: headache (4.6%), 
dizziness (1.2%), constipation (1.2%) and diarrhea 
( 1.6% ) .
Other reactions have been reported in clinical trials 
but occurred under circumstances where a causal 
relationship could not be established. However, in 
these rarely reported events, that possibility cannot 
be excluded. Therefore, these observations are 
listed to serve as alerting information to physicians.
Gastrointestinal 8.0%
Nausea 1.6%
Vomiting 0.9%
Anorexia 0.5%
Abdominal discomfort 0.3%
Dry mouth 0.2%
Nervous System/Psychlatrlc 7.3%
Insomnia 0.6%
Somnolence 0.4%
Anxiety 0.3%
Paresthesia 0.3%
Depression 0.2%
Libido decreased 0.1%
Respiratory 4.4%
Bronchospasm <0.1%
Body as a Whole 3.0%
Fatigue 0.6%
Asthenia 0.3%
Fever 0.2%
Musculoskeletal 1.7%
Musculoskeletal pain 0.1%
Arthralgia 0.1%
Skin 1.7%
Pruritus 0.4%
Rash 0.3%
Alopecia 0.2%
Flushing 0.2%
Acne 0.1%
Dry skin 0.1%
Cardiovascular 1.0%
Palpitations 0.2%
Special Senses 0.9%
Taste disorder 0.1%
Tinnitus 0.1%
Orbital Edema <0.1%
Urogenital 0.9%
The adverse reactions reported for PEPCID® 
Tablets may also occur with PEPCID® I.V. In 
addition, transient irritation at the injection site has 
been observed with PEPCID® I.V.
Laboratory Abnormalities
Laboratory parameters may be affected during 
treatment with PEPCID®, but the changes are 
usually not considered serious. Among the 
laboratory changes that were reported during 
clinical trials were increases in AST, ALT, BUN, and 
serum creatinine. These changes were rarely of 
clinical significance.
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Only three patients had to be discontinued from 
therapy because of laboratory adverse experiences, 
however laboratory abnormalities were present at 
baseline.
SYMPTOMS AND TREATMENT 
OF OVERDOSAGE
There is no experience to date with deliberate 
overdosage. Doses of up to 640 mg/day have been 
employed in patients with pathological hyper­
secretory conditions with no serious adverse 
effects. In the event of overdosage, treatment 
should be symptomatic and supportive. Un­
absorbed material should be removed from the 
gastro intestina l tract, the patient should be 
monitored, and supportive therapy should be 
employed.
The oral LD50 of famotidine in male and female rats 
and mice was >5000 mg/kg.
DOSAGE AND ADMINISTRATION 
DUODENAL ULCER 
Acute Therapy
The recommended adult oral dosage of PEPCID® 
(famotidine) for acute duodenal ulcer is 40 mg once 
a day at bedtime. Treatment should be given for 
4-8 weeks, but the duration of treatment may be 
shortened if healing can be documented. Healing 
occurs within 4 weeks in most cases of duodenal 
ulcer.
Maintenance Therapy
For the prevention of recurrence of duodenal ulcer, 
it is recommended that therapy with PEPCID® be 
continued with a dose of 20 mg once a day at 
bedtime, for a duration of up to 6-12 months 
depending on the severity of the condition. 
BENIGN GASTRIC ULCER 
Acute Therapy
The recommended adult oral dosage for acute 
benign gastric ulcer is 40 mg once a day at bedtime. 
Treatment should be given for 4 to 8 weeks, but the 
duration of treatment may be shortened if healing 
can be documented.
PATHOLOGICAL HYPERSECRETORY CON­
DITIONS (SUCH AS ZOLLINGER-ELLISON  
SYNDROME)
The dosage o f PEPCID® in pa tients w ith  
pathological hypersecretory conditions varies with 
the individual patient. The recommended adult oral 
starting dose for pathological hypersecretory 
conditions is 20 mg q6h. In some patients, a higher 
starting dose may be required.
Doses should be adjusted to individual patient 
needs and should continue as long as clinically 
indicated. Doses up to 160 mg q6h have been 
adm inistered to some patients w ith severe 
Zollinger-Ellison syndrome.
Intravenous Administration
In some hospitalized patients with pathological 
hypersecretory conditions or intractable ulcers, or 
in patients who are unable to take oral medication, 
PEPCID® I V. may be administered. The recom­
mended dosage is 20 mg every 12 hours.
Intravenous injection therapy should be changed to 
oral treatment as soon as the acute situation is 
under control.
Concomitant Use with Antacids
Antacids may be given concomitantly if needed. 
Dosage Adjustment for Patients with Severe Renal 
Insufficiency
In patients with advanced renal insufficiency, i.e., 
with a creatinine clearance less than 10 mL/min., 
the elimination half-life of PEPCID® may exceed 
12 hours reaching approximately 24 hours in anuric 
patients.
To avoid excess accumulation of the drug, the 
dosing interval of PEPCID® may be prolonged to 
36-48 hours as indicated by the patient's clinical 
response.
PHARMACEUTICAL INFORMATION
COMPOSITION
Tablets
Each tablet for oral administration contains either 
20 mg or 40 mg of famotidine.
Injection
Each mL of the solution for intravenous injection 
contains 10 mg of famotidine and the following 
inactive ingred ien ts : L-aspartic  acid 4 mg, 
mannitol 20 mg, and Water for Injection, q.s., 1 mL. 
The multidose injection also contains benzyl 
alcohol 0.9% added as preservative.
RECONSTITUTION 
Parenteral Products
Dilution of PEPCID® I.V. 
for Infusion
PEPCID® I.V. 
Solution
V0I....3 ot 
Compatible 
I.V. Solution
Final
Volume
Final
Concentration
Rate of 
Infusion
2  m L 3  m L 5  m L 4  m g /m L N o t le s s  th a n  
2  m in u te s
2  m L 8  m L 10  m L 2  m g /m L N o t le s s  th a n  
2  m in u te s
2 m L 10 0  m L 10 2  m L 0 .1 9 6  m g /m L 1 5 -3 0  m in u te s
PEPCID® I.V. Solutions are compatible with:
Water for Injection
0.9% Sodium Chloride Injection 
5% Dextrose Injection 
10% Dextrose Injection 
Lactated Ringer's Injection 
Sodium Bicarbonate Injection 5%
STABILITY AND STORAGE 
RECOMMENDATIONS 
PEPCID® I.V. Solution
Store at 2 - 8°C. Protect from light. If solution 
freezes, bring the solution to room temperature; 
a llow  s u ff ic ie n t tim e  to  so lu b ilize  a ll the 
components.
Diluted PEPCID® I.V. Solutions should be used 
within 24 hours due to the possibility of microbial 
contamination during preparation.
NOTE: Parenteral drug products should be 
inspected visually for particulate matter and 
d isco loura tion p rio r to adm inistra tion 
whenever solution and container permit.
DOSAGE FORMS AND AVAILABILITY
Tablets PEPCID® (fa m o tid in e  tab le ts ) are 
D-shaped, film-coated tablets supplied as follows:
No. Ca 8102 - 20 mg be ige co lo u re d , 
coded 963. Available in bottles of 100 tablets. 
No. Ca 8103 - 40 mg light brownish orange, 
coded 964. Available in bottles of 100 tablets.
No. Ca 3539 - PEPCID® I.V., 10 mg per 1 mL, is a 
clear, colourless solution and is available as a non- 
preserved unit dose containing 2 mL of injectable 
solution. Available in 10 x 2 mL vials.
No. Ca 3541 - PEPCID® I.V., 10 mg per 1 mL, is a 
clear, colourless solution and is available as a 
preserved m ultip le dose conta in ing 4 mL of 
injectable solution. Available in 4 mL vials.
HUMAN PHARMACOLOGY
In both normal volunteers and hypersecretors, 
PEPCID® inhibited basal nocturnal and daytime 
gastric secretion, as well as secretion stimulated by 
a variety of stimuli, such as pentagastrin and food.
After oral administration, the onset of the anti- 
secretory effect occurred within one hour; the 
maximum effect was dose-dependent, occurring 
within one to three hours. Duration of inhibition of 
secretion was 10 to 12 hours. After intravenous 
administration, the maximum effect was achieved 
within 30 minutes. Single intravenous doses of 10 
and 20 mg inhibited basal nocturnal secretion fora 
period of 10-12 hours. The 20 mg dose was 
associated with the longest duration of action in 
most subjects. Single oral doses of 20 and 40 mg 
inhibited basal nocturnal acid secretion in all 
subjects; mean gastric acid secretion was inhibited 
by 86% and 94%, respectively, for a period of at least 
10 hours. Sim ilar doses given in the morning 
suppressed food-stimulated acid secretion in all 
subjects, with mean suppression of 76% and 84%, 
respectively, 3 to 5 hours after drug, and of 25% and 
30%, respectively, 8 to 10 hours a fte r drug; 
however, in some subjects who received the 20 mg 
dose, the antisecretory effect was dissipated earlier, 
within 6-8 hours. There was no cumulative effect 
with repeated doses. The basal nocturnal intra- 
gastric pH was raised by evening doses of 20 and 
40 mg of PEPCID® to mean values of 5.0 and 6.4, 
respectively. When PEPCID® was given in the 
morning, the basal daytime interdigestive pH at 3 
and 8 hours after 20 or 40 mg of PEPCID® was 
raised to about 5.0.
Fasting and postprandial serum gastrin levels may 
be s ligh tly  elevated during periods o f drug 
antisecretory effect, and with chronic therapy an 
increase in gastric bacterial flora may occur. Gastric
emptying and exocrine pancreatic function are not 
affected by PEPCID®.
Other effects
Systemic pharmacologic effects of PEPCID® in the 
CNS, cardiovascular, respiratory or endocrine 
systems have not been found to date. Serum 
prolactin levels do not rise after intravenous bolus 
doses of 20 mg PEPCID® and no antiandrogenic 
effects have been detected.
Pharmacokinetics
PEPCID® is incompletely absorbed. The bioavaila­
bility of oral doses is 40-45%. Bioavailability may be 
slightly increased by food, or slightly decreased by 
acntacids; however, these effects are of no clinical 
consequence. PEPCID® undergoes minimal first- 
pass metabolism. After oral doses, peak plasma 
levels occur in 1-3 hours. Plasma levels after 
multiple doses are similar to those after single 
doses. Fifteen to 20% of PEPCID® in plasma is 
protein bound. PEPCID® has an elimination half-life 
of 2.5-3.5 hours. PEPCID® is eliminated by renal 
(65-70%) and metabolic (30-35%) routes. Renal 
clearance is 250-450 mL/min., indicating some 
tubular excretion.
Twenty-f ive to 30% of an oral dose and 65-70% of an 
intravenous dose are recovered in the urine as 
unchanged com pound. The on ly  m etabo lite  
identified in man is the S-oxide. There is a close 
relationship between creatinine clearance values 
and the elimination half-life of PEPCID®. In patients 
with severe renal insufficiency, i.e., creatinine 
clearance less than 10 mL/min., PEPCID® elim i­
na tio n  h a lf - l ife  may exceed 20 hours  and 
adjustment of dosing intervals may be necessary 
(see PRECAUTIONS, DOSAGE AND ADMINIS­
TRATION). In e lderly patients, there are no 
clinically significant age-related changes in the 
pharmacokinetics of PEPCID®.
PRODUCT MONOGRAPH AVAILABLE
ON REQUEST
(320-a,9,87)
®Trademark Merck & Co., Inc./
Merck Frosst Canada Inc., R.U.
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CLASSIFIED ADVERTISING
As a further service to its readers the Canadian Journal of Surgery is pleased to accept suitable classified advertisements. The deadline is 1 
month before issue date. Regular classified rates (for each insertion): $55.00 for the first 40 words or less, additional words 70i£ each (additional 
$21.00 for frame). Special Display under 100 words, 2>/s in X  2Vs in, $125.00. $15.00 charge (first insertion only) for CJS box numbers. Display 
rates available on request. VISA, MASTERCARD AND AMERICAN EXPRESS ACCEPTED.
Copy should be mailed to the Canadian Journal of Surgery, PO Box 8650, Ottawa, Ontario K1G 0G8.
Box replies should be addressed as follows: Box — , Canadian Journal of Surgery, PO Box 8650, Ottawa, Ontario K1G 0G8.
SURGICAL ONCOLOGIST U n ivers ity  o f M an ito b a  D e p a rtm e n t o f S u rg e ry
T h e  D e p a rtm e n t o f S urge ry , F a c u lty  o f M e d ic in e , U n ive rs ity  o f M a n ito b a  and  th e  H ea lth  S c ie n c e s  C e n tre  and  St. B o n ifa c e  
G e n e ra l H o sp ita l a re  s e e k in g  a  c o n tin g e n t g e o g ra ph ica l fu ll-t im e  s u rg ic a l o n co lo g is t.
S p e c if ic  re s p o n s ib ilit ie s  inc lude :
C lin ica l c a re  in a d v a n ce d  s u rg ica l o n c o lo g y  and  la b o ra to ry  o r c lin ic a l re se a rc h ; te a c h in g  un d e rg ra d u a te  and  p o s tg ra d u a te  
tra in e e s ; and  a d m in is tra tiv e  re sp o n s ib ilit ie s .
C a n d id a te s  m us t have  s e n io r s p e c ia lty  q u a lif ica tio n s  in g e n e ra l su rg e ry  in th e  co u n try  o f cu rre n t p ra c tice  a n d  m u s t be 
e lig ib le  fo r  re g is tra tio n  w ith  th e  C o lle g e  o f P hys ic ians  and  S u rg e o n s  o f M a n ito b a . C e rtifica tio n  in genera l s u rg e ry  by the  
R oya l C o lle g e  o f P hys ic ians  and  S u rg e o n s  o f C anada  is p re fe rre d . A d d itio n a l c lin ic a l a n d /o r  resea rch  tra in in g  in o n c o lo g y  
is  re q u ired .
S a la ry  a n d  a c a d e m ic  ra n k  w ill be  c o m m e n s u ra te  w ith  e x p e rie n c e  a nd  qu a lif ica tio n s .
T h e  U n ive rs ity  o f M a n ito b a  e n c o u ra g e s  a p p lic a tio n s  fro m  q u a lif ie d  w o m e n  and  m en, inc lud ing  m e m b e rs  o f v is ib le  
m in o rit ie s , a b o rig in a l p e o p le , a n d  p e rs o n s  w ith  d is ab ilitie s . T h e  u n iv e rs ity  p ro v id e s  a  s m o k e -fre e  w o rk  e n v iro n m e n t. In 
a c c o rd a n c e  w ith  C a n a d ia n  im m ig ra tio n  re q u ire m e n ts , p r io rity  w ill be  g ive n  to  C anad ian  c itize n s  o r p e rm a n e n t re s id e n ts .
In te re s te d  c a n d id a te s  s h o u ld  app ly , e n c lo s in g  a cu rricu lu m  v ita e  in w ritin g  to : Dr. R .J .W . B lan ch ard , P ro fe s s o r  and  
H e a d , D e p a r tm e n t  o f  S u rg e ry , H e a lth  S c ie n c e s  C e n tre , G C 4 1 1 -8 2 0  S h e rb ro o k  S t., W in n ip e g , M a n ito b a , 
C A N A D A  R 3A  1R9.
A p p lic a tio n s  w ill be  a c c e p te d  un til th e  p o s itio n  is fille d . —S91-44
Plastic
Surgeon
S u d b u ry  G e n e ra l H o s p ita l,  a 3 0 2  bed  
c o m m u n i ty  H o s p ita l a n d  d e s ig n a te d  tra u m a  
c e n tre  f o r  N o r th e a s te rn  O n ta r io ,  re q u ire s  a 
s e c o n d  P la s t ic  S u rg e o n .
A  w id e  s c o p e  o f p ra c t ic e  is  a v a ila b le  
in c lu d in g  c o s m e t ic ,  h a n d , b u rn s  a n d  fa c ia l 
t ra u m a  s u rg e ry .  S u d b u ry  G e n e ra l is  a w e ll 
e q u ip p e d  H o s p ita l w ith  s o p h is t ic a te d  
d ia g n o s t ic  a n d  a ll s u p p o r t  s e r v ic e s  
U n d e rs e rv ic e d  a re a  g ra n ts  a re  a v a ila b le .
= .  1
The  S u d b u ry  re g io n , w ith  a p o p u la ­
t io n  o f 1 5 1 ,3 1 4  a n d  to ta l c a tc h m e n t  a re a  o f 
2 4 0 ,0 0 0 ,  is  th e  m a jo r  c e n tre  in  N o r th e a s te rn  
O n ta r io  a n d  o f fe r s  an  e x c e lle n t  e n v iro n m e n t  
f o r  fa m i ly  life  p o s s e s s in g  e x c e lle n t s u m m e r  
a n d  w in te r  re c re a t io n a l fa c i l i t ie s ,  a s y m p h o n y ,  
p ro fe s s io n a l liv e  th e a tre  a n d  a U n iv e rs ity .
SLDRURY
G eneral
HOTITAL
o f  t h e  I m m a c u l a t e  
H eart o f  M a r y
F u r th e r  in fo r m a t io n  c a n  be o b ta in e d  
b y  c o n ta c t in g :
D r .  P .  N e l i g a n -  P la s t ic  S u rg e o n  
o r
Reply to 
D irector ot 
Human 
Resources
Sudbury 
General Hosp ita l 
700 Pans Street 
Sudbury. O ntario 
P3E3B5
D r .  R .  P a r r a g a -  C h ie f o f  S ta ff
A lw a y s  th e r e  to  Care. — S 9 1 - 4 5
HEAD
DIVISION OF PLASTIC SURGERY
S unnybrook Health Science Centre, a 1200 bed acute and 
chron ic  fu lly a ffilita ted hospital o f the Univers ity  o f Toronto, 
and the  m ajor level one regional trauma unit fo r m etropolitan 
To ron to  and the University of Toronto, has in itia ted a search 
fo r a Head of the Division of P lastic Surgery.
The  Head should have exh ib ited leadersh ip  and strong 
in terpersonal skills to  d irect this dynamic d ivision in to  the next 
decade. The candidate should have expertise, and experience 
in a t least one o f the follow ing: the hosp ita l’s m ajor program s of 
traum a, oncology, or the  departm ental program  of hand sur­
gery. S pecific  expertise in c ran iom axillo fac ia l traum a and re­
construc tive  surgery is desirable since th is C entre w ill becom e 
the  designated adult craniofacial surgical cen tre  a t the Uni­
vers ity  o f Toronto. The candidate could a lso have expertise 
in head and neck cancer a n d /o r skin cancer o r expertise in 
hand surgery.
T he  cand ida te  shou ld  a lso have th e  sk ills  requ ired to  
guide the academ ic undergraduate and postgraduate  teaching 
program s, as well as the  research program s associa ted w ith 
the  D ivision.
A ll in terested candidates please reply by M arch 15th, 1991
to:
Chairm an of the S earch C om m ittee  
Dr. Marvin Tile  
Room  333
2075 Bayview Avenue  
Toronto, Ontario  
M4N 3M5
— S 9 1 -4 3
H E A L T H
SCIEN CE
C E N T R E
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University of Ottawa— Faculty of Medicine 
Chair of the University Division of General Surgery
The University of Ottawa invites applications for the position of 
Chairperson of the University Division of General Surgery.
Applicants must be eligible to practise in Ontario and hold 
certification of the Royal College of Physicians and Surgeons of 
Canada in general surgery. The faculty is seeking an individual with 
a track record of clinical and academic excellence, leadership 
skills and potential to develop a strong research program in 
general surgery.
The division is responsible for directing both undergraduate 
teaching and postgraduate programs in general surgery in the 
Ottawa Civic Hospital and Ottawa General Hospital and Children’s 
Hospital of Eastern Ontario. The successful candidate will hold a 
joint appointment as Chair of the University Department of General 
Surgery and Head at one of the affiliated teaching hospitals.
The faculty is seeking an individual who will hold a full-time 
University appointm ent. Salary and fringe benefits  are 
commensurate with qualifications and experience, and are in 
accordance with existing scales at the University of Ottawa.
Priority will be given to Canadian citizens and permanent residents 
of Canada in accordance with Canadian immigration requirements. 
Employment equity is university policy.
A working knowledge of both English and French is desirable and 
a commitment to support bilingualism within the faculty is 
essential.
Applicants are requested to forward their curriculum vitae and the 
names of three referees prior to May 15, 1991.
John F. Seely, MD.
Dean, Faculty of Medicine 
University of Ottawa 
451 Smyth Road 
Ottawa, Ontario 
K1H 8M5
Universite d’Ottawa — Faculte de medecine
Chaire de la division universitaire de chirurgie generale
L’Universite d’Ottawa accueille les candidatures a la direction de sa 
chaire de chirurgie generale.
Les candidats et candidates doivent etre admissibles a exercer la 
profession en Ontario et posseder I’agrement a titre de specialiste du 
College royal des medecins et chirurgiens du Canada, tout en faisant 
preuve de realisations et d’experience en chirurgie generale Clinique 
et universitaire. Le poste comporte un role de direction dans les milieux 
universitaire, hospitalier et communautaire et la preference sera 
accordee a une personne competente qui s’est engagee dans la voie 
de I’excellence universitaire en enseignement et en recherche.
La division a la responsabilite de fournir un enseignement de qualite 
au niveau prediplome et postdoctoral dans les hopitaux affilies offrant 
une_ formation en chirurgie generale soit I’Hopital Civic d’Ottawa, 
I'Hopital General d ’Ottawa et I’Hopital pour enfants de I’Est de 
I’Ontario. La personne retenue assumera une double affectation a la 
direction de la chaire de chirurgie generale de I’universite et a la 
direction de chirurgie generale dans un des hopitaux d’enseignement 
mentionnes.
La faculte est a la recherche d’une personne pour combler un poste 
a temps complet. Le traitement et les avantages sont fonction de la 
formation et de I’experience, conformement a I'echelle en vigueur a 
I’Universite d’Ottawa.
En vertu des exigences canadiennes relatives a I’immigration, la 
priorite est accordee aux personnes de citoyennete canadienne et de 
residence permanente au Canada. L’universite a une politique d’egalite 
en matiere d’emploi.
Une connaissance de I’anglais et du francais est desirable. Un 
engagement a promouvoir le bilinguisme au sein de la faculte est 
essentiel.
Priere d’envoyer les demandes, accompagnees d’un curriculum vitae 
et du nom de trois repondants, a I’adresse ci-dessous avant le 15 mai 
1991.
John F. Seely, MD 
Doyen, Faculte de medecine 
Universite d’Ottawa 
451, chemin Smyth 
Ottawa (Ontario)
The Department of Surgery 
University of Toronto
announces
Post Graduate Courses 
in Laparoscopic Cholecystectomy 
for General Surgeons
The courses are scheduled between January and June 1991 
and will be two days in duration. They will involve theoretical 
and practical sessions in the surgical laboratory and in the 
operating room.
For further information write or call:
Dr. Steven M. Strasberg - Course Director 
Mount Sinai Hospital 
Room 1225
600 University Avenue 
Toronto, Ontario 
M5G 1X5
Fax: (416) 586-8392 
Tel: (416) 586-8420
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FELLOWSHIP, CARDIOPULMONARY 
TRANSPLANTATION: ON -  Busy heart, 
heart-lung and lung transplant centre perform­
ing 45-50 transplants a year requires a board 
eligible/certified thoracic surgeon to work as 
a transplant fellow commencing July 1991. 
Responsibilities will include donor and recipi­
ent operations, postoperative care and partic­
ipating in ongoing experimental and clinical 
research protocols. Contact: Dr. Neil
McKenzie, University Hospital, PO Box 
5339, London, ON N6A 5A5. -S91-46
GENERAL SURGEON: BC -  In beautiful agri­
cultural valley at south end of Kootenay Lake, 
southeastern B.C. Referral population 15 000 
with broad-based economy and mild climate. 
Many recreational and cultural opportunities. 
This 44-acute-bed-hospital staffed by six 
GPs, three GP/anesthetists and one GP/OB- 
/Gyn. Involved in UBC Family Practice Resi­
dency program. Equipped with colonoscope, 
gastroscope, and two operating rooms. Po­
tential gross at least $250 000. Contact: Dr. 
John Kennedy, Chief of Staff, Creston Val­
ley Hospital, Bag 3000, Creston, BC VOB 
1 GO. Tel: (604) 428-9371: or (604) 
428-3562, evenings. -S90-40
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Head of
Surgical Oncology
The British Columbia Cancer Agency and its 
Vancouver Clinic, and the Department of Surgery, 
University of British Columbia, are seeking an out­
standing academic surgical oncologist to serve as 
the Head of Surgical Oncology. The individual we 
seek is expected to plan, implement, and coordinate 
clinical and academic programs that foster the 
d eve lopm en t of surg ical oncology in B ritish  
Colum bia. The applicant should have attained 
national and international stature in surgical oncol­
ogy and demonstrate a record of excellence in 
scholarship, clinical service and administration. 
Anticipated start date is July 1,1991.
The British Columbia Cancer Agency and the 
University of British Columbia are committed to 
the Federal Government’s employment equity pro­
gram and encourage applications from all qualified 
individuals. In accordance with Canadian Immigra­
tion requirements, priority will be given to Cana­
dian citizens and permanent residents of Canada.
Interested applicants should forward a letter of 
application and updated curriculum vitae, to Dr. 
David Klaassen, Director, B.C. Cancer Agency & 
C hair, Search C om m ittee for H ead, Surgical 
Oncology, at the address shown below.
BRITISH COLUMBIA 
CANCER AGENCY
600 West 10th Avenue
Vancouver, British Columbia, Canada V5Z 4E6
S91-41
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THE SURGEON S CHOICE
STERILE SINGLE USE SURGICAL BLADES &  SCALPELS
SURGICAL BLADES
Superb sharpness, foil wrapped individually in quick- 
dispenser boxes. Made from the highest quality materials, 
for assured uniformity.
Available in all sizes:
#'s 10, 11, 12, 14, 15A, 15, 20,21,22, 23, 24 and 25.
Any size, 100 per box.
VERY SPECIAL: $9.99/bx REGULAR $17.95
SCALPELS WITH BLADES - SINGLE USE
Each scalpel is packed in a polyester and aluminum foil to 
protect blade edges. Unique dispenser box of 20 scalpels. 
Each scalpel in individually inspected.
Available in all sizes:
10, 11, 12, 14, 15A, 15, 20, 21,22, 23, 24 and 25.
Any size, 20 per box.
SUPER SPECIAL: $6.99 Box of 20 REGULAR $10.95
STAINLESS STEEL HANDLES
Made from Rust-Free stainless steel. Arrow shaped design for assured grip. Simply The Finest. Guaranteed
VERY SPECIAL: $6.95
-
MICROBLADES AND MICROKNIVES
These Microblades have been developed in conjunction with leading surgeons and have achieved the aim of 
developing a well balanced instrument to ensure precision and consistency in microsurgery.
• Sterile and disposable.
• Microblade cutting edges are available in four standard angles.
• Blade after blade, cutting edges are precision-ground for sharpness 
and consistent cutting angles.
MAXOM
polyglyconate monofilament absorbable suture
Easier 
handling 
first throw 
to last
Maxon. A softer, more supple suture that offers strength, 
superior handling characteristics and patient benefits.
DAVIS+GECK
MEDICAL DEVICE DIVISION 
Cyanamid Canada Inc.
A  World Leader in Wound Management
